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Summary 
Diabetic kidney disease (DKD) is the foremost microvascular complication of diabetes 
mellitus, which is characterised as persistent albuminuria and progressive loss of kidney 
function induced by diabetes. The health burden of DKD is substantial and continues 
to grow in parallel with the escalating prevalence of diabetes. Despite current 
pharmacotherapies including hypoglycaemic agents, hypotensive drugs and renin-
angiotensin system (RAS) inhibitors, substantial residual risk of DKD initiation and 
progression remains. Considering the increasing prevalence of DKD, novel renal 
protective therapeutics are in great need. Chinese herbal medicine (CHM) has been 
used since antiquity in some countries and regions, and is still being used to treat kidney 
diseases in combination with contemporary medicine. Guided by traditional knowledge 
and contemporary practice of herbal application, existing and potentially novel 
therapeutics for DKD may be evaluated and further developed from CHM. To-date, the 
development of therapeutics from CHM has been impeded by general lack of clinical 
evidence, complex chemical profiles and unclear mechanisms of action. Moreover, the 
conventional drug application of the “one target, one drug” approach has been a 
limitation when it comes to complex and multi-factorial clinical presentations such as 
DKD. CHM is a complex intervention that commonly involves a number of herbal 
ingredients clinically for treating individual patients with DKD.   
 
Objectives 
Guided by a “whole evidence” framework, the aims of this research are to: 
 Evaluate the classical literature evidence of CHM as a treatment for DKD   
 Evaluate the clinical trial evidence of CHM as adjunctive therapy for DKD  
 Explore and propose the bioactive compounds and pharmacological 
mechanisms of promising CHM for DKD 
 
Review of classical literature  
A search of the classical Chinese medicine literature was conducted in the Zhong Hua 
Yi Dian (ZHYD, 5th Edition, 2014). A total of 278 DKD-relevant classical citations 
with treatment information were identified and analysed. These citations were derived 
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from 68 classical Chinese medicine books spanning from AD 583 to AD 1895. Based 
on the rating results, there were 23 citations that were most likely DKD. Ba wei wan, 
Liu wei di huang wan and Hui xiang san were the most frequently cited formulae for 
DKD. The herbs frequently used were huang qi (Astragalus membranaceus (Fisch.) 
Bge. var. mongholicus (Bge.) Hsiao), ren shen (Panax ginseng C. A. Mey.), wu wei zi 
(Schisandra chinensis (Turcz.) Baill.), tian hua fen (Trichosanthes kirilowii Maxim.) 
and huang lian (Coptis chinensis Franch.). It was found that citations with positive 
turbid urine symptoms used huang qi more often than other high-frequency herbs.  
 
Systematic reviews of randomised controlled trials 
The Cochrane handbook of systematic reviews of interventions (version 5.1.0) guided 
the methods of the systematic reviews. The first systematic review included 20 
randomised controlled trials (RCT) with 2719 DKD patients comparing CHM with 
placebo. Meta-analysis suggested that CHM reduced greater albuminuria than placebo, 
regardless of whether RAS inhibitors were concurrently administered. When CHM was 
used as an adjunct to RAS inhibitors, estimated glomerular filtration rate (eGFR) was 
improved in the CHM group compared with the placebo group. The adverse events (AE) 
rates were low and similar between CHM and placebo groups. Huang qi was used most 
frequently among included RCTs.  
 
Accroding to the results of the first systematic review and classical literature review, 
the herb huang qi was selected as a subject for further study. The second systematic 
review included 66 RCTs employing sole huang qi preparations with 4785 DKD 
participants. Overall, the included studies have substantial risk of bias due to 
methodological shortfalls. The meta-analysis showed that additional use of huang qi 
injection reduced albuminuria, proteinuria and serum creatinine concentration 
compared to conventional therapy alone. An anti-albuminuria effect was also reported 
in the oral huang qi preparation group. The safety of huang qi prepareations was 
uncertain because AEs were only reported in one third of included studies. More 
detailed safety evaluation particularly for huang qi injections are needed due to severe 
allergic reactions after injections have been observed.  
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Network pharmacology study 
Network pharmacology is a novel drug discovery approach that uses data from high-
throughput experiments, omics studies and other biological research and integrates and 
analyses them as a whole. It was applied to visualise and predict the complex 
relationships underlying the numerous DKD targets and multiple herbal compounds. 
 
The herb huang qi was selected for the network pharmacology study based on the 
results reported above. Searching retrieved 103 distinct human targets related to DKD. 
Thirty-eight (38) bioactive compounds from huang qi were identified, with a 
corresponding 327 targets. The huang qi–DKD PPI network contained 2269 shared 
targets, and 127 of these were considered to play central communication roles. These 
key targets were enriched in 174 biological pathways and the most significant pathways 
were integrin-linked kinase (ILK) signalling, tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) signalling, transforming growth factor beta (TGF-
β)/Smad2/3 signalling, vascular endothelial growth factor (VEGF) and VEGF receptor 
(VEGFR) signalling network and glypican/glypican-1 pathway. Further analysis of the 
herbal compounds-key targets-pathways network revealed that quercetin, calycosin, 
formononetin, kaempferol, isorhamnetin, betulinic acid, gamma-sitosterol, (24S)-24-
Propylcholesta-5-ene-3beta-ol and bifendate were directly associated with 21 key 
targets enriched in the top 10 pathways.  
 
Conclusion 
By employing a whole evidence strategy, this research systematically evaluated the 
current best available evidence about CHM as adjunctive therapy for DKD, from both 
historical and contemporary perspectives. Classical literature evidence indicated that 
huang qi was commonly used in DKD-like disorders, particularly for those presenting 
with turbid urine (cloudy or foamy urine). With moderate to low quality evidence from 
RCTs, CHM may have beneficial effects on renal function and albuminuria beyond 
those reported by conventional treatment alone in adults with DKD. Moreover, 
adjunctive use of sole huang qi preparations with RAS inhibitors appeared to lowering 
albuminuria/proteinuria, as well as reducing serum creatinine concentration in the short 
term. The pharmacological actions of huang qi could be mediated by ILK signalling, 
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TGF-β/Smad signalling, NF-κB pathway and glypican/glypican-1 pathway. Eight 
compounds with direct potential to regulate key targets are provided as new therapeutic 
development candidates for DKD. Hence, further research is warranted to determine 
their clinical benefit. 
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1 Introduction 
1.1 Background 
Diabetic kidney disease (DKD), previously known as diabetic nephropathy, is the 
foremost microvascular complication of diabetes mellitus [1, 2]. DKD is a sub-category 
of chronic kidney disease (CKD) attributed to diabetes. Both primary and secondary 
diabetes can develop DKD. It often develops in those with a long history of diabetes 
and poor glycaemic control, which results in kidney complications.  
 
DKD is a global health burden and is increasing due to the large number of people with 
diabetes. Diabetes patients who develop DKD are at greater risk of progression to end 
stage kidney disease (ESKD) and cardiovascular disease (CVD) compared to the 
general population [3, 4]. Due to its inconspicuous onset and progressive nature, DKD 
creates a large socioeconomic burden leading to significant direct and indirect costs on 
the health system and individuals. Current treatments are limited to glycaemia 
management, blood pressure control and anti-albuminuria agents of renin–angiotensin 
system (RAS) inhibitors [1, 2, 5]. An unmet need exists for novel renoprotective 
therapeutics in DKD patients who are unresponsive to current pharmacotherapies or 
those have deteriorating renal function without albuminuria. 
 
In East Asia, Chinese herbal medicine (CHM) is widely used in parallel with 
conventional therapies to treat several kinds of nephropathies [6]. Traditional Chinese 
medicine theory uses a holistic approach, and understands and treats disease with a 
different paradigm to conventional medicine. Due to the multi-component nature of 
medical plants, the herbal therapies of Chinese medicine (CM) are multi-target and 
multi-action, and do not specifically focus on one disease pathway or cellular process 
but affect the person as a whole [7, 8]. Under the pressure of the growing burden of 
DKD, CHM may be useful in the discovery and development of novel interventions to 
prevent, slow or even halt the development of DKD. 
 
The predominant “one target, one drug” paradigm of new drug discovery and 
development is challenged by the complex pathogenic nature of chronic, multi-factorial 
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diseases like DKD. Potent agents in preclinical studies often fail to show clinical 
efficacy or safety in human subjects, leading to wasted time and resources [9]. The 
conventional single target–based approach is inefficient in the field of CHM 
development as well. The chemicals and molecular mechanism of action corresponding 
to the effects of CHM are difficult to distinguish due to its multi-component naure. 
Moreover, the synergric effect of CHM is hard to elucilate at a system level in the 
conventional approach. The unclear biological mechanisms under CHM raise concerns 
regarding its effect and safety, especially in patients with kidney impairment [2, 5].  
 
With the advances of systems biology, chemistry and bioinformatics, a novel paradigm 
for new drug discovery and development named “network pharmacology” was 
proposed to solve the problem of the low productivity of traditional drug discovery [10]. 
This new pattern is capable of integrating the high-throughput data generated from 
“omics” studies, chemical experiments and other pharmacological research. 
Consequently, the complex interaction relationships among each component within the 
biological system can be clearly presented and analysed in a network manner. The 
network pharmacology approach may be helpful in CHM therapeutic development, as 
the molecular basis of herbal products can be studied in a systematic way [11]. 
 
1.2 Aims and research questions 
The aim of this research is to identify and assess historical and modern literature 
evidence regarding the use, efficacy and safety of CHM for DKD. In addition, the 
common CHM are explored via a network pharmacology method to elucidate the 
potential targets and action mechanisms for treating DKD. The research questions of 
this project are:  
 
 Which herbal formulae and individual herbs were used in historical Chinese 
medicine literature to treat DKD? 
 Is CHM effective and safe for DKD, in terms of mortality, disease progression, 
albuminuria/proteinuria excretion and kidney function? 
 What are the proposed pharmacological mechanisms of CHM for DKD? 
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1.3 Significance of the research 
Currently, conventional treatments for DKD focus on risk factor control, while renal 
protective therapies are limited. The prognosis for DKD patients is poor and they are at 
high risk of CVD and mortality, especially those who progress to ESKD. Treatments 
that prevent DKD progression will help to reduce healthcare expenditure and improve 
patients’ quality of life (QoL). With network pharmacology technology, the CHM used 
in historical Chinese medical literature and in contemporary clinical trials may provide 
leads for new drug development and therapeutic targets for future DKD research. 
 
1.4 Organisation of the thesis 
Chapters One to Three introduce the thesis.  
 
In Chapter One, the background, objectives, research questions and significance of 
this research project as well as the thesis structrure are introduced.  
 
Chapter Two provides an overview of the therapeutic development of CHM. The value 
of CHM and challenges in the development process are introduced. The conventional 
approach for new drug discovery and development is reviewed, with discussion of its 
limitations for complex diseases. A “whole evidence” strategy that combines evidence 
from historical literature, modern clinical trials and network pharmacology findings is 
proposed for therapeutic development of CHM.   
 
Chapter Three includes a review of background knowledge of DKD from both 
conventional medicine and CM perspectives. The epidemiology, burden, risk factors, 
pathogenesis, pathology, diagnosis and clinical management of DKD in conventional 
medicine are introduced. The origin, aetiology, pathogenesis and herbal treatments of 
DKD from the viewpoint of CM are also summarised. Limitations of current 
pharmacotherapies and the pressing need for more renal protective therapies are 
highlighted.  
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Guided by the “whole evidence” strategy, Chapter Four and Five include a systematic 
evaluation of historical and modern literature on DKD.  
 
Chapter Four presents the results of a text-mining method applied to systematically 
search and evaluate the use of CHM for DKD in classical CM literature. Three ancient 
terms of DKD were used and classical citations with varing degrees of relevance to 
DKD were identified from a database of 1156 classic medical books. Descriptive 
analysis was conducted to determine the dynasty distribution of citations and search 
terms. Frequency analysis was performed to determine the most commonly reported 
formulae and herbs for typical symptoms of DKD.  
 
Chapter Five includes an analysis of the efficacy and safety of CHM by means of 
systematic review and meta-analysis of randomised, placebo-controlled trials. Findings 
reported in this chapter provide clinical evidence of CHM for DKD. This systematic 
review has been published in a peer-reviewed international medical journal and the 
chapter reflects the manuscript.  
 
Evidence from Chapters Four and Five indicates that the herb huang qi (Scientific name: 
Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao) is the most 
promising treatment for DKD. Therefore, huang qi was selected as the research subject 
for Chapter Six and Seven, a systematic evaluation of evidence of clinical trials and the 
network pharmacology analysis.   
 
Chapter Six includes a systematic review and meta-analysis of huang qi as adjunctive 
therapy for DKD. Findings reported in this chapter provide clinical evidence about 
huang qi preparations for DKD. This systematic review has been published in a peer-
reviewed international medical journal and the chapter reflects the manuscript.   
 
Chapter Seven presents the results of the network pharmacology study of huang qi. 
The potential bioactive components and action mechanisms hypothesis of huang qi in 
the treatment of DKD are proposed. Further verified experiments and new drug 
candidates can be designed based on the findings of this chapter. 
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Chapter Eight includes the overall findings of the research, as well as limitations and 
future applications.  
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2 Therapeutic Development of Chinese Herbal Medicine 
2.1 Introduction 
In this chapter, the value of Chinese herbal medicine (CHM) and challenges of drug 
development from CHM are introduced. The conventional approach for new drug 
discovery, development and limitations is also included. To address current issues, a 
“whole evidence” strategy that combines evidence of classical literature and modern 
clinical trials with network pharmacology findings is proposed for therapeutic 
development of CHM.   
 
2.2 Value of Chinese herbal medicine development  
Chinese Medicine (CM) is a traditional medical system rooted in the practices of 
Chinese culture since antiquity. In the view of CM, disease is caused by the imbalance 
of two contrary yet complementary forces named yin and yang in the human body [8]. 
To restore the harmony of yin and yang, herbal remedies sourced from plants are one 
of the dominant interventions, which is known as Chinese herbal medicine (CHM). 
Dating back to the Han dynasty (AD 220), the earliest Materia Medica entitled 
Shennong’s Classic of Materia Medica 神农本草经 recorded the medical uses of 252 
herbs based on the experience of eminent CM practitioners at that time [12]. In the 
modern Chinese Pharmacopoeia, over 600 herbal medicinals are indexed and under the 
monitoring and regulation of the Chinese Food and Drug Administration, and are 
approved to be used in clinical settings in China [13].  
 
Focusing on the whole body rather than the disease itself and using herbs make CHM 
attractive to consumers. In China, CM is recognised as primary healthcare for advice 
and treatment, and is used alongside conventional (Western) medicine. It is estimated 
that almost 20% of health care services are delivered by CM hospitals, and CM 
therapies can be accessed in half of rural clinics [14, 15]. A survey from the World 
Health Organization (WHO) showed that the number of member states with herbal 
medicine regulation rose from 65 to 119 from 1999 to 2012 [16]. The export value of 
CM products in European markets increased by 19% annually, of which  80% were 
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herbal products [17]. In the Middle East, a survey conducted in Saudi Arabia showed 
that approximately 65% of patients held favourable attitudes towards herbal medicines 
[18]. In North America, up to 35% of adults received complementary therapies at least 
once a year [19]. As an important component of the Complementary and Alternative 
Medicine (CAM) system, CM therapies are popular and increasingly used and 
recognised worldwide.  
 
The extensive use of CHM in China and increasing global acceptance have raised 
research interest from academia and industry. The multi-component nature of CHM 
makes it a rich source of natural products with therapeutic potential. A survey conducted 
over 30-years showed that 34% of newly approved small-molecule drugs were sourced 
from natural products [7]. The most well-known medicine discovered and developed 
from CHM is the antimalarial drug artemisinin, which is the bioactive component 
extracted and isolated from the plant Artemisia annua L. (Chinese herb name qing hao 
青蒿) [20]. The discovery of the antimalarial effect of artemisinin and its derivates 
successfully solved the drug-resistance crisis in the 1970s and has saved thousands of 
lives worldwide. Since 2005, artemisinin-based combination therapies have been 
recommended by WHO as the most effective antimalarial therapy available so far [21].  
 
CHM is not only a chemical pool of therapeutic compounds, but also a rich source of 
therapeutic leads for single- and multiple-component drug discovery. In the prototype 
CHM library of the US National Cancer Institute, a total of 3,709 fractions were 
collected from 80 herbal species, with an average of 45 fractions per herbal sample [22]. 
Subsequent studies identified a chemical entity with anti-angiogenesis activity from 
these herbal fractions, which could be the chemical basis for a novel cancer therapy. 
According to analysis of new chemical entities approved by the US Food and Drug 
Administration (FDA) between 1981 and 2010, drugs originating from natural products 
were more diverse in chemical structures and physiochemical features than synthetic 
drugs [7]. Moreover, natural compounds occupied a larger chemical space than 
synthetic compounds and covered a different space area, representing diversity in CHM 
compounds [23, 24]. Since there are fundamental differences between natural and 
synthetic compounds, using compounds from CHM is a good strategy to enhance the 
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diversity and integrity of the chemical library for new drug screening and optimisation. 
 
2.3 Conventional approach for new drug discovery and development 
2.3.1 Conventional processes 
Therapeutic agents, commonly called drugs, are chemical substances used to treat 
diseases, to relieve symptoms or to aid diagnosis for health-maintenance purposes. 
Historically, drugs were discovered unintentionally and obtained from medical plants 
without prior knowledge of action mechanisms. With the advent of chemistry, biology 
and pharmacology, therapeutic molecules can be synthesised, driven by target-based 
hypothesis [25]. New drug discovery and development refer to the whole process from 
therapeutic target identification to new drug marketing. It is a time-consuming, costly 
and risky process which can be broken down to several phases (Figure 2-1).  
 
 
Figure 2-1 Conventional new drug discovery and development process  
Abbreviation: IND: investigated new drug. Adapted from Pharmaceutical Research and 
Manufacturers of America 2007 [26].  
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The first phase of conventional new drug discovery and development is to identify and 
validate the biological target implicated in the disease, such as a protein or nucleic acid. 
It is important to ensure that the candidate target can be modulated by drugs, with 
sufficient evidence advocating the links between the target and therapeutic hypothesis. 
The second phase is to screen and optimise chemical leads based on the knowledge of 
disease targets. In this stage, a group of bioactive compounds responding to the 
proposed targets (the “hits”) are filtered from a chemical library, then narrowed down 
by in vivo activity studies. The chemical structures of promising compounds are then 
optimised and designed to promote their “druggable” properties. Thirdly, pharmacology 
experiments are conducted for the candidate compounds to further examine their action 
mechanisms, efficacy, toxicity and pharmacokinetic features. The candidate drugs that 
pass through the above stages enter a sequence of clinical trials to test their efficacy and 
safety in human subjects as the fourth stage. Only after a drug passes through the 
clinical trials and shows salutary results, will it be reviewed by the FDA as a new 
therapeutic agent for marketing approval [25].  
 
2.3.2 Limitations of conventional approach 
It has been well recognised that the process of new drug discovery and development 
requires huge investment and close cooperation between the pharmaceutical industry, 
governments and academia. The overall cost of post-clinical research in the private-
sector was estimated at about $1.7-$2.2 billion in the 2000s, and the cost is higher in 
studies focusing on more recent periods [27]. In a survey including 10 out of the top 50 
multinational pharmaceutical firms, the total capitalised cost from clinical trials to 
approval was up to $2558 million per drug in the early 2010s. Compared to the cost in 
the 1990s, the cost of later new drug development stages increased with an 8.5% annual 
growth rate [27]. By publication analysis, a study focused on the public sector revealed 
that all 210 FDA newly approved drugs during 2010–2016 were directly or indirectly 
associated with projects funded by the US National Institutes of Health (NIH). These 
NIH-funded projects consumed $115.3 billion in total, accounting for nearly 20% of 
the whole NIH budget in the same time interval [28]. Additionally, over 90% of these 
NIH-funded projects contributed to basic experiments on drug targets rather than 
chemical entities, which are early stages of the new drug discovery process. The 
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resources needed for new drug discovery and development are so huge that investment 
from the private and public sectors is essential. 
 
Despite the high expenditure and resource input from industry and academia, the 
outputs of novel therapeutics are still unsatisfactory. Even in the top 50 pharmaceutical 
firms, the success rate of new drug approvals was as low as 7.9%–12.8% [29]. The 
average annual number of new FDA-approved drugs was 30 in the early half of the 
2000s, then reduced to 20.2 in the latter half [30, 31]. Although the mean number of 
new FDA-approved drugs has slightly rebounded to 44 since 2012, the sale value per 
drug has been slipping from $1.4 billion in 2014 to $0.9 billion in 2017 [32]. Decreasing 
projected sale values in recent years have partially resulted from the less common 
approval of first-in-class drugs, which take 20–25 years from bench to bedside [31, 33]. 
Collectively, the low productivity and enormous investments are pressing challenges 
for new drug discovery and development. 
 
To address the problems of low productivity and low success rates, effort has been made 
to investigate the reasons for the failures in new drug discovery and development. From 
2013 to 2015, there were 218 candidate drugs terminated in phase II/III clinical trials. 
The vast majority, 174 out of the 218, were terminated due to insufficient efficacy and 
safety, accounting for 52% and 24% of total failures, respectively [9]. A study based on 
data from the largest four pharmaceutical firms reported consistent findings. Of 812 
investigated compounds during 2000–2010, clinical safety was the primary cause of 
failure for phase I trials and unsatisfactory efficacy for phase II trials [34]. Clinical trials 
are only conducted after the candidate drugs have passed through the preclinical 
research phases, and failure at the clinical trial phase significantly impinges on the 
industry, considering the time and resources that have been invested. The discrepancy 
between laboratory potency and clinical efficacy/safety of candidate drugs, especially 
for multifactorial diseases, raises doubts about the conventional “one target, one drug” 
discovery pattern. 
 
2.4 Challenges of Chinese herbal medicine therapeutic development 
CHM has a long history of use and is increasingly used worldwide, but there are 
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challenges and barriers that impede the development and application of CHM. 
  
Lack of high-quality clinical evidence regarding the efficacy and safety of CHM is one 
of the most defects. There are a large number of historical books that document the 
usage, formulation, indications and contraindications of CHM. However, rigorous 
evaluation of the benefits and harms of CHM by unbiased methods is necessary but 
currently unavailable. By 2008, 42 systematic reviews with a focus on CHM were 
recorded in the Cochrane Database of Systematic Reviews. Of these CHM reviews, 55% 
reported that there were no or insufficient good-quality trials to support the use of CHM. 
Among the other 19 reviews that suggested possible benefits of CHM, 26% made 
conclusions based on individual trials instead of meta-analysis. The poor 
methodological quality and high heterogeneity in the majority of included trials made 
the conclusions in favour of CHM less convincing [35]. The numbers of published 
systematic reviews and registered clinical trials of CHM have grown substantially since 
2008, but pitfalls in trial design, protocol transparency, search integrity and report 
quality have reduced the trustworthiness and translation of these CHM evidence into 
clinical practice [36, 37].   
 
Unclear chemical compositions and action mechanisms are another recurring criticism 
received during development and application of CHM [38]. As mentioned earlier, the 
compounds that constitute medical plants including CHM are complex. In addition, 
chemical compositions of raw herbs may vary due to different origins, harvest seasons 
and manufacturing procedures [39-41], not to mention that CHM is mostly prescribed 
in the form of multi-ingredient formulae, whereby several herbs are cooked and taken 
together to achieve synergistic effects. The typical “one disease, one target, one drug” 
paradigm is difficult to align with the theory of CM in order to identify the herbal 
compounds corresponding to specific therapeutic effects and to fully elucidate the 
pharmacological mechanism of CHM. Novel and advanced approaches addressing the 
features of CHM are needed to close the knowledge gap between traditional practice 
and modern pharmacology. 
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2.5 Whole-evidence strategy for Chinese herbal medicine development 
CHM has been practised for thousands of years, with large amounts of classical 
literature that records the clinical observation of eminent doctors in ancient times. 
However, rigorous evaluation of efficacy and safety is required for all types of clinical 
interventions, including CHM. Unclear bioactive components and action mechanisms 
are the foremost obstacles for CHM assessment and development. Therefore, a “whole 
evidence” strategy that combines evidence from historical literature and contemporary 
clinical trials with network pharmacology findings is proposed for CHM development 
[42]. 
 
2.5.1 Evidence from historical literature 
CHM and other medical plants are now largely treated as sources of chemical 
compounds. However, the value of traditional use of CHM to guide new drug discovery 
and development has been neglected. Traditional use of CHM is a type of empirical 
knowledge formed and repeatedly tested over generations. Nowadays, traditional 
knowledge is still used to guide CM clinical practice. The selection of herbal candidates 
for drug discovery can be informed by the traditional use of herbs, saving time and 
resources by narrowing scope [43].  
 
Traditional use of herbs for specific diseases can be identified by systematic searching 
of the classical CM literature. Topics covered in historical literature include medical 
theory, Materia Medica, prescriptions (formulae) and case records. During the 
development of artemisinin, the breakthrough low-temperature extraction procedure 
was inspired by an ancient text description on how to deal with the raw herb [20]. The 
nephrotoxicity of CHM containing aristolochic acids could have been realised earlier if 
related historical literature regarding traditional use of herbs had been reviewed [44]. 
Thus, traditional knowledge of CHM, as an alternative evidence source, should be 
encouraged in new drug discovery and development, particularly evidence suggesting 
that the same herbs were used in different regions or are still in use in contemporary 
clinical practice [45].   
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2.5.2 Evidence from clinical trials 
From the perspective of evidence-based medicine (EBM), medical interventions should 
be carefully examined, regardless of whether they are conventional medicine or CAM. 
Evidence generated from clinical trials is ranked at a higher level than that from 
experimental studies due to the substantial interspecies differences [46]. Among 
different types of clinical trials, randomised controlled trials (RCTs) have been labelled 
the “gold standard” for evaluating the benefits and harms of tested therapeutics [47]. 
The prospective randomised allocation and comparative group design of RCT minimise 
the risk of bias of measurements, which makes it the most reliable approach to 
demonstrate the causation relation between interventions and treatment outcomes. 
  
As the concept of EBM was introduced to the field of CM, the number of clinical trials 
investigating CM therapies has increased in the last few decades. Data from the largest 
clinical trials registry, ClinicalTrial.gov, indicates that the number of registered CM 
trials was 95 in 2000–2005 and jumped to 779 in 2010–2015. Of the 1270 registered 
CM clinical trials, 86.5% had randomised designs and 80.2% had comparator settings 
[37]. It should be noted that the molecular bases and action mechanisms of these CM 
therapies are largely unclear. 
 
As CHM is already widely used, it is suggested that clinical trials can be the starting 
point in the new drug discovery pipeline of CHM (Figure 2-2). In this efficacy-based 
approach, in vivo and in vitro studies are conducted after the efficacy and safety of CHM 
are confirmed in RCT with the purpose of monitoring chronic toxicity, identifying 
active components, clarifying action mechanisms and improving preparations [48]. It 
appears that the results of good-quality RCTs were still recognised as solid evidence 
even though their molecular and pharmacological bases were not fully understood. The 
efficacy-based approach can identify ineffective and/or toxic herbal therapies much 
earlier, saving time and resources spent on herbal remedies doomed to fail.  
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Figure 2-2 Comparison of the conventional mechanism-based approach and CHM 
specific efficacy-based approach  
Adapted from Tang JL 2006 [48]. 
 
2.5.3 Exploring action mechanisms using network pharmacology 
2.5.3.1 Network features of biology systems  
Biology systems refer to a group of interrelated biological objects that function together 
to maintain homeostasis. Biological systems can be viewed at several scales, spanning 
the micro scale of cells to the macro scale of organism populations. Within a biological 
system, no matter whether a yeast or a human body, the biological components are 
numerous and interdependent. Recent advances in systems biology reveal an abundance 
of biological components and the complexity of their interactions, which are 
represented in a network manner [49]. In a biological network, the “nodes” are used to 
represent molecules, cells, diseases or individuals and the “edges” connecting nodes 
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represent an interaction relationship [50]. According to the composition and function, 
there are several types of networks in biological systems, including protein–protein 
interaction (PPI) networks, gene regulatory networks, signalling networks and 
metabolic networks [49, 51]. All these networks are interrelated and work together to 
maintain biological function. 
 
The network feature lead to discovery of the “scale-free” and robust properties of the 
biological system, which were not revealed in previous studies focusing on individual 
genes or molecules [50, 52]. In a “scale-free” network, a small proportion of nodes have 
more connections and higher centrality than most of the nodes. These functionally 
important but small number of nodes are defined as the “hubs” (Figure2-3). Due to the 
scale-free network structure, biological systems can remain intact even when some 
nodes (but not the hubs) are randomly removed. These properties were confirmed by 
the Genome 5000 projects, which found that only 10% of knockout druggable genes 
resulted in therapeutic relevant phenotype changes [53]. In other words, the biology 
networks are robust as long as the hubs remain unchanged. 
 
 
 
Figure 2-3 Sample of scale-free network 
Note: The dark nodes represent the hubs and the white nodes represent common 
components. Adapted from Seo H et al. 2013 [54]. 
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2.5.3.2 Network Pharmacology as an alternative therapeutic development 
approach 
The findings of the scale-free nature and robustness of biological networks provide 
fresh perspectives regarding diseases and new drug discovery, potentially eliminating 
the failure of clinical efficacy and unexpected safety issues with traditional drug 
discovery. Conventionally, new drug discovery is based on the hypothesis of the single 
most important target mechanism; therefore, the drug is a highly selective ligand that 
fits the “disease-causing” target. In contrast, from the view of network biology, diseases 
are perturbed state of normal biological networks involving changes in a set of key 
molecules. Absence, overexpression or dysfunction of single key molecules or groups 
of key molecules can cause diseases by damaging network integrity. Disease can also 
result from the misregulation, misdirection or inappropriate strength of interactions 
between the hub components in biological networks [50, 51]. Considering the 
robustness of biological networks, desired efficacy can only be achieved when a 
candidate drug modulates the therapeutic hub target(s) and restores the normal network. 
Moreover, the candidate drug should have little or no effects on other key targets within 
the same network in order to avoid undesired effects. Guided by the above knowledge, 
a new paradigm for drug discovery entitled “network pharmacology” was proposed by 
Andrew Hopkins in 2008 [10]. 
 
The network pharmacology approach has been widely used to accelerate and to 
optimise the preclinical stages of new drug discovery and development processes. 
Firstly, biology networks enable the integrated representation of genomics, proteomics, 
metabolomics and interactome information, so the functions of individual molecules 
can be assessed in a system-level context. The network analysis approach is capable of 
identifying the functionally important targets from the large number of biological 
components, reducing the risk of picking irrelevant targets for further study [51]. One 
example is the ErbB3 as a cancer therapeutic target which was discovered by 
computational analysis of the ErbB receptor signal network, leading to development of 
a novel anticancer human monoclonal antibody, MM-121 [55]. In the chemical leads 
screening and optimisation stage, the pharmacokinetic properties, toxicity and action 
targets of new chemical entities can be predicted by network pharmacology approaches, 
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therefore expanding the chemical libraries and accelerating the drug discovery process 
[51].    
 
2.5.3.3 Chinese medicine network pharmacology 
The foundational hypothesis of network pharmacology, “multi-targets, multi-
component therapeutics”, is highly consistent with the holistic approach of CM. To 
decode the complex action mechanisms of multi-component interventions like CHM, 
network pharmacology may be helpful. Multilevel data about components and 
interactions underlying biological processes can be incorporated and analysed by 
network pharmacology approaches. In fact, before the concept of network 
pharmacology was more widely accepted, a network-based CM research framework 
was already proposed by Li et al., subsequently developed as a new research area of 
Traditional Chinese Medicine (TCM) network pharmacology [11, 56]. 
 
With the framework of TCM network pharmacology, four general steps are involved to 
reveal the molecular basis and potential action mechanisms of herbs (Figure 2-4) [11]. 
The first step is to identify gene and genes products contributing to specific diseases, 
and to construct a disease-specific molecular network based on the biomolecular 
interaction relationships. Meanwhile, the chemical compounds contained in each herb 
are collected and the target network of these compounds is built based on experimental 
data and/or in silico prediction. Lastly, the herbal target network is mapped to the 
disease-specific network, followed by qualitative and/or quantitative analysis of 
molecular interactions to identify the significant bioactive compounds and the hub 
targets. Potential action mechanisms can then be proposed according to the functional 
analyses results of the hub targets and further verified by experiments. 
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Figure 2-4 Research framework of CM network pharmacology for herbal therapy  
Adapted from Li et al. 2012 [11]. 
 
Since network pharmacology has been employed in the field of CM, the bioactive 
components and action mechanisms of several commonly used herbal therapies have 
been elucidated. For instance, 19 compounds contained in Ge gen qin lian (GGQL), a 
CHM formula, were identified as the bioactive components contributing to its anti-
diabetic properties. According to the network analysis, these GGQL bioactive 
compounds were likely involved in regulating multiple type-2 diabetes biological 
processes, including glucose homeostasis, glucose transport and glucose metabolism. 
Subsequently, an in vitro study verifed that one of these GGQL bioactive compounds, 
4-hydroxymephenytoin, can stimulate insulin secretion, improve insulin resistance and 
increase glucose consumption [57]. In the same research framework, the bioactive 
components and action targets of the Ma zi ren wan formula for functional constipation, 
Ma xing shi gan decoction for asthma, Angelica sinensis for acute myocardial infarction 
(AMI) and others have been successfully deciphered [58-60].  
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2.6 Summary 
CHM has a long history of use in China and is increasingly used worldwide. Due to its 
multi-component nature, CHM is a significant source for novel chemical compounds 
with therapeutic potential. However, the development and application of CHM are 
impeded due to a lack of clinical evidence, complex chemical profiles and unclear 
action mechanisms. These issues cannot be addressed by the conventional new drug 
development paradigm of “one disease, one target, one drug”. Therefore, a “whole 
evidence” strategy that integrates evidence from traditional use documented in 
historical CM literature, contemporary clinical trials and network pharmacology 
findings is proposed for CHM development. 
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3 Overview of Diabetic Kidney Disease 
3.1 Introduction 
This chapter presents an overall background to diabetic kidney disease (DKD), 
including up-to-date knowledge of epidemiology, risk factors, pathology, pathogenesis 
and clinical management. 
 
DKD is the foremost microvascular complication of diabetes mellitus [1, 2]. It is a sub-
category of chronic kidney disease (CKD) caused by diabetes, with unique features 
compared with other CKD aetiologies. Both insulin-dependent (type 1) and non-
insulin-dependent diabetes (type 2) can develop DKD. It often develops in those with 
long-term diabetic history and poor glycaemic control, which results in kidney 
complications. The primary clinical feature of DKD is persistent 
albuminuria/proteinuria and progressive loss of kidney function. The typical 
pathological changes include mesangial expansion, basement membrane thickening 
and glomerular sclerosis.  
 
3.2 Prevalence and burden 
The prevalence of renal damage (defined as albuminuria or declined glomerular 
filtration rate) in diabetic populations is reported to be between 12.3% and 70% [61, 
62]. The variable DKD prevalence could be due to differences in study locations, study 
subjects, research dates etc. A global cross-sectional study including 24,151 type 2 
diabetic patients from 33 countries indicated that 49% were comorbid with albuminuria 
[63]. In a prospective study in the UK, the prevalence of albuminuria among the 5000 
participants was 30.2% ten years after of diagnosis of type 2 diabetes [64]. Similar 
stable prevalence was observed in the USA (27%) and Norway (31%) despite more 
frequent use of glycaemic-control medications and renin–angiotensin system (RAS) 
inhibitors during the past two decades [65-67]. 
 
Although the prevalence of DKD has been stable in some regions in recent years, the 
epidemic magnitude of diabetes still poses a global healthcare challenge. By 2045, it is 
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estimated the prevalence of diabetes will be 9.9%, equalling about 628 million people 
worldwide [68]. Moreover, the majority of newly diagnosed cases are from developing 
countries and areas with large populations but limited healthcare resources, such as 
China, India Africa and Latin America [69]. Currently, nearly 50% of type 2 diabetic 
patients in India are diagnosed with CKD and 20% of Chinese diabetic patients already 
suffer from significant CKD [70, 71]. Even more concerning, the number of patients 
with DKD is rising in both hospital and general populations in China, which makes 
DKD the leading cause of kidney disease [72]. The increasing prevalence of DKD is 
also reported in North America among people with glomerular diseases [73]. If the trend 
continues, the prevalence of DKD is very likely to grow, leading to greater demands on 
healthcare resources [74].  
 
The health burden of DKD is heavy, largely due to the close relationship between DKD, 
CVD and the development of ESKD. Diabetes has been the leading cause of ESKD in 
developed countries for decades [74, 75]. It accounts for approximately 45% of new 
dialysis patients in the USA, 37% in Australia and 43% in Japan [75-77]. Both patients 
with DKD and those with ESKD are at higher risk of mortality than the general 
population and CVD is the primary cause of death [78-80]. For DKD patients secondary 
to type 2 diabetes, fatal events are more likely to happen even before the progression to 
ESKD [81]. 
 
In North America, medical costs for patients with CKD and diabetes rose 70.2% 
between 2008 and 2012, nearly $25,000 per patient-year, while similar costs for patients 
without CKD, diabetes or chronic heart failure (CHF) increased by only 4.1% [4]. In 
Australia, DKD accounts for a substantial economic burden. The annual cost for renal 
replacement therapy was almost three times the cost for acute CVD [82]. The total 
direct health care costs reach almost $1 billion per annum for early stage DKD and 
$300 million for ESRD patients. 
 
3.3 Risk factors 
Predisposing genetic features, gender, ageing, ethnicity and a family history of diabetes 
are irreversible risk factors for DKD. Several meta-analyses indicate that susceptibility 
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to DKD is related to polymorphism in the angiotensin-converting enzyme (ACE) gene, 
methylenetetrahydrofolate reductase gene and endothelial nitric oxide synthase gene 
[83-85]. But the identified genetic variants can not fully explain the family cluster 
phenomenon of DKD. Male diabetes patients seem to be more susceptible to DKD, but 
the sexual difference could be the result of inconsistent definitions of DKD. In the UK 
Prospective Diabetes Study (UKSPD), male sex was the independent risk factor for 
albuminuria while females were at greater risk of a low glomerular filtration rate (GFR) 
[86]. African-Americans are more likely to develop DKD and the rate of renal function 
decline is accelerated in Indo-Asians more than other ethnic groups [87, 88].  
 
Hyperglycaemia is a widely recognised risk factor for DKD which plays a major role 
in both disease initiation and progression. Long duration of diabetes, poor control of 
glycaemia, insulin resistance and advanced glycation end products are all closely 
associated with DKD [89, 90]. Thus, blood glucose management is crucial for diabetes 
patients to prevent and defer DKD progression. Hypertension and dyslipidemia are also 
putative risk factors for DKD, irrespective of type 1 or type 2 diabetic status [86, 91]. 
These three risk factors constitute the cornerstone of DKD management strategy.  
 
Modifiable risk factors of DKD in terms of lifestyle include smoking, low physical 
activity and high salt intake [89, 90, 92]. In addition, anaemia, a procoagulant state, 
obesity, an inflammation state, endotoxins, vitamin D deficiency and 
hypomagnesaemia may also be risk factors for DKD [89, 90, 93, 94].  
 
3.4 Pathogenesis 
The pathogenesis of DKD is complex and not completely understood. Hyperglycaemia 
is confirmed as a prerequisite for the development of DKD which is compounded by 
subsequent haemodynamic alterations [95, 96]. The cascades induced by metabolic and 
haemodynamic pathways, including oxidative stress and inflammation, overlap, 
interact and feed back to the two main pathways, leading to the development of DKD.  
 
High blood glucose triggers the initiation of DKD via several pathways: non-enzymatic 
glycosylation, which generated advanced glycation end products (AGEs); activation of 
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the protein kinase C (PKC) pathway; acceleration of the aldose reductase (polyol) 
pathway; and stimulation of the hexosamine pathway [97]. As a result, pathological 
products accumulated from the above processes induce oxidative stress and the release 
of pro-inﬂammatory and pro-fibrotic mediators, accelerating the development of DKD 
[98, 99].  
 
From the haemodynamic aspect, the alternation in the glomerular haemodynamic is the 
result of RAS activation, which is mainly triggered by increased angiotensin II and 
upregulated expression of endothelial-1 [96]. Prostanoids, nitric oxide and TGF-β1 
induced by hyperglycaemia contribute to the change in arteriole resistance in glomeruli 
[95]. As the glomerular afferent arterioles dilate, the efferent arterioles constrict and the 
inter-glomerular pressure increases, resulting in hyperfusion and hyperfiltration. The 
enforced intra-glomerular mechanical strain stimulates the release of cytokines and 
growth factors, overlapping with metabolic and other pathways again [95, 100].  
 
Abnormal metabolic, haemodynamic and subsequent oxidative stress and inflammatory 
processes eventually lead to functional and structural changes in the kidneys. Both 
proliferation and hypertrophy are observed in mesangial cells, together with 
overproduction of extracellular matrix expansion in the mesangial area. In addition, 
mesangial cells take part in maintaining the normal structures of glomerulus vasculature. 
The abnormality of mesangial cells and vascular endothelial damage in the glomerulus 
are associated with nodule lesion formation. In addition to the damage in the glomerulus, 
the fibrotic cytokines, growth factors and inflammatory mediators also cause fibrotic 
lesions in the tubule-interstitial. Podocyte loss and impaired integrity are also observed 
[89]. All these pathogenic processes and structural changes occur before the clinical 
manifestations of excess albuminuria and declining GFR.  
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Figure 3-1 Pathogenesis of DKD 
Abbreviations: GBM: glomerular basement membrane; RAS: renin-angiotensin 
system; ROS: reactive oxygen species.  
 
3.5 Pathology 
Renal biopsy often shows structural changes in the kidneys of people with DKD before 
clinical manifestations such as increased albuminuria (formerly termed 
microalbuminuria). The predominant histologic changes in the glomeruli in DKD are 
mesangial expansion, glomerular basement membrane thickening and glomerular 
sclerosis [101, 102]. In some cases, the glomerular sclerosis may manifest the 
characteristic nodular appearance named “the Kimmelstiel-Wilson lesion (K-W 
nodules)” [103]. The US Renal Pathology Society developed a classification for DKD 
in 2010, in which glomerular lesions were defined and the severities of interstitial and 
vascular lesions were scored (Table 3-1) [104].  
 
Although this pathological classification of DKD was reported to have good 
reproducibility, its clinical utility has not been fully clarified. Associations between 
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pathological classifications and the renal endpoint events, such as initiation of renal 
replacement therapy, progression to ESKD or doubling of serum creatinine, were 
investigated in two Chinese studies with similar designs. Both studies indicated that the 
severity of glomerular lesions was closely related to the renal outcomes, while the 
interstitial inflammation was not an independent predictor. Conflicting results were 
found regarding the levels of interstitial fibrosis and tubular atrophy [105, 106]. In order 
to improve the prediction of renal survival based on the pathological findings, an overall 
pathological risk score (D-score) was developed, but its validity still needs to be 
examined in diverse populations [107]. 
 
Table 3-1 Renal Pathology Society classification of DKD 
Glomerular lesions  
Class I Isolated glomerular basement membrane thickening. Basement membranes >430 
nm in males (>age 9) and 395 nm in females.  
No evidence of mesangial expansion, increased mesangial matrix or global 
glomerulosclerosis involving >50% of glomeruli. 
Class II Mild (class IIa) or severe (class IIb) mesangial expansion.  
A lesion is considered severe if areas of expansion > the mean area of a capillary 
lumen are present in >25% of the total mesangium. 
Class III At least one Kimmelstiel–Wilson lesion (nodular intercapillary 
glomerulosclerosis) is observed and <50% global glomerulosclerosis. 
Class IV Advanced diabetic sclerosis. There is >50% global glomerulosclerosis. 
Interstitial and vascular lesions 
Interstitium 0: no areas of IFTA; 1: areas of IFTA <25%; 2: areas of IFTA 25–50%; 3: areas 
of IFTA >50%. 
Immunocyte 
infiltrate 
0: no T lymphocytes or macrophage infiltrate present.  
Scores of 1 or 2 are assigned if infiltrate is limited to the area surrounding atrophic 
tubules or if infiltrate is not limited, respectively. 
Vascular Scores of 0, 1 or 2 are assigned if no arteriolar hyalinosis, one arteriole or more 
than one arteriole with hyalinosis is present. 
The most severely affected arteriole is assigned a score of 0, 1 or 2 if there is no 
intimal thickening, intimal thickening < thickness of the media or intimal 
thickening > thickness of the media. 
Abbreviations: IFTA: interstitial fibrosis and tubular atrophy. Adapted from Tevaert et 
al. 2010 [104]. 
 
3.6 Diagnosis 
DKD is asymptomatic in the early stages and usually identified when patients are 
assessed for diabetes. In advanced DKD, physical examination may reveal hypertension, 
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oedema or symptoms of other diabetic complications such as blurry vision and 
numbness in the extremities. In patients who develop advanced DKD, ESKD symptoms 
of uremia may be the chief complaint [108].  
 
In cases with an unclear diagnosis or when other causes of CKD are suspected, renal 
biopsy can be used to definitively diagnose diabetic glomerulopathy. However, in 
patients with type 2 diabetes and microalbuminuria, 30% of them may have normal or 
near-normal biopsy results [2]. In order to distinguish kidney diseases from other 
underlying causes in the diabetic population, the term DKD, instead of diabetic 
nephropathy, is applied as a presumptive diagnosis of kidney disease caused by diabetes. 
Meanwhile, the term ‘diabetic glomerulopathy’ is reserved for biopsy-proven kidney 
disease caused by diabetes [2]. 
 
The clinical diagnosis of DKD is based on abnormal urinary albumin excretion and 
diabetic history [2]. Albuminuria is the early indicator of DKD, and is categorised as 
microalbuminuria and macroalbuminuria. In individuals with diabetes and showing 
macroalbuminuria, with or without microalbuminuria, plus diabetic retinopathy, this 
indicates a probable diagnosis of DKD. In addition, individuals with type 1 diabetes for 
at least 10 years who present with microalbuminuria were considered to have DKD [2]. 
In the recent Chinese guideline, the diagnostic criteria was modified so that diabetes 
patients with diabetic retinopathy and any stage of CKD will be considered to have 
DKD [109]. This modification was made to avoid misdiagnosis of those with declined 
eGFR (estimated GFR) but without albuminuria.  
 
Excretion of albuminuria can be measured differently including a spot test of the urinary 
albumin-creatinine ratio (ACR) or a timed test of the urinary albuminuria excretion rate 
(UAER). Infections, fever, recent vigorous exercise and other factors could falsely 
elevate albumin excretion; therefore, they need to be differentiated. Abnormal increase 
of urinary albumin excretion is defined as over 30 mg/g creatinine measured by ACR 
or over 20 µg/min by UAER (Table 3-2). Although the terms ‘microalbuminuria’ and 
‘macroalbuminuria’ have been widely used to indicate disease severity, it should be 
noted that these cut-off points are arbitrary. Changes of albuminuria level within either 
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normal or abnormal ranges are associated with risk of cardiovascular events and renal 
function loss, due to its continous nature [1].  
 
Table 3-2 Abnormality of albumin excretion 
Category Spot collection  
(mg/g creatinine) 
24-hour collection 
(mg/24h) 
Timed collection 
(µg/min) 
Normal <30 <30 <20 
Microalbuminuria 30-300 30-300 20-200 
Macroalbuminuria >300 >300 >200 
References: [2, 5] 
 
Along with quantitative urinary albumin assessment, serum creatinine should be 
measured to estimate the GFR. Although albuminuria is an early indicator of DKD, 
studies have found a substantial percentage of type 2 diabetes patients with decreased 
eGFR without increased urinary albumin excretion. Therefore diabetes patients with 
declining GFR, especially those accompanied with diabetes retinopathy, after excluding 
other underlying causes of kidney disease, would be considered to have impaired 
kidney function due to DKD [109].  
 
Since the number of people with diabetes is large and albuminuria can be seen in several 
conditions, other underlying causes of kidney diseases in diabetic patients should be 
taken into consideration when making a diagnosis, especially in the following 
circumstances: 
 Absence of diabetic retinopathy 
 Low or rapidly decreasing GFR 
 Rapidly increasing proteinuria or presence of nephrotic syndrome 
 Refractory hypertension 
 Presence of active urinary sediment 
 Signs or symptoms of other systemic disease; or 
 >30% reduction in GFR within 2–3 months after initiation of angiotensin-
converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) 
medications. 
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Evidence from a systematic review of 48 studies suggested that non-diabetic renal 
disease (NDRD) and mixed forms of DKD and NDRD are commonly seen in diabetic 
patients [110]. It should be noted that judgements based on history and clinical 
parameters alone may lead to misdiagnoses. To preclude other potential diseases, renal 
biopsy should be considered.  
 
3.7 Treatment and management 
3.7.1 Non-pharmacotherapies 
Lifestyle modification is one of the cornerstone interventions in the management of 
both diabetes and DKD. Smoking cessation is recommended to prevent DKD 
progression [2, 109]. At least 150 minutes of moderate-intensity physical activity per 
week benefits the non-dialysis DKD population, but adverse events induced by 
inappropriate sports should be avoided by making an individualised sports plan [109]. 
Obesity is a potential promotor for DKD deterioration, thus DKD patients are 
recommended to maintain their body mass index (BMI) in the normal range [2]. 
  
Diet modification includes reducing salt intake to reduce hypotension [111]. As for 
daily protein intake, the recommended daily allowance (RDA) is 0.8 g/kg body weight 
for diabetic patients with CKD stage 1–4 and higher levels for those on dialysis [1]. 
There were reports of kidney function improvement with an extremely low protein diet 
(0.6 g/kg bodyweight) in the DKD population, but the benefits for renal outcomes and 
nutrition status need more evidence [112, 113].  
 
3.7.2 Pharmacotherapies 
Current treatment strategy for DKD is mainly focused on the primary disease (diabetes) 
and risk factor management. In addition, the discovery of renal-protective effects of 
RAS inhibitors and their wide application have significantly reduced the incidence and 
progression of DKD among diabetic populations. Yet effective therapies to prevent or 
stop DKD deterioration are still limited, especially medications restoring kidney injury. 
Novel agents targeting specific pathogenesis pathways of DKD have been developed, 
some of which have failed and others require further testing. 
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3.7.2.1 Glycaemia control 
As the primary initiator and promotor, hyperglycaemia is the putative treatment target 
of DKD. It has been confirmed by several large-scale clinical trials with five to ten 
years of follow-up that diabetes patients with lower glycaemic levels are less likely to 
develop albuminuria and ESKD [114-116]. The benefits of tight glycaemic control 
persisted after the termination of intervention, known as metabolic memory [117].  
 
However, higher death rates were observed in the more intensive glycaemic control 
group (targeting haemoglobin A1c [HbA1c] at 6%) in the Action to Control 
Cardiovascular Risk in Type 2 Diabetes (ACCORD) trial [118]. Compared to less 
intensive glycaemic control, pooled analysis showed stringent glycaemic control had 
no benefits in decreasing risk of important clinical outcomes such as ESKD, death and 
major CVD [5]. As a result, a target HbA1c of around 7% was suggested for diabetes 
patients [5]. Meanwhile, individualised glycaemic targets are recommended to optimise 
blood glucose management, particularly in the elderly, patients with limited life 
expectancy and those at risk of hypoglycaemia [1, 5].  
 
Since some classes of hypoglycaemia drugs are metabolised or directly excreted by the 
kidneys, hypoglycaemia agents for patients with kidney impairment should be 
cautiously selected [119, 120]. For example, the first-line hypoglycaemia medicine 
metformin should be used under close monitoring in patients with eGFR less than 45 
mL/min and is contraindicated once eGFR drops below 30 mL/min due to the risk of 
lactic acidosis resulting from impaired renal function [121]. The second generation 
sulfonylureas, which are the alternative first-line medication for type 2 diabetes, should 
also be avoided in people with eGFR <45 mL/min. Only pioglitazone, rosiglitazone and 
insulin require no dose adjustment in DKD patients [119, 120].  
 
There are some new glucose-lowering agents that appear to be renal protective 
independent of hypoglycaemia pathways, including dipeptidyl peptidase-4 (DDP-4) 
inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose co-
transporter 2 (SGLT2) inhibitors. Both DDP-4 inhibitors and GLP-1 receptor agonists 
are incretin-based therapies and show anti-albuminuria properties [122-124]. But the 
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evidence of incretin-based therapies in terms of renal clinical outcomes is contradictory. 
Meta-analysis of RCTs with treatment duration longer than 12 weeks favoured GLP-1 
receptor agonists compared to placebo to prevent incident nephropathy in type 2 
diabetes patients, while pooled results of RCTs with 200 or more participants suggested 
no difference regarding DKD onset [125, 126]. For DKD patients with substantial renal 
injury, it is unclear whether incretin-based therapies affect the progression to ESKD 
[127].  
 
As for SGLT2 inhibitors, both canagliflozin and empagliflozin decreased by about 40% 
the risk of renal endpoints, such as initiation of renal replacement therapy, doubled 
levels of serum creatinine and renal deaths in individual large-scale placebo-controlled 
trials [128, 129]. But it should be noted that all these trials only enrolled type 2 diabetic 
patients with substantial risk of CVD and the renal effect was analysed as a secondary 
outcome. Additionally, a higher risk of amputation with canagliflozin raised safety 
concerns. Whether SGLT2 inhibitors can prevent or retard the progression of DKD and 
their safety profile still needs further study with kidney-related primary outcomes.  
 
3.7.2.2 Blood pressure control  
Hypertension is commonly seen in diabetes patients and plays an important role in the 
development and deterioration of DKD. In type 2 diabetes patients who failed to 
maintain blood pressure (BP) less than 140/85 mmHg, the risk of incidence of DKD 
was 38% higher than for those who achieved target BP [130]. In diabetes patients with 
established DKD, the risk of ESKD and the rate of eGFR decline progressively 
increased as mean systolic BP rose from 120 to 150 mmHg and dialytic BP rose from 
80 to over 90 mmHg [131]. Meta-analysis showed an association of every 10 mmHg 
decrease in systolic BP with a 13% and 17% risk reduction in death and albuminuria in 
type 2 diabetes patients with baseline BP over 140 mmHg [132]. But the benefits of 
aggressive BP lowering strategies, especially in normotensive diabetes patients, remain 
controversial [133]. Thus, a relatively conservative treatment BP target of less than 
130/80 mmHg and tailored according to individuals’ CVD and renal risks is 
recommended in current guidelines [1, 2].  
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As for hypotensive agents for the DKD population, the RAS blockages of either ACEi 
or ARB are the putative drug of choice [1, 5]. Systematic reviews suggested a 20% risk 
reduction of ESKD in DKD patients treated with ARB and 20–30% lower risk of 
doubling serum creatinine in those received either ACEi or ARB therapy [134, 135]. In 
diabetes patients without renal injury, there was evidence that ACEi was superior to 
placebo in terms of preventing the onset of albuminuria and reducing the risk of death, 
irrespective of hypertension [136]. In addition, the renoprotection of ACEi and ARB 
was independent of its hypotensive properties, and may be mediated by reducing 
urinary albumin leakage, thus preventing the subsequent cascade reaction. A network 
meta-analysis comparing the efficacy and safety of different classes of hypotensive 
agents as treatment for DKD, and the ARB monotherapy or combination used of ACEi 
and ARB were showed to have the greatest benefits regarding the outcome of 
progression to ESKD [134].  
 
Although the discovery of extra renoprotective properties of ACEi and ARB was a 
major step forward in the treatment of DKD, limitations exist in the use of RAS 
inhibitors. Serval RCTs were conducted to evaluate the efficacy and safety of dual 
blockage in RAS in combination with use of ACEi and ARB. Unfortunately, the 
combination therapy not only increased the risks of death, dialysis and doubling of 
serum creatinine, but also had more adverse events, including hypotension, 
hyperkalemia and acute kidney injury [137, 138]. As a result, this combination strategy 
is not recommended clinically [139, 140].  
 
After the failure of the combination of ACEi and ARB, the add-on effect of a more 
complete RAS inhibitor, the direct renin inhibitor (aliskiren), together with ACEi or 
ARB was examined. Aliskiren combined with losartan decreased albuminuria more 
than losartan alone, and was independent of blood presure lowering effect [141]. 
However, the later Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal 
Disease Endpoints (ALTITUDE) trial including 8,000 DKD participants was 
prematurely terminated due to more adverse events and higher incidences of stroke in 
the aliskiren plus ACEi or ARB arm [142] and no additional renal benefit effect was 
observed in the combination therapy group. A systematic review suggested the risk of 
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hyperkalaemia was 58%–67% higher when adding aliskiren to ACEi or ARB than 
monotherapy, regardless of whether hypertensive patients had diabetes [143].  
 
Except for the direct renin inhibitors ACEi and ARB, the mineralocorticoid receptor 
antagonists (MRA) are the remaining agents with RAS manipulation effect (Figure 3-
2). For those already on ACEi or ARB, the ‘aldosterone escape’ was observed and it 
was considered to be responsible for the suboptimal therapeutic effect [144]. Therefore, 
both steroidal (spironolactone and eplerenone) and non-steroidal (finerenone) MRA 
have been tested to assess their effect and safety in the DKD population based on other 
RAS inhibitors. A systematic review including 15 RCTs of spironolactone, two RCTs 
of eplerenone and one RCT of finerenone showed lower albuminuria levels in the 
adjunctive MRA group, but no differences in eGFR compared to ACEi or ARB alone 
[145]. Moreover, the risk of hyperkalaemia was significantly increased in the MRA arm. 
In a pilot RCT of the non-steroidal MRA finerenone, it appeared to be tolerated in DKD 
patients with moderately impaired renal function (40% of participants with baseline 
GFR <60mL/min) and it reduced albuminuria in a dose-dependent manner [146]. 
Further studies to validate these findings are ongoing.  
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Figure 3-2 The renin-angiotensin system (RAS) and related inhibitors 
Abbreviations: ACE: angiotensin-converting enzyme; ARB: angiotensin receptor 
blockers; MRA: mineralocorticoid receptor antagonists. Note: The solid lines represent 
activated effect and the dotted lines represent inhibited effects. 
 
3.7.2.3 Dyslipidaemia management 
Albuminuria, declined eGFR, diabetes and dyslipidaemia are all strong, independent 
risk factors for CVD [147, 148]. In cases of DKD, risk of cardiovascular events is much 
higher than for general population. A substantial number of DKD patients prematurely 
die even before progressing to ESKD. In current guidelines, the initial goal of lipid-
lowering therapy is to reduce the risk of cardiovascular events in this high-risk subgroup 
[5, 149].  
 
Association between dyslipidaemia and incident albuminuria or declined renal function 
in either type 1 or type 2 diabetes patients is supported by recent research [150, 151]. 
However, it is still unclear if lipid-lowering therapy is valuable for this group of patients. 
Systematic reviews show that statin therapy has positive effects on reducing 
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albuminuria excretion, but no difference on eGFR or serum creatinine versus placebo 
and limited evidence regarding renal clinical outcomes [152, 153]. In addition to 
systematic alternations of lipid profiles, there is accumulating evidence that abnormal 
lipid metabolism also contributes to DKD [154]. The role lipids play in the development 
and progression of DKD still needs further investigation.  
 
3.7.3 Novel therapies 
Novel therapeutic strategies which aim to address the underlying pathogenesis and 
potential risk factors of DKD are being developed. As stated above, inflammation and 
oxidative stress induced by hyperglycaemia are critical in the pathogenesis of DKD. 
Theoretically, antioxidant or anti-inflammatory agents targeting the kidney could be 
beneficial to prevent or delay progression of DKD. However, the clinical evidence is 
less promising: bardoxolone methyl failed due to increased incidence of CVD, worse 
BP and albuminuria excretion [155]; vitamin B derivatives showed no effect on 
creatinine clearance, GFR or BP [156]; and vitamin D receptor activators’ effect on 
albuminuria was uncertain and they appeared to be less tolerated [157]. Pentoxifylline 
used to be applied for claudication but was then tested as a potential treatment for DKD 
because of its anti-inflammatory properties. Integrated data from eight RCTs indicated 
anti-albuminuria effect of pentoxifylline when used with ACEi or ARB in the DKD 
population, but there is a lack of evidence for long-term renal outcomes [158].  
 
In addition to the inflammation and oxidative stress pathways, there are new therapies 
targeting haemodynamic mechanisms. Sulodexide is an anti-thrombotic agent 
composite of heparin and dermatan sulfate which has albuminuria- and proteinuria- 
reducing properties [159]. But its efficacy in DKD has been controversial since a phrase 
III clinical trial with 1248 participants observed no extra benefits in ESKD and doubling 
of serum creatinine endpoints [160].  
 
Another new agent targeting haemodynamic pathways reported inconclusive results 
with the endothelin-1A receptor (ET1AR) blockade. It down regulated the activity of 
endothelin-1, leading to reduction of system and glomerular hypertension. An early 
RCT of avosentan was terminated after four months’ follow-up due to more 
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cardiovascular events and deaths in the avosentan arm [161]. To avoid cardiovascular 
adverse events, the new ET1AR blockade atrasentan was applied instead. A 12-week 
RCT showed 35%–38% lower levels of ACR in the atrasentan group, while more 
participants withdrew due to adverse events in the high-dose atrasentan group [162]. A 
phrase III trial of atrasentan with the primary outcomes of renal endpoints (doubling of 
serum creatinine, ESKD and renal death) was terminated early due to low endpoint 
event rates, leaving inconclusive the efficacy and safety of atrasentan in the DKD 
population.  
 
3.7.4 Limitations of current management 
Although the risk factor control strategy and the application of ACEi and ARB have 
significantly reduced the risks of mortality and ESKD over the past decades, an unmet 
need exists for new therapies for the DKD population. For example, the choice of 
glycaemia-lowering drugs is limited for those in advanced stages, who are the same 
subgroup with high risks of rapid disease progression and hypoglycaemia events. For 
BP control, it should be noted that BP targets are hard to achieve and may require 
combinations of different classes of anti-hypertensive drugs. Moreover, the milestone 
therapy of RAS inhibitors may fail in some diabetes and DKD patients. A risk prediction 
model based on data from the Irbesartan Diabetic Nephropathy Trial (IDNT) and the 
Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan 
(RENAAL) trial indicated that the absolute risk reduction of ARB was 3.4%, leading 
to a residual 4.7% risk of ESKD and 25.8% risk of CVD and death [163]. The varing 
treatment effects resulted in a substantial proportion of DKD patients remaining at high 
risk for ESKD, CVD and mortality despite RAS inhibitor therapy. Novel therapies for 
DKD targeting different pathogenic pathways are being developed. Some promising 
treatments failed to show efficacy and safety in clinical trials, and some remain 
underexamined. 
 
3.8 Diabetic kidney disease in Chinese Medicine 
3.8.1 Origin and development 
DKD is a modern disease definition based on laboratory tests and renal pathological 
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examination. Therefore, the exact term DKD cannot be found in the historical Chinese 
medicine (CM) literature. Yet a large number of texts describing symptoms and signs 
highly consistent with DKD can be found in the classical literature. As early as the Han 
dynasty, there were classical texts describing polyuria in patients with diabetic 
symptoms in the CM medical book named Synopsis of Prescriptions of the Golden 
Chamber 金匮要略. During the Shui and Tang dynasties, physicians at that time 
already observed that ulcer and oedema could develop in patients suffering from long-
term diabetic symptoms (from the books: Treatise on the Pathogenesis and 
Manifestations of All Diseases诸病源候论 and Medical Secrets of an Official 外台秘
要). In a book published in the Ming dynasty (Tips of Syndrome Diffitiation and 
Treatments 证治要诀), detailed records of urinary changes (sweet, turbid, cloudy and 
oil-like) in patients with a long diabetic-like history can be seen.    
 
The treatment of DKD symptoms can be traced back to ancient CM disease name(s) 
such as Xiao shen消肾, Shen xiao肾消 and Xia xiao下消. Although these three terms 
were used interchangeably in classical literature, the concept of Xia xiao was considered 
more general than the other two terms. According to the classical literature, typical 
symptoms covered by these three terms included muscle dystrophy in the lower half of 
the body, bone and joint pain, being thirsty with or without drinking a lot, frequent 
urination and disturbed and sweet urine [164, 165].  
 
3.8.2 Aetiology and pathogenesis 
Based on the theory of Cm, both internal causes and external factors contribute to the 
development of DKD. It should be noted that the concept of Kidney in CM is not 
aligned with the physical kidney known in conventional medicine. Constitutional 
insufficiency and deficiency in the five zang organs (especially Kidney deficiency) 
serve as the internal causes of DKD as Miraculous Pivot 灵枢 says “People with five 
zang organ deficiency are vulnerable to the disease Xiao dan 消瘅”.  In this susceptible 
population, DKD is very likely to be initiated by dietary irregularities and liquor 
addiction, as Peaceful Holy Benevolent Prescriptions 太平圣惠方 accounts: “San xiao 
三消 is rooted from constitutional kidney deficiency and triggered by daily unhealthy 
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greasy food intake”. Additionally, DKD can result from emotional disorders, internal 
damage due to overexertion and fatigue, untimely or erroneous treatment, or 
overconsumption of medicinals with warm and dry flavours.  
 
The pathogenesis of DKD from a CM perspective is streamlined as the following 
dynamics. In healthy status, the physiological function of the body (summarised as yang) 
is maintained by the support of biological components (summarised as yin). In the 
initial stage, Kidney deficiency leads to an internal dryness-heat status and fluid-
humour depletion, undermining the yin components in the human body. Thus, patients 
may experience thirst even with excess fluid intake, fatigue and lack of strength, dry 
eyes with blurred vision or numbness of the limbs under this qi and yin depleting stage, 
all of which could be explained by the failure to nourish the zang organs and meridians. 
As the disease continues to deteriorate, the long-term detriment to the yin component 
begins to affect the yang function.   
 
In the Kidney, the diminished storage and astringency function results in essence 
draining, which symptomatically produces turbid and oily urine. Moreover, impaired 
Kidney qi transformation function causes retention of waste fluid, so patients manifest 
with lower-limb oedema. The spleen and Liver may also be dysfunctional due to their 
close relation with the Kidney. In the advanced stage, this further develops to dual 
damage of the yin and yang and congestion of dampness turbidity and static blood. 
Additionally, symptoms and signs indicating pathological changes in blood stasis and 
dampness turbidity are also frequently observed in DKD patients. Symptoms and signs 
suggesting severe disease conditions, including oliguria, pitting oedema, nausea and 
vomiting can be observed. 
 
3.8.3 Chinese herbal medicine 
Due to the different stages of DKD in CM theory, treatments should be tailored to 
individuals based on their clinical manifestations and underlying pathological changes, 
which is known as the principle of “syndrome differentiation and treatment” in CM. As 
the traditional knowledge of DKD has been passed down and evolved, the CM 
syndromes most frequently seen in DKD patients are summarised in the experts’ 
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consensus-based guidelines and textbooks, accompanied by corresponding herbal 
treatments (Table 3-3).  
 
In clinical practice, physicians usually modify the recommended formulae to fit the 
personal needs of each patient; therefore the herbal ingredients can be different in 
prescriptions for DKD patients under the same syndrome.  
 
Although there are published systematic reviews of specific formulae and CHM 
preparations, the poor methodological and reporting quality of these reviews makes 
them unreliable and not informative enough in clinical decision-making [166]. High-
quality evidence regarding the overall efficacy and safety of CHM as treatment for 
DKD is still lacking. 
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Table 3-3 Chinese medicine syndromes and treatments for DKD  
Syndrome 
Differentiation 
CHM formulae  
Function of 
Formulae 
Herbal Ingredients 
Dual deficiency 
of qi and yin 
Shen qi di huang 
tang 参芪地黄汤 
Tonify qi and 
yin 
dang shen 党参, huang qi 黄芪, fu 
ling 茯苓, shu di huang 熟地黄, shan 
yao 山药, shan zhu yu 山茱萸, mu 
dan pi 牡丹皮, ze xie 泽泻 
Liver-Kidney yin 
deficiency 
Qi Ju Di huang 
wan杞菊地黄丸 
Enrich the 
Kidney and 
nourish the 
Liver 
gou qi zi 枸杞子, ju hua 菊花, shu di 
huang 熟地黄, shan zhu yu 山茱萸, 
shan yao 山药, fu ling 茯苓, ze xie 泽
泻, mu dan pi 牡丹皮 
Spleen-Kidney 
yang deficiency 
Fu zi li zhong wan 
附子理中丸 with 
Zhen wu tang 真武
汤 
Warm the 
Kidney and 
fortify the 
Spleen 
fu zi 附子, sheng jiang 生姜, dang 
shen 党参, bai zhu 白术, fu ling 茯苓, 
bai shao 白芍, gan cao 甘草 
Dual deficiency 
of qi and Blood 
Dang gui bu xue 
tang 当归补血汤 
with Ji sheng shen 
qi wan 济生肾气丸 
Tonify qi and 
Blood 
huang qi 黄芪, dang gui 当归, fu zi 附
子, rou gui 肉桂, shu di huang 熟地
黄, shan yao 山药, shan zhu yu 山茱
萸, fu ling 茯苓, mu dan pi 牡丹皮, ze 
xie 泽泻, che qian zi 车前子, niu xi 牛
膝 
Dual deficiency 
of yin and yang 
Jin gui shen qi wan 
金匮肾气丸 
Tonify both 
yin and yang 
gui zhi 桂枝, fu zi 附子, shan yao 山
药, shan zhu yu 山茱萸, shu di huang 
熟地黄, fu ling 茯苓, ze xie 泽泻, mu 
dan pi 牡丹皮 
References: [167-169]. 
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4 Text-mining the Chinese Classical Literature for Diabetic 
Kidney Disease 
 
4.1 Introduction 
The long history of use and development of CM has produced and accumulated large 
amounts of medical literature. The historical medical books provide traditional 
knowledge of the aetiology, diagnosis, treatment, and prognosis of many disorders. 
Potentially effective therapies for specific diseases may be found or inspired by 
reviewing the historical literature. One of the most famous cases of new drug 
development through CM historical literature was the discovery of the anti-malaria drug 
artemisinin. The herb- processing approach that unlocked the true potential of 
artemisinin and propelled the drug discovery was recorded in a book written in the Han 
Dynasty (AD 317–420). The book noted the extraction procedure of the herb so the 
bioactive compounds can be used [20]. 
 
Although diabetes and its complications are contemporary diseases, there are many 
descriptions highly consistent with the symptoms and signs of diabetes in the classical 
CM literature [170]. For example, the clinical syndrome of diabetes characterised by 
thirsting, excessive hunger, weight loss, and sweet and frequent urination was identified 
in classical literature, naming as Xiao Ke disease (In Chinese: 消渴) [171]. The earliest 
descriptions of Xiao Ke disease written in the book The Yellow Emperors’ Classic of 
Internal Medicine stated that, Xiao Ke disease was seen in rich and obese people, and 
was induced by overconsumption of sweet and fatty foods. According to the pediatric 
monograph (Compendium of Pediatrics) published in the Qing dynasty, Xiao Ke disease 
can also occur in children and adolescents. The Long-term complications of Xiao Ke 
disease included gangrenous necrosis of the foot, blindness, edema etc. were also 
recorded in medical books from different dynasties [172]. In the digital collections of 
historical CM literature (Zhong Hua Yi Dian), citations related to Xiao Ke disease were 
identified in 477 out of 1156 books[173]. 
 
The inconsistency bewteen the plentiful CM literature of Xiao Ke disease and the low 
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prevalence of diabetes and its complications in ancient China may be caused by the 
“sampling bias”. Famous CM physicians in ancient China were more likely to serve 
royal families and upper-class patients rather than the general population. These 
patients usually had much higher food intake, better living conditions and longer life 
span that allow diabetes and its complications develop. Thus, the ancient experience 
and knowledge about diabetes were recorded and preserved by the famous doctors’ 
monographs and then passing down for generations.  
 
As an important source of evidence, traditional knowledge about the CM treatments for 
diabetes and its renal complication has been passed down via the historical literature 
and still influences contemporary CM practice. Therefore, a systematic and 
comprehensive review of the classical literature to identify potential herbal therapies 
for DKD is necessary. Further studies can be planned based on the findings and may 
lead to novel therapeutics. 
 
In this chapter, a text-mining method for systematic evaluation of classical literature is 
reported; it determined which formulae and herbs had been frequently used to treat 
DKD in CM.  
 
4.2 Methods 
The methods used in this section follow the principles and standard operating 
procedures developed by the China-Australia International Research Centre for 
Chinese Medicine (a collaborative partnership between RMIT University and the 
Guangdong Provincial Hospital of Chinese Medicine) and the work of Dr Brian May 
[174, 175].  
 
4.2.1 Search strategies 
4.2.1.1 Database 
Search of the CM historical literature was conducted in the 5th Edition of the Zhong 
Hua Yi Dian 中华医典 (ZHYD, Encyclopedia of Traditional Chinese Medicine). The 
ZHYD is the largest collection of CM historical literature with a searchable feature 
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[174]. It is in CD-ROM format and contains the contents of 1156 books in the field of 
CM [176]. All books in the ZHYD are categorised according to their bibliographical 
properties and grouped as Theory Classics, Diagnostics, Materia Medica, Formularies 
(Prescriptions), Acupuncture and Moxibustion etc., and a search scope can be specified 
in one or more of the above groups. Searching can be performed in three ways: a search 
of headings, a search of book names, and a search of body texts (Figure 4-1). 
 
 
Figure 4-1 Search interface of Zhong Hua Yi Dian 
 
4.2.1.2 Search terms  
The definition and diagnosis of DKD are based on modern laboratory tests and the term 
‘DKD’ is not available in the historical literature. Zhang et al. developed a set of 
classical terms which are representative of DKD [170]. Briefly, the method that Zhang 
et al. used to develop the set of terms included collecting information from medical 
dictionaries, CM textbooks, DKD monographs and publications about classical terms 
of DKD. The frequency of 31 classical terms in different sources was calculated and 
summarised. Then, a questionnaire survey was conducted among 35 nephrologists from 
tertiary CM hospitals across China, to obtain their opinions on the consistency between 
each candidate term and DKD. Finally, eight out of the 31 terms recommended by over 
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50% of nephrologists were cross checked for their corresponding modern diseases in 
modern CM textbooks, monographs and dictionaries. 
  
Among the eight expert-recommended terms, ancient expressions about the symptoms 
of oedema (Shui zhong 水肿), turbid urine (Niao zhuo 尿浊), fatigue (Xu lao虚劳) and 
anuria with vomiting (Guan ge关格) were not representative enough for DKD as they 
also refer to other kidney or internal diseases in the modern literature. Another expert-
recommended term, the Xiao Ke (消渴), referrs to the whole process of diabetes 
therefore it is too broad for the concept of DKD. The classical terms that best represent 
DKD, as it is known today, is Shen Xiao 肾消, Xia Xiao 下消, and Xiao Shen 消肾. 
There was consensus by the nephrologists that these three terms were suitable, and they 
only referred to DKD in the modern textbooks and monographs. Considering their 
sensitivity and specificity, the terms Shen Xiao, Xia Xiao and Xiao Shen were adopted 
as search terms in this research.  
 
4.2.2 Data collection and screening 
4.2.2.1 Data collection  
Searching was conducted by looking up the three search terms in body texts. The hit 
number for each search term was recorded. The passages of text containing the search 
terms were copied into a Microsoft Excel spreadsheet with information about identified 
term, location in ZHYD, book name and whether it provided treatment data. After 
removing duplicates, the preliminary dataset of DKD relevant historical literature was 
obtained. 
 
The second step was searching for literature with herbal treatment information from the 
preliminary dataset. Historical literature with treatment data but in the form of case 
reports were excluded due to their different nature. A citation referred to one formula 
with its treated symptoms/signs. If a passage of text mentioned more than one formula, 
two or more citations were generated. All citations were retrieved and documented in a 
new spreadsheet with information about the identified term, book name, original texts, 
symptoms/signs description, formula name and herbal ingredients. For the purpose of 
characteristics analysis, information including author, publication dynasty and 
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publication year was added for each citation. The reference sources and procedures 
were adapted from the methods of May et al. [177].  
 
For those citations that only mentioned the formulae name without ingredients, 
additional sources were consulted in order to find the missing ingredients. Firstly, the 
formula name was used as a search term to identify its ingredient descriptions within 
the same book. If text of ingredient descriptions was not found in the same book, then 
other books written by the same author were searched. If ingredients were still not found, 
then the corresponding formulae were excluded from the frequency analysis of 
ingredients. As a result, DKD treatment data from historical literature was developed 
in the form of a citations pool. 
 
4.2.2.2 Data screening 
Citations that met one of the following criteria were excluded:  
 Originating from books published after the modernisation of CM, defined as 
after 1949 [178] 
 Originating from the Prescriptions book (方剂书), which was written to assist 
memory of formulae ingredients (e.g. Prescriptions in Rhymes 汤头歌诀);  
 Describing exclusive aetiologies or symptoms/signs of DKD such as priapism 
(original text: 强中) and haematuria (original text: 小便赤似血色).  
 
The screening was first finished by one researcher and then was checked by another. 
Each excluded citation was marked in a separate column in the spreadsheet with a 
justification. Any disagreement was resolved by consulting a CM nephrologist who was 
experienced in historical literature.  
4.2.3 Data rating 
Since searches in ZHYD may find many references, a rating system was developed to 
categorise citations with varing degrees of relevance to modern DKD. 
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4.2.3.1 Rating system development  
Firstly, current diagnosis criteria of DKD in the guidelines and textbooks of 
contemporary medicine were reviewed [2, 5, 108]. Long-term diabetic history, typical 
symptoms/signs of diabetes and manifestations of kidney injury were found to be the 
key aspects in modern clinical diagnosis of DKD. Thus, the rating categories include 
presentation of typical symptoms/signs, duration of condition, symptoms/signs of 
retinopathy and exclusive symptoms for differential diagnosis. The details of the rating 
items are shown in Table 4-1. 
 
Numerical codes were used in each rating item according to:  
 Code 0: the citation did not mention the relevant information  
 Code 1: the citation included relevant information but was not explicit  
 Code 2: the citation included the target expression. 
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Table 4-1 Rating categories, items and possible expression in CM literature 
Category and items Possible expression (Pin yin & Chinese) 
History of diabetes  
Terms relating to diabetes Xiao Ke 消渴, Nei Xiao 内消, San Xiao 三消, Shang Xiao 
上消, Xiao Zhong 消中, Zhong Xiao 中消 
Profuse drinking and profuse urine Yin yi sou yi 饮一溲一, Yin yi sou er 饮一溲二 
Sweet urine Tian 甜, Gan 甘, Tang 糖, Mi 蜜 
Symptoms of diabetes  
Frequent urination Shuo 数, Duo 多, Da li 大利, Wu du 无度, Bu jin 不禁 
Increased thirst Ke 渴, Duo yin 多饮, Yin shui 饮水, Shan yin 善饮 
Increased appetite Xiao Shi 消食, Ji 饥, Yu shi 欲食, Shan shi 善食 
Weight loss Shou 瘦, Wei 痿, Xi 细 
Symptoms of kidney injury 
Turbid urine (protein urine) Bai zhuo 白浊, Zhi ye 脂液, Gao you 膏油, Gao 膏 
Oedema of lower limbs Shui zhong 水肿, Tui zhong 腿肿 
Disease duration 
Chronic or long-term Jiu 久, Bu cuo 不瘥, Bu yu 不愈 
Symptoms/signs of retinopathy 
Blurred vision Mu hun 目昏, Shi zhan hun miao 视瞻昏渺, Shi wu mo hu 
视物模糊 
Exclusive symptoms 
Haematuria Niao xie 尿血, Xiao bian chi 小便赤 
 
 
Secondly, a hierarchy of relevance to DKD in the rating system was constructed based 
on the following criteria (Table 4-2): (1) history of diabetes; (2) symptoms/signs of 
diabetes; and (3) symptoms/signs of kidney injury. Citations fulfilling all three criteria 
were most likely to refer to DKD as it is known today. Citations that satisfied the third 
criterion plus the first or second criteria were possibly DKD. Citations only meeting the 
third criterion were conditional DKD. Other citations were unclear as to their relevance 
to DKD. The overall score ranged from 0 to 3 representing a low to high degree of 
similarity of the historical citations to modern DKD.  
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Table 4-2 Hierarchy of relevance to DKD 
Relevance to DKD Score Score criterion 
Unclear 0 
Does not include any symptoms of kidney injury or not enough 
information to judge 
Conditional DKD 1 Only includes symptoms of kidney injury 
Possible DKD 2 
Includes diabetes history and symptoms of kidney injury, or 
symptoms of diabetes and symptoms of kidney injury 
Most likely DKD 3 
Includes diabetes history and symptoms of diabetes and symptoms 
of kidney injury 
 
4.2.3.2 Data rating procedure 
Each rating category and its items were listed in separate columns in the spreadsheet 
for each citation. Based on the original texts for each citation, codes were allocated to 
each rating item under different categories. Judgements of relevance scoring were made 
based on the coding results of all rating categories. Four citations pools with different 
relevance to DKD were obtained.   
 
The rating procedure was independently conducted by two reviewers. Before all 
citations were rated, a pilot trial was done to test the consistency of coding results 
between the two reviewers and to test the validity of the rating system. Any 
disagreement on rating and relevance scoring was resolved by discussion with a third 
CM nephrologist or by consulting CM dictionaries. 
  
4.2.4 Data analysis 
Data analysis included two parts. The first part was a descriptive analysis of the citation 
characteristics to present an overview of DKD records in historical literature. The 
second part was a frequency analysis of the formulae and herbal ingredients, leading to 
discovery of the most frequently used formulae and herbs for DKD in antiquity. The 
analysis was performed in the Statistical Package for the Social Sciences (SPSS) 
software (version 21, IBM). 
 
4.2.4.1 Descriptive analysis of citation characteristics 
The dynasty distributions of citations and search terms were analysed for all treatment 
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citations. The dynasty of each citation and term was determined based on the written or 
publication years of the cited CM books. In addition, the hit frequency of each search 
term in ZHYD and different citation pools was calculated.  
  
4.2.4.2 Frequency analysis of formulae and herbs 
The herb names were standardised before analysis, to ensure the same herb with 
multiple names was calculated altogether (Appendix 1 includes a list of herbs and their 
corresponding Pin yin and scientific names that are referenced in this thesis). For 
example, shan yao 山药 and huai shan 淮山 were both considered to be the same herb; 
thus it was standardised to be the same name. Formulae were evaluated and 
standardised based on formulae names and composite ingredients. If two formulae had 
the same names but different ingredients, a number was added after the formulae names, 
for instance Ba wei wan 1 八味丸 1 and Ba wei wan 2 八味丸 2. If two formulae shared 
identical ingredients but with different names, the name that appeared earlier was kept. 
The changes were separately documented in the spreadsheet. 
  
After herbs and formulae standardisation was completed, frequency analysis was 
conducted for the “treatment citation”, “conditional DKD citation”, “possible DKD 
citation” and “most likely DKD citation” pools separately. Frequency analysis of herbs 
for turbid urine and oedema was also conducted based on different citation pools.  
 
4.3 Results 
4.3.1 Search, screening and rating results 
In total, the three search terms Shen Xiao, Xia Xiao, and Xiao Shen were mentioned in 
1214 citations in classical CM literature. After duplicate, non-treatment paragraph and 
case report removal, the number of citations which contained treatment information 
was 331. 
 Among the 331 treatment citations, 53 citations were excluded for satisfying at least 
one exclusion criteria. One citation retrieved from Brief Summary of Materia Medica 
Prescriptions本草简要方 was excluded since the book was published in 1965. Another 
citation from Prescriptions in Rhymes 汤头歌诀 was also excluded. Another 51 
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citations were excluded because of symptoms/signs descriptions indicating non-DKD 
aetiologies. For instance, original texts indicating haematuria (赤似血色, 小便数或赤, 
小便赤黄, 赤白浊, 如血色), medication misuse (饵金石, 服金石药) and priapism (不
交精出, 茎长而坚, 阴茎强) were found in these excluded citations. After screening, 
278 treatment citations remained for rating of relevance to DKD.  
 
Among the 278 treatment citations, the number of citations scored with 0, 1, 2 and 3 
points were 194, 24, 37 and 23, respectively. As a result, the most likely DKD citations 
pool included 23 citations with a rating score of 3. In the same manner, the possible 
DKD citations pool included 37 citations and the conditional DKD citations pool 
included 24 citations (see Figure 4-2).  
 
 
Figure 4-2 Searching, screening and rating results of historical literature 
4.3.2 Citation characteristics 
4.3.2.1 Publication dynasty 
The citations were retrieved from 68 distinct historical CM books which were written 
from AD 583 to 1895. The earliest document was found in the Variorum of Experiential 
Prescriptions 集验方 published in the Han Dynasty and the most recent record was 
from the Minor formulae of Difficult and Emergency Issues 疑难急症简方 published 
 54 
 
in the Qing Dynasty. 
  
Table 4-3 shows the dynastic distribution of treatment citations. The number of 
treatment citations motably increased after the Tang Dynasty. The official prescription 
monograph published in the Song Dynasty, Peaceful Holy Benevolent Prescriptions太
平圣惠方 together with another prescriptions monograph (Ji Feng Prescriptions for 
Universal Relief 鸡峰普济方) in the same period contributed 13.7% (38 citations) of 
the total treatment citations. In the Yuan Dynasty, there was a significant drop in the 
number of citations. Then the number of citations increased in the Ming and Qing 
dynasties, accounting for over 70% of total citations. The book that contributed the 
most citations (40 citations) with a proportion of 14.4%, was the Prescriptions for 
Universal Relief 普济方, which was the most comprehensive pharmacopoeia in CM 
history and written in the Ming Dynasty. 
  
Table 4-3 Dynastic distribution of treatment citations 
Dynasty No. of treatment citations (%) 
Before Tang Dynasty (before 618) 1 (0.4%) 
Tang and 5 Dynasties (618–960) 8 (2.9%) 
Song and Jin Dynasties (960-1279) 66 (23.7%) 
Yuan Dynasty (1271–1368) 4 (1.4%) 
Ming Dynasty (1368–1644) 128 (46.0%) 
Qing Dynasty (1644–1911) 71 (25.5%) 
Ming Guo/Republic of China (1912–1949) 0 (0%) 
Total 278 (100%) 
 
4.3.2.2 Dynasty of search terms   
The dynastic distribution pattern of each search term was different (Figure 4-4). The 
term Shen Xiao appeared in CM books across different dynasties. The citations before 
the Tang and in the Tang and Yuan dynasties were mainly located by this term. As for 
the term Xiao Shen, it was mentioned frequently since the Song and Jin dynasties. Lastly, 
the term Xia Xiao was not used in the classical texts with treatment information until 
the Ming Dynasty.  
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Figure 4-3 Dynastic distribution of search terms 
 
Citation frequency and proportion of each term are presented based on different citation 
pools (Table 4-4). In the ZHYD, the term Xiao Xia located nearly twice the number of 
citations as the other two terms. In the treatment citations pool, the number of citations 
identified by Xiao Xia was half of those identified by Shen Xiao or Xiao Shen. In the 
three DKD relevant citation pools, the terms retrieving the largest number of citations 
were different. Shen Xiao was mentioned in 58.3% of citations in the conditional pool, 
while 67.6% of citations in the possible pool recorded Xiao Shen. In the most likely 
citations pool, the three search terms found almost the same number of citations.  
 
Table 4-4 Citation frequency of each search term in different pools 
Search term 
Citation frequency (n, %) 
ZHYD 
(n=1,214) 
Treatment 
citations pool 
(n=278) 
Most likely 
citations 
pool (n=23) 
Possible 
citations 
pool (n=37) 
Conditional 
citations pool 
(n=24) 
Shen Xiao 324 (26.7) 109 (39.2) 8 (34.8) 9 (24.3) 14 (58.3) 
Xia Xiao 556 (45.8) 53 (19.1) 8 (34.8) 3 (8.2) 6 (25) 
Xiao Shen 334 (27.5) 116 (41.7) 7 (30.4) 25 (67.6) 4 (16.7) 
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4.3.3 Most common formulae 
4.3.3.1 Formulae in treatment citations pool 
A total of 194 citations without enough information for judgements of relevance to 
DKD were included in the “treatment citations” pool. In this citation pool, 128 distinct 
formulae consisting of 143 different herbs were reported in the 278 citations. The 
formulae were diverse, as more than half were cited once and the remaining 30% were 
mentioned less than three times. The top ten most commonly cited formulae and their 
ingredients are listed in Table 4-5. 
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Table 4-5 Common formulae in treatment citations pool 
Formulae name Herb ingredients  No. of 
citations 
Ba wei wan 
八味丸 
fu zi 附子, rou gui肉桂, shu di huang 熟地黄, shan zhu yu 山茱
萸, ze xie泽泻, mu dan pi牡丹皮, shan yao山药, fu ling茯苓 
16 
Liu wei di huang wan 
六味地黄丸 
shu di huang 熟地黄, shan zhu yu 山茱萸, ze xie泽泻, mu dan 
pi牡丹皮, shan yao山药, fu ling茯苓 
15 
Hui xiang san 
茴香散 
xiao hui xiang 小茴香, chuan lian zi 川楝子 12 
Bai fu ling wan 
白茯苓丸 
fu ling茯苓, fu pen zi覆盆子, huang lian黄连, ren shen人参, 
tian hua fen天花粉, shu di huang熟地黄, bi xie萆薢, xuan shen
玄参, ji nei jin鸡内金, shi hu石斛, she chuang zi蛇床子 
9 
Lu jiao (single herb) 
鹿角 
lu jiao鹿角 7 
Modified Ba wei wan 
八味丸加减 
wu wei zi五味子, shu di huang 熟地黄, shan zhu yu山茱萸, ze 
xie泽泻, rou gui肉桂, mu dan pi牡丹皮, shan yao山药, fu ling
茯苓 
6 
Ge gen wan  
葛根丸 
ge gen葛根, gua lou瓜蒌, qian dan铅丹, fu zi 附子 6 
Huang qi wan 
黄芪丸 
huang qi黄芪, shan zhu yu山茱萸, ren shen人参, wu wei zi五
味子, shu di huang熟地黄, ji nei jin鸡内金, rou cong rong 肉
苁蓉, niu xi牛膝, bu gu zhi补骨脂, lu rong鹿茸, mai dong麦
冬, di gu pi地骨皮, fu ling茯苓, xuan shen玄参 
5 
Ping bu wan 
平补丸 
tu si zi菟丝子, shan zhu yu山茱萸, dang gui当归, yi zhi ren益
智仁, chuan lian zi 川楝子, niu xi 牛膝, hu lu ba 葫芦巴, du 
zhong杜仲, ba ji tian巴戟天, rou cong rong 肉苁蓉, ru xiang
乳香 
5 
Shen li wan 
肾沥丸 
ji nei jin鸡内金, yuan zhi远志, ren shen人参, huang qi黄芪, 
sang piao xiao桑螵蛸, ze xie泽泻, shu di huang熟地黄, rou gui
肉桂, dang gui当归, long gu龙骨, gan cao甘草, mai dong麦
冬, wu wei zi五味子, ci shi磁石, fu ling茯苓, chuan xiong川
芎, xuan shen玄参 
5 
 Note: The use of some herbs may be restricted in some countries; readers are advised 
to comply with relevant regulations.  
 
Ba wei wan 八味丸 was the most frequently cited formula in the treatment citations 
pool, followed by Liu wei di huang wan 六味地黄丸. The herb ingredients of these two 
formulae were highly homologous. The earliest record of the formula Ba wei wan was 
found in the book Synopsis of Prescriptions of the Golden Chamber 金匮要略 written 
in the Han Dynasty. It was named Shen qi wan 肾气丸 and was indicated for diabetic 
patients who were comorbid with obvious thirst and profuse urine (original text: 男子
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消渴, 小便反多, 以饮一斗, 小便一斗, 肾气丸主之). The fu zi 附子 and rou gui 肉桂 
in Ba wei wan were used to generate yang qi in the Kidney in order to decrease the 
excessive urine. Liu wei di huang wan derived from Ba wei wan was created for 
children in the Song Dynasty. Dr Zhu Danxi 朱丹溪 from the Yuan Dynasty made use 
of its nourishing yin feature to treat turbid urine caused by pathogenic fire in Kidney 
(original text: 火盛于下，为肾消。病则烦躁，小便浊，淋如膏油之状。论云：焦
烦水易亏者是也。六味地黄丸主之).  
 
Besides Liu wei di huang wan, there was another formula modified based on Ba wei 
wan and frequently cited in this pool. The fu zi in the original Ba wei wan was replaced 
by wu wei zi. This formula was named Modified ba wei wan. This small modification 
was suggested by Dr Zhang Zihe 张子和 to avoid the excess warm-dryness induced by 
taking fu zi in summer. The sour and sweet flavours of wu wei zi are good for yin 
formation, in addition to its securing essence and reducing urination.  
 
The formula Hui xiang san 茴香散 was one of the three formulae with a citation 
frequency greater than ten in this pool. It was first mentioned as a treatment for Shen 
Xiao 肾消 with initial symptoms of turbid urine by Dr Liu Wansu 刘完素 in the Jin 
Dynasty. This citation was repeatedly cited by pharmacopeia in the Ming and Qing 
dynasties, such as the Compendium of Materia Medica本草纲目 and Prescriptions for 
Universal Relief 普济方. The composition of Hui xiang san is simple and only 
contained two herbs: xiao hui xiang 小茴香 and chuan lian zi 川楝子. The xiao hui 
xiang can warm the Kidney and Bladder, while chuan lian zi reinforces the action by 
regulating qi.  
 
Another formula that appeared nine times was Bai fu lin wan 白茯苓丸. It has been 
cited in several pharmacopeia since the Song Dynasty. This formula was designed for 
patients with a long-term diabetic history and therefore at high risk of kidney injury. 
The prominent symptoms were muscle atrophy and weakness in the lower limbs 
(original text: 治消肾, 因消中之后, 胃热入肾, 消烁肾脂, 令肾枯燥, 遂致此疾, 即两
腿渐细, 腰脚无力, 白茯苓丸方). 
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The formula Ge gen wan 葛根丸 was first described by Dr Zhang Zihe 张子和 for 
patients with Xiao Shen 消肾 who suffered from thirst and were drinking large amounts 
of water daily. The herb gua lou 瓜蒌 was one of the ingredients in the records from 
the Song and Jin dynasties. But in the citations in the Ming Dynasty, gua lou was 
removed and replaced with tian hua fen 天花粉. These two herbs are from the same 
plant but different parts. Tian hua fen is good for nourishing yin and thus may exert 
better effect in relieving thirst.  
 
The formulae mentioned in five citations each were Huang qi wan 黄芪丸, Ping bu 
wan 平补丸, and Shen li wan肾沥丸. The indications of these three formulae were 
similar, for diabetic patients with polyuria, muscle wasting and weakness in the lower 
extremities. The majority of ingredients contained in these formulae replenish Kidney 
yang function.  
 
4.3.3.2 Formulae in most likely DKD citations pool 
The citations that metioned diabetic history, diabetic symptoms and kidney injury 
symptoms were considered most likely to be DKD. Although the number of citations 
included in the most likely DKD pool was only 23, there were 14 different formulae 
recorded. The highest citation frequency was three and 50% of formulae only appeared 
once. The formulae mentioned more than once in this most likely pool are listed in 
Table 4-6. 
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Table 4-6 Common formulae in most likely DKD citations pool 
Formula name Herb ingredients No. of 
citations 
Liu wei di huang wan 
六味地黄丸 
shu di huang熟地黄, shan zhu yu 山茱萸, ze xie泽泻, mu dan 
pi牡丹皮, shan yao山药, fu ling茯苓 
3 
Sao si tang 
缲丝汤 
jian si茧丝 3 
Gu ben wan 
固本丸 
sheng di huang 生地黄, shu di huang 熟地黄, tian dong天冬, 
mai dong麦冬 
2 
Hua cong rong wan 
花苁蓉丸 
hua cong rong 花苁蓉, ze xie泽泻, wu wei zi五味子, ba ji tian
巴戟天, di gu pi地骨皮, gua lou瓜蒌, ci shi磁石, ren shen人
参, chi shi zhi赤石脂, gan jiang干姜, yu yu liang禹余粮, sang 
piao xiao桑螵蛸, mang xiao芒硝 
2 
Ren shen fu ling san 3 
人参茯苓散 3 
ren shen人参, bai zhu白术, dang gui当归, chi shao赤芍, da 
huang大黄, zhi zi栀子, ze xie泽泻, lian qiao连翘, tian hua 
fen天花粉, ge gen葛根, fu ling茯苓, rou gui肉桂, mu xiang
木香, huo xiang藿香, han shui shi寒水石, gan cao甘草, shi 
gao石膏, hua shi滑石, mang xiao芒硝 
2 
Tian hua wan 
天花丸 
huang lian黄连, bai bian dou白扁豆, zhu sha朱砂, fu ling茯
苓, mu li牡蛎, zhi mu知母, ku shen苦参, tian hua fen天花粉, 
tie fen铁粉, lu hui芦荟, jin bo金箔, yin bo银箔   
2 
Zhi bo ba wei wan 
知柏八味丸 
zhi mu知母, huang bo黄柏, shu di huang熟地黄, shan zhu yu
山茱萸, ze xie泽泻, mu dan pi牡丹皮, shan yao山药, fu ling
茯苓 
2 
Note: The use of some herbs may be restricted in some countries; readers are advised 
to comply with relevant regulations.  
 
The most common formulae were Liu wei di huang wan 六味地黄丸 and Sao si tang 
缫丝汤. Citations in this pool clearly described that Liu wei di huang wan was used for 
turbid urine resulting from diabetes progression (original text: 肾消者，饮一溲二。
其溲如膏油，即膈消、消中之传变). The Sao si tang that originated from books in 
the Ming Dynasty, also known as Reeling silk decoction, shared the same citation 
frequency as Liu wei di huang wan in this pool. It contained only one ingredient, that 
is, jian si 茧丝 (silk cocoon or silk floss). The citation stated that Sao si tang was 
extremely effective as a treatment for turbid urine, thirst and weight loss caused by 
diabetes. Diet restriction by avoiding salty foods with Sao si tang was described in the 
citations as well (original text: 缲丝汤治肾消，白浊，及上中二消、饥渴不生肌肉，
其效如神...忌食盐物). 
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Gu ben wan 固本丸, Hua cong rong wan 花苁蓉丸, Tian hua wan 天花丸, Ren shen 
fu lin san 人参茯苓散 and Zhi bo ba wei wan 知柏八味丸 were mentioned in multiple 
citations in this pool. These formulae were all created for long-term diabetes with severe 
thirst and frequent and turbid urine, except for Hua cong rong wan which was 
prescribed for diabetes with lower extremity oedema. 
 
4.3.3.3 Formulae in possible DKD citations pool 
The possible DKD citations pool consist of 37 citations that mentioned a history or 
symptons of diabetes, in addition to the symptoms of kidney diseases. The possible 
DKD citations pool included 22 different formulae. The most common formulae were 
cited four times, while more than half of the formulae were used once. Formulae in this 
pool mentioned more than once are shown in Table 4-7. 
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Table 4-7 Common formulae in possible DKD citations pool 
Formula name Herb ingredients No. of 
citations 
Hui xiang san 
茴香散 
xiao hui xiang 小茴香, chuan lian zi川楝子 4 
Ci shi tang 
磁石汤 
ci shi磁石, huang qi黄芪, du zhong杜仲, ren shen人参, wu wei 
zi五味子, shu di huang熟地黄    
3 
Tu si zi san 
菟丝子散 
tu si zi菟丝子, pu huang蒲黄, ci shi磁石, huang lian黄连, rou 
cong rong 肉苁蓉, wu wei zi五味子, ji nei jin鸡内金   
3 
Shen fu tang 
参附汤 
ren shen人参, fu zi 附子, qin dai青黛 2 
Huang lian wan 
黄连丸 
huang lian黄连, tian hua fen天花粉, shen di huang生地黄 2 
Huang qi san 2 
黄芪散 2 
huang qi黄芪, ji nei jin鸡内金, wu wei zi五味子 2 
Lu rong wan 
鹿茸丸 
lu rong鹿茸, rou cong rong肉苁蓉, huang qin 黄芩, ren shen人
参, tu gua gen土瓜根, ji nei jin鸡内金, tu si zi菟丝子 
2 
Ren shen fu ling 2 
人参茯苓散 2 
ren shen人参, bai zhu白术, ze xie泽泻, tian hua fen天花粉, jie 
geng桔梗, zhi zi栀子, lian qiao连翘, ge gen葛根, huang qin黄
芩, da huang大黄, bo he薄荷, fu ling茯苓, gan cao甘草, shi gao
石膏, hua shi滑石, han shui shi寒水石, sha ren砂仁 
2 
Tie fen wan 
铁粉丸 
tie fen铁粉, shen di huang 生地黄, ji nei jin鸡内金, mu li牡蛎, 
huang lian 黄连 
2 
Yuan tu dan 
元菟丹 
fu ling茯苓, tu si zi菟丝子, lian zi莲子, wu wei zi五味子, shan 
yao山药 
2 
Note: The use of some herbs may be restricted in some countries; readers are advised 
to comply with relevant regulations.  
 
Hui xiang san 茴香散 was the most frequently cited formula in this pool. The citations 
that mentioned Hui xiang san in this pool were all retrieved from pharmacopeia 
published in the Ming and Qing dynasties.  
 
Ci shi tang 磁石汤 and Tu si zi san 菟丝子散 were both cited in three different citations 
in prescription monographs from the Song and Ming dynasties. The formula Ci shi tang 
was prescribed to diabetic patients with severe turbid urine and weight loss or weakness. 
The appearance of urine was described as greasy like fat (original text: 治消肾, 小便
白浊如凝脂, 形体羸瘦, 磁石汤方). Lamb kidney soup should be added to boil with 
the other ingredients in Ci shi tang. Therefore, Ci shi tang was also called Shen li tang 
肾沥汤 which highlighted the combination of herbs and lamb kidney. Likewise, Tu si 
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zi san was indicated for diabetic patients with turbid urine as well as frequent urine 
(original text: 治消肾，小便多，白浊，或不禁，菟丝子散方). 
 
The other formulae mentioned twice in this pool were Shen fu tang 参附汤, Huang lian 
wan 黄连丸, Huang qi san 2 黄芪散 2, Lu rong wan 鹿茸丸, Ren shen fu lin san 2 人
参茯苓散 2, Tie fen wan 铁粉丸 and Yuan tu dan 元菟丹. These formulae were all 
targeted for turbid urine with or without thirst, polyuria, muscle wasting and weakness 
following by diabetes.  
 
4.3.3.4 Formulae in conditional DKD citations pool 
For citations that only contained search terms and descriptions of kidney injury 
symptoms, they were included in the conditional DKD citations pool. In the conditional 
DKD citations pool, 14 distinct formulae were identified from 24 citations, only three 
of which were cited more than once (Table 4-8). 
 
Table 4-8 Common formulae in conditional DKD citations pool 
Formula name Herb ingredients No. of 
citations 
Hui xiang san 
茴香散 
xiao hui xiang 小茴香, chuan lian zi川楝子 7 
Huang qi san 1 
黄芪散 1 
huang qi黄芪, mai dong麦冬, fu shen茯神, long gu龙骨, tian 
hua fen天花粉, shu di huang熟地黄, ze xie泽泻, bai shi zhi白
石脂, sang piao xiao 桑螵蛸, gan cao甘草 
2 
Sang piao xiao wan 
桑螵蛸丸 
sang piao xiao 桑螵蛸, tu si zi 菟丝子, shu di huang 熟地黄, 
shan zhu yu山茱萸, huang lian黄连 
2 
Note: The use of some herbs may be restricted in some countries; readers are advised 
to comply with relevant regulations.  
 
The formula Hui xiang san 茴香散 again, was cited the highest number of times. Hui 
xiang san in this pool was cited seven times, much more than the other formulae. A 
formula named Modified hui xiang san 加减茴香散 which was similar but had slightly 
different herbal ingredient was also found in this pool. The composition of Modified 
Hui xiang san was xiao hui xiang 小茴香, chuan lian zi 川楝子 plus wu wei zi 五味子. 
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It was first cited in a book written by Dr Zhu Danxi 朱丹溪 and had the same indications 
as Hui xiang san, which was to treat turbid urine in Shen Xiao 肾消 disease.  
 
In this pool, Huang qi san 1 黄芪散 1 and Sang piao xiao wan 桑螵蛸丸 were both 
cited twice. Both formulae were given to those with turbid urine. But Huang qi san 1 
contained ingredients with cool properties and nourishing yin action, therefore was 
more suitable for those with comorbidity and agitation. Sang piao xiao wan included 
sang piao xiao 桑螵蛸 as the main medicinal ingredient for its strong astringent effect 
to reduce longstanding urinary essence (protein) excretion (original text: 治消肾，小
便白浊，久不瘥，桑螵蛸丸方).  
 
4.3.4 Most common herbs 
The common herbs from each citation pool are summarised as follows (Table 4-9). 
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Table 4-9 Common herbs in different citation pools 
Citation pool Herb name (pin yin) English name No. of 
citations 
Treatment citations fu ling 茯苓 Poria 129 
shu di huang 熟地黄 Rehmanniae Radix Praeparata 121 
ze xie 泽泻 Alismatis Rhizoma 105 
ren shen 人参 Ginseng Radix Et Rhizoma 94 
shan zhu yu山茱萸 Corni Fructus 93 
shan yao 山药 Dioscorea Rhizoma 73 
mu dan pi牡丹皮 Moutan Cortex 71 
huang qi 黄芪 Astragali Radix 67 
tian hua fen 天花粉 Trichosanthis Radix 62 
wu wei zi 五味子 Schisandrae Chinensis Fructus 61 
Most likely DKD 
citations 
fu ling茯苓 Poria 12 
ze xie泽泻 Alismatis Rhizoma 12 
shu di huang 熟地黄 Rehmanniae Radix Praeparata 11 
shan zhu yu 山茱萸 Corni Fructus 9 
mu dan pi 牡丹皮 Moutan Cortex 8 
shan yao 山药 Dioscorea Rhizoma 8 
ren shen 人参 Ginseng Radix Et Rhizoma 6 
tian hua fen 天花粉 Trichosanthis Radix 5 
zhi mu 知母 Anemarrhenae Rhizoma 5 
huang lian 黄连 Coptidis Rhizoma 4 
jian si茧丝 Silk cocoon, Silk floss 4 
wu wei zi 五味子 Schisandrae Chinensis Fructus 4 
Possible DKD 
citations 
ren shen人参 Ginseng Radix Et Rhizoma 14 
wu wei zi五味子 Schisandrae Chinensis Fructus 14 
fu ling茯苓 Poria 12 
huang lian黄连 Coptidis Rhizoma 10 
ji nei jin鸡内金 Galli Gigerii Endothelium 
Corneum 
9 
shu di huang熟地黄 Rehmanniae Radix Praeparata 9 
huang qi 黄芪 Astragali Radix 8 
mu li 牡蛎 Ostreae Concha 7 
tu si zi菟丝子 Cuscutae Semen 7 
ci shi 磁石 Magnetitum 6 
shan yao 山药 Dioscorea Rhizoma 6 
ze xie 泽泻 Alismatis Rhizoma 6 
Conditional DKD 
citations 
shu di huang熟地黄 Rehmanniae Radix Praeparata 11 
chuan lian zi川楝子 Toosendan Fructus 8 
shan zhu yu山茱萸 Corni Fructus 8 
xiao hui xiang 小茴香 Foeniculi Fructus 8 
gan cao甘草 Glycyrrhizae Radix Et Rhizoma 6 
shan yao山药 Dioscorea Rhizoma 6 
ze xie泽泻 Alismatis Rhizoma 6 
dang gui当归 Angelicae Sinensis Radix 5 
fu ling茯苓 Poria 5 
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Citation pool Herb name (pin yin) English name No. of 
citations 
huang bo 黄柏 Phellodendri Chinensis Cortex 5 
huang qi黄芪 Astragali Radix 5 
Note: The use of some herbs may be restricted in some countries; readers are advised 
to comply with relevant regulations.  
 
4.3.4.1 Herbs in treatment citations pools 
In the treatment citations pool, 143 different herbs were identified from almost 300 
formulae. The frequency of herbs varied from one to 129 and the median frequency was 
6. The summarised frequency of the top 10 herbs occupies 39.5% of the cumulative 
percentage. Thus, the top 10 herbs were regarded as the common herbs of the treatment 
citations pool. 
 
The most commonly used herbs of the treatment citations pool were fu ling 茯苓, 
followed by shu di huang 熟地黃 and ze xie 泽泻. Each of these top three herbs was 
used in over 100 of the formulae. The formulae ingredients of Liu wei di huang wan 六
味地黄丸 were all included in the top ten list, suggesting that Liu wei di huang wan 
may be the core treatment formula. Other high-frequency herbs tonified the Kidney qi 
(ren shen 人参 and huang qi 黄芪), replenished yin (tian hua fen 天花粉) and secured 
the Kidney essence (wu wei zi 五味子). These commonly cited herbs correspond with 
the CM theory that the basic mechanism of DKD is Kidney deficiency and essence 
leakage.  
 
4.3.4.2 Herbs in most likely DKD citations pool 
In the most likely DKD citations pool, there were 61 unique herbs used in 14 formulae. 
The highest frequency of herbs was 12 citations while the lowest was one and the 
median frequency was 2. The top 7 herbs were considered the common herbs in this 
pool because these herbs contributed a cumulative percentage of 48.9%.  
 
Fu ling, shu di huang and ze xie were the most common herbs. The herbs constituting 
Liu wei di huang wan occupied the top 6 positions in this pool. The herbs ren shen, wu 
wei zi and tian hua fen were also found in the list. Additionally, the ingredient of the 
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single-herb formula jian zi 茧丝 was also in the common herbs list. 
 
The herbs zhi mu 知母 and huang lian 黄连 targeted the Kidney meridians and cleared 
heat, purged fire and nourished the yin function. Its frequent application in the most 
likely pool indicated that heat or fire pathogen in the Kidney may play an important 
role in the disease process.  
 
4.3.4.3 Herbs in possible DKD citations pool 
Among the possible DKD citations, 65 different herbs constituted the 22 formulae in 
this pool. The herb frequency ranged from 14 to one, with a median of 2. There were 
12 unique herbs in the high-frequency herbs list, which represented 46.2% of herb 
frequency.  
 
The top 3 most commonly used herbs were ren shen, wu wei zi and fu ling. In addition 
to the majority ingredients of Liu wei di huang wan, herbs with the action of securing 
essence and reducing urination (ji nei jin 鸡内金 and tu si zi 菟丝子) were frequently 
cited. Herbs used to subdue Kidney yang were commonly reported in this pool as well, 
including ci shi 磁石 and mu li 牡蛎. This implied that reinforcing yang in the Kidney 
was important in treatment for DKD. 
 
4.3.4.4 Herbs in conditional DKD citations pool 
In the conditional DKD citations pool, the total number of unique herbs identified was 
46. About half of the herbs were cited once or twice and the highest frequency was 11. 
The summarised frequency of the top four herbs occupied 52.9% of the cumulative 
percentage of frequency, thus these herbs were regarded as the common herbs. 
Although the most commonly cited formula in this pool was the Hui xiang san 茴香散, 
the top herb with a frequency of 11 times was shu di huang. Then the ingredients of Hui 
xiang san (xiao hui xiang 小茴香 and chuan lian zi川楝子) together with shan zhu yu 
山茱萸 shared second place. In this common herb list, herb with blood-activating action 
(dang gui 当归) was found, which correspond to the blood stasis syndromes in some 
DKD patients. 
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4.3.5 Common herbs for DKD symptoms/signs 
In total, 73 citations reporting the presentation of turbid urine were included in analysis. 
The number of citations in each pool and the most cited herbs are shown in Table 4-10. 
The most cited herbs for turbid urine were highly consistent with the common herbs 
lists for DKD (seen in Table 4-9) except for huang qi 黄芪, which commonly appeared 
in citations mentioning turbid urine but was not listed in the common herbs of the 
conditional DKD pool, which indicated that huang qi may be specific for symptom of 
turbid urine.  
 
Oedema was reported in three citations using the formulae Huang cong rong wan花苁
蓉丸 and modified ba wei wan 加减八味丸. Frequency analysis of these herbs was not 
performed due to the limited number of citations.  
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Table 4-10 Common herbs for turbid urine 
Citation pool 
(citations 
included) 
Herb name (pin yin) English name No. of 
citations 
Most likely 
DKD 
citations 
(n=20) 
fu ling茯苓 Poria 12 
shu di huang 熟地黄 Rehmanniae Radix Praeparata 11 
ze xie泽泻 Alismatis Rhizoma 10 
shan zhu yu 山茱萸 Corni Fructus 9 
mu dan pi 牡丹皮 Moutan Cortex 8 
shan yao 山药 Dioscorea Rhizoma 8 
tian hua fen 天花粉 Trichosanthis Radix 5 
zhi mu 知母 Anemarrhenae Rhizoma 5 
huang lian 黄连 Coptidis Rhizoma 4 
jian si茧丝 Silk cocoon, Silk floss 4 
Possible DKD 
citations 
(n=35) 
ren shen人参 Ginseng Radix Et Rhizoma 14 
wu wei zi五味子 Schisandrae Chinensis Fructus 14 
fu ling茯苓 Poria 12 
huang lian 黄连 Coptidis Rhizoma 10 
ji nei jin鸡内金 Galli Gigerii Endothelium Corneum 9 
shu di huang 熟地黄 Rehmanniae Radix Praeparata 9 
huang qi 黄芪 Astragali Radix 8 
mu li 牡蛎 Ostreae Concha 7 
tu si zi菟丝子 Cuscutae Semen 7 
ci shi 磁石 Magnetitum 6 
shan yao 山药 Dioscorea Rhizoma 6 
ze xie 泽泻 Alismatis Rhizoma 6 
Conditional 
DKD 
citations 
(n=18) 
shu di huang 熟地黄 Rehmanniae Radix Praeparata 11 
shan zhu yu 山茱萸 Corni Fructus 8 
gan cao甘草 Glycyrrhizae Radix Et Rhizoma 6 
shan yao山药 Dioscorea Rhizoma 6 
ze xie泽泻 Alismatis Rhizoma 6 
chuan lian zi川楝子 Toosendan Fructus 5 
dang gui当归 Angelicae Sinensis Radix 5 
fu ling茯苓 Poria 5 
huang qi黄芪 Astragali Radix 5 
Abbreviation: n: number of citations. Note: The use of some herbs may be restricted in 
some countries; readers are advised to comply with relevant regulations.  
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4.4 Discussion 
4.4.1 Summary of findings 
In the field of CM, historical medical literature spans more than 2500 years and is still 
of great value in guiding modern clinical practice. In the case of DKD, although there 
was no ancient disease name directly corresponding to the modern definition of DKD, 
descriptions consistent with clinical manifestations of DKD can be located by specific 
terms. These terms were basically typical symptoms and signs of diabetes and its 
complications.  
 
The three terms employed as search terms in this study were Shen Xiao, Xia Xiao and 
Xiao Shen. Nearly 300 citations with treatment information were identified by these 
search terms. Comparing the dynasty distribution and hit frequency in different citation 
pools of the three terms, it was observed that none of the terms was superior to the 
others in terms of identifying historical literature about DKD. Therefore, citations 
retrieved by any of the three terms were equally important as information sources.  
 
Citations spanned from the Tang to the Qing dynasties in Chinese history. However, 
most citations were found in books written or published in the Ming Dynasty (1369–
1644) and Qing Dynasty (1645–1911), most of which were official prescription 
monographs and medical encyclopaedias.  
 
All included citations provided treatment information related to internal administration 
of herbal medicine. A variety of formulae with different indications were identified in 
the citations. Comparing the common formulae identified in different citations pools, 
Liu wei di huang wan and Hui xiang san were the most frequently cited formulae. The 
former and its modified formulae, such as Shen qi di huang tang 参芪地黄汤, Qi ju di 
huang wan 杞菊地黄丸 and Ji shen shen qi wan 济生肾气丸, have been widely used 
and are recommended in CM guidelines today [167-169]. This confirmed that 
information from CM historical literature can inform contemporary clinical practice.  
 
But another commonly cited formula, Hui xiang san, was seldom applied or mentioned 
as treatment for DKD today. The reason could be the potential toxicity of chuan lian zi 
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川楝子 raising concerns in modern practice. There was a report of toxic hepatitis after 
taking the medicinal ku lian 苦楝, which has the same genus as chuan lian zi [179, 180]. 
Thus, the use of Hui xiang san is limited today.  
 
There were approximately 150 unique herbs found in the treatment citations. The herbs 
commonly reported in different citation pools were mainly tonics and astringents with 
meridian entry into the Kidney. Several heat-clearing herbs and blood-activating herbs 
were also commonly mentioned. This indicated that elimination of pathogens and 
reinforcement of body essence were both important and should be considered together 
in the treatment of DKD. By comparing the common herbs list of the diseases with the 
lists of symptoms, huang qi 黄芪 was identified as specific for turbid urine.   
 
Although the majority of common herbs in the historical literature have been used up 
until today, some herbs should be used with caution, especially in those with kidney 
impairment. For example, the ingredient ci shi 磁石 requires special processing from 
the raw material and it cannot be boiled in iron cookware.  
 
4.4.2 Limitations 
There were several limitations which may impact on the results. First of all, the search 
scope was limited by the search terms. Despite the selected terms being relatively 
specific to find the citations consistent with DKD more than other ancient terms, they 
were not broad enough to retrieve all citations potentially related to DKD. The number 
of included citations was relatively small. Future development of Boolean search 
functions in the ZHYD may enlarge the treatment citations pool and provide a more 
comprehensive evaluation. 
 
Secondly, the lack of direct evidence to confirm the consistency between ancient terms 
and modern DKD is an unavoidable limitation in classical CM literature study. 
Although citations describing exclusive aetiologies or symptoms/signs of DKD were 
excluded and a rating system of relevance to DKD was developed, it cannot be assured 
that disorders described in the classical citations were equal to modern DKD.  
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Lastly, frequency analysis of formulae and herbs was conducted to find the most 
common treatment methods. But it should be noted that the most commonly cited 
formulae or herbs may not be the most effective interventions. It should also be noted 
that formulae and herbs identified from this study may not be specific for DKD. Some 
of them can be prescribed as treatments for other diseases. In the CM theory, some 
diseases with different causes may share the same pathogenesis, therefore they can be 
treated by identical formulae. For example, the formula Liu Wei Di Huang Wan is 
constructed with the function of replenishing yin, especially targeting on the Kidneys. 
Thus, Liu Wei Di Huang Wan is a treatment option for various diseases involved with 
Kidney yin deficiency.  
 
4.5 Summary  
The ancient disease terms Shen Xiao, Xia Xiao and Xiao Shen were useful in locating 
historical literature possibly related to DKD. The most frequently cited formulae in the 
classical literature were Ba wei wan, Liu wei di huang wan and Hui xiang san. 
Furthermore, the commonest herbs in classical literature for DKD treatment were those 
with tonifying Kidney, securing essence, clearing heat and activating blood action. The 
herb huang qi was frequently appeared in citations relating to turbid urine, indicating 
its potency in targeting relief of proteinuria.   
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This chapter has been published in the journal BMJ Open. 
5 Chinese Herbal Medicine for Diabetic Kidney Disease: A 
Systematic Review and Meta-analysis of Randomised 
Placebo-controlled Trials 
 
5.1 Introduction 
Diabetic kidney disease (DKD) is one of the most common complications of diabetes. 
As the prevalence of diabetes continues to grow globally, it is estimated that the number 
of DKD patients will double by 2025 [181]. Since patients with DKD are at markedly 
higher risks of progression to end stage kidney disease (ESKD) and cardiovascular 
disease (CVD), the socioeconomic and public health burden of DKD is significant [3, 
4]. Effective therapies in preventing and treating DKD are therefore of critical 
importance.  
 
Glycaemic management, blood pressure (BP) control and renin–angiotensin system 
(RAS) inhibitors are the mainstay of treatment for DKD and has been successful in 
reducing risk of disease onset or progression [2, 5]. However, unmet needs exist in 
diabetes patients intolerant of or unresponsive to current pharmacotherapies, and those 
DKD patients with deteriorating renal function yet normo-albuminuria [66, 182, 183]. 
Some promising therapies addressing novel targets, such as sulodexide and 
bardoxolone methyl, have been found to be ineffective and/or harmful, while several 
others, including sodium-glucose cotransporter 2 (SGLT-2) inhibitors and 
mineralocorticoid receptor antagonist and phosphodiesterase inhibitors, are still under 
evaluation [155, 160, 184]. 
 
To facilitate the discovery of new therapeutic agents for patients with diabetes and 
impaired renal function, screening candidates from natural products including Chinese 
herbal medicine (CHM) which have been traditionally used for symptoms associated 
with this indication may offer insights into a more targeted approach for therapeutic 
development. With respect to CHM, relevant records of treatment of DKD symptoms 
in Chinese classical literature date back to the Han Dynasty (AD 202–220) and it has 
evolved to contemporary literature including  randomised controlled trials (RCTs) 
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concerning the use of CHM for diabetes and its complications [170]. Multi-ingredient 
herbal decoctions, and manufactured products of Abelmoschi Corolla and Cordyceps 
have been recommended for patients with DKD in the clinical practice guidelines of 
Chinese Medicine (CM) [168, 185]. However, these guidelines were based on experts’ 
consensus rather than outcomes of systematically evaluated, best available clinical 
evidence. Moreover, safety concerns exist due to the potential for aristolochic-acid 
nephrotoxicity with some herbal products [5, 186]. Even though legislation and quality 
control have been reinforced in recent years, the general lack of information regarding 
the safety profiles of some herbal formulae due to their multi-compound nature has 
limited their application [5, 6]. 
 
In recent years, there have been a growing number of clinical trials and systematic 
reviews of CHM for DKD but not of placebo-controlled trials. We therefore undertook 
a systematic review and meta-analysis of randomised, placebo-controlled trials to 
evaluate the efficacy and safety of oral CHM as adjunctive treatment for DKD. 
 
5.2 Methods 
This systematic review was conducted following the Cochrane Handbook of Systematic 
Reviews of Interventions and reported in accordance with the PRISMA guidelines [187, 
188]. The protocol was registered in the PROSPERO database and can be accessed 
online (Registry number: CRD42015029293). 
  
5.2.1 Search strategy  
A comprehensive search was conducted in the following databases irrespective of 
publication status or language: MEDLINE, EMBASE, Cumulative Index of Nursing 
and Allied Health Literature (CINAHL), Cochrane Central Register of Controlled Trials 
(CENTRAL), Allied and Complementary Medicine Database (AMED), China 
BioMedical Literature (CBM), China National Knowledge Infrastructure (CNKI), 
Chonqing VIP (CQVIP) and Wanfang. The former five databases were in English while 
the latter four were in Chinese. Databases were searched from inception to May 2018. 
The US National Institutes of Health register (ClinicalTrials.gov), the Australian New 
Zealand Clinical Trial Registry (ANZCTR), the Chinese Clinical Trial Registry 
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(ChiCTR) and the European Union Clinical Trials Register (EU-CTR) were searched 
for completed but unpublished trials. Further, reference lists of related systematic 
reviews were reviewed for additional publications.  
 
Search terms included “diabetic nephropathy”, “diabetic kidney disease”, 
“albuminuria”, “Traditional Chinese Medicine”, “randomised controlled trial” and their 
synonyms. All terms were mapped to controlled vocabulary (where applicable) in 
addition to being searched as keywords. The MEDLINE search strategy is provided in 
Appendix 2.  
 
5.2.2 Eligibility criteria  
Eligible studies had to fulfill the following criteria: (1) randomised controlled trial 
design; (2) included primary diabetes adults with persistent albuminuria/proteinuria, 
which was defined as an albumin excretion rate (AER) more than 20 µg/min, an 
albumin-to-creatinine ratio (ACR) larger than 30 mg/g [2, 5] or 24-hour proteinuria 
over 0.5 g/d (the overt DKD stage defined by Mogensen and used as in DKD diagnostic 
criteria in China) [189, 190]; (3) oral CHM as intervention which could have been either 
single or multiple ingredients in any form (decoction, granules, capsules etc.); (4) 
CHM-matched placebo was applied in the control group; (5) both intervention and 
control groups received the same conventional treatments of DKD, including 
comprehensive management of glycaemia, BP, serum lipid level, life-style and nutrition 
in accordance with Kidney Disease Outcomes Quality Initiative (KDOQI) clinical 
practice guidelines’ recommendation [2, 5];  and (6) the study reported at least one of 
the primary outcomes. Studies including patients with albuminuria that was not caused 
by diabetes, patients who already had ESKD or those receiving renal replacement 
therapy were excluded. 
 
5.2.3 Outcomes of interest 
Primary outcomes of interest included albuminuria/proteinuria, kidney function, 
number of participants progressing to ESKD, all-cause mortality and adverse events, at 
the end of treatment or follow-up. Progression to ESKD was defined as initiation of 
renal replacement therapy or estimated GFR (eGFR) lower than 15 mL/min/1.73m2. 
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Kidney function was reflected by the measurement of serum creatinine (Scr) 
concentration and glomerulus filtration rate (GFR). Likewise, quantitative 
measurement of albuminuria and proteinuria included urinary albumin excretion rate 
(AER), albumin-to-creatinine ratio (ACR), 24-hour urine protein excretion (UP) and 
protein-to-creatinine ratio (PCR).  
 
Secondary outcomes included cardiovascular mortality, all-cause hospitalisation, 
quality of life (QoL) measured by validated scales, indicators of risk factor control 
(such as fasting blood glucose, glycated haemoglobin [HbA1c], BP, total cholesterol, 
triglycerides, low-density lipoprotein cholesterol [LDLC], and high-density lipoprotein 
cholesterol [HDLC]). All outcomes were reported with specified units at the end of 
treatment or at the end of follow-up. 
 
Safety outcomes included numbers and type of adverse events and serious adverse 
events during the study period.  
 
5.2.4 Study selection and data extraction 
Titles and abstracts identified in searching were screened by one reviewer and then 
checked by another (LZ and XQ) against the predefined criteria. After title and abstract 
screening, possibly relevant studies underwent full-text review by LZ and were cross-
checked by LY to confirm their eligibility. Any disagreement was resolved by consensus 
and discussion with a third reviewer (JS or ALZ). 
 
Two reviewers (LZ and LY) independently extracted data from eligible studies into a 
pre-designed spreadsheet. A third reviewer (JS) cross-checked the data. Study design 
characteristics, trial locations, demographic features (age, types of diabetes, baseline 
albuminuria, kidney function, etc.), intervention and control protocol (herbal 
ingredients, dosage, frequency, treatment duration, follow-up period, etc.) and outcome 
measures were recorded. Authors of studies with missing data were contacted by email 
or telephone to obtain additional data. 
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5.2.5 Data synthesis and analysis 
All studies satisfying the eligibility criteria were included for qualitative synthesis. For 
continuous variables, mean and standard deviation of each study were obtained and 
pooled as mean difference (MD) or standardised mean differences (SMD) with a 95% 
confidence interval (CI). SMD was used in the meta-analysis of albuminuria and 
proteinuria outcomes due to the different scales used in the included studies such as 
microgram per minute (µg/min), milligram to gram (mg/g) and milligram per day 
(mg/24 hours). For dichotomous data, risk ratios (RR) were calculated with a 95% CI. 
Considering the diversity of interventions and potential heterogeneity among included 
studies, a random-effect model was applied in all meta-analyses. Review Manager 
Software (RevMan, version 5.3) was used to perform the statistical analysis [191]. 
 
Pre-defined subgroup analysis included baseline DKD severity and CHM formulae. 
Heterogeneity between studies was detected by using the Cochrane Q statistic and I2 
test. For outcomes with substantial heterogeneity (I2 levels >50%), subgroup analyses 
were performed to explore potential sources, whereby results were stratified by factors 
such as different measured approaches for the same outcome. Sensitivity analysis was 
performed by excluding studies with high/unclear risk of bias in the domain of random 
sequence generation. Publication bias was explored when 10 or more studies were 
included in one meta-analysis by visual inspection of funnel plots for asymmetry.  
 
5.2.6 Quality assessment  
The methodological quality of each individual study was assessed by two reviewers 
(LZ and LY) in parallel according to the Cochrane Risk of Bias (ROB) Tool [192]. For 
the domain of other sources of bias, baseline imbalance and conflicts of interest were 
evaluated. Each domain was judged as high, low or unclear risk of bias with 
justifications. The consistency was checked by a third reviewer (LZ) and disagreements 
were resolved by discussion with methodologists (ALZ and XG).  
 
To evaluate the overall quality of evidence for primary outcomes, the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) approach was 
applied [193]. A panel group was formed to make the GRADE evaluation, which 
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included methodologists, CM practitioners and conventional medicine physicians. The 
assessments of evidence started at “high quality” and were downgraded when 
significant risk of bias, indirectness, inconsistency, imprecision of estimated effect or 
publication bias were detected.  
 
5.2.7 Patient and public involvement 
Patients and the public were not directly involved in this systematic review. 
 
5.3 Results 
5.3.1 Description of studies 
The comprehensive search retrieved over 50,000 citations and 7255 of them were 
examined in full-text (Figure 5-1). Eighty-five percent of the studies were excluded 
due to lack of a placebo control. As a result, 20 eligible studies with 23 publications 
involving 2719 DKD participants were included [194-216]. For studies with multiple 
reports, the most recent publication or the one with primary outcomes was used, and 
complementary outcomes data from other reports was extracted and merged. 
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Figure 5-1 PRISMA flowchart 
Abbreviation: CHM: Chinese herbal medicine; DKD: diabetic kidney disease; RCT: 
randomised controlled trial.   
 
Characteristics of the included studies are summarised in Table 5-1. All 20 studies were 
conducted in China. Except for one study [194] written in English, all others were 
published in Chinese language between 2000 and 2017. Enrolled participants were all 
diabetic patients with persistent albuminuria or proteinuria but varied in terms of 
baseline kidney function. The mean age was 55.1 years old (range 20 to 79 years). Three 
studies [204, 205, 207] used herbal compounds or a single herb as intervention while 
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the remaining 17 studies used CHM formulae with multi-ingredients. The ingredients 
of CHM used in each study are provided in Table 5-2. The most common herbal 
ingredients used by ten or more studies was Astragali radix (15 trials), Rehmanniae 
radix (11 trials) and Rhei radix et rhizoma (10 trials). All studies applied CHM-matched 
placebo, except for one [202] which made Captopril (comparator) identical in 
appearance to CHM (intervention). Treatment duration ranged from 4 weeks to 2 years 
(median 3 months). There was no outcome data with respect to cardiovascular mortality 
and all-cause hospitalisation among the included studies. 
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Table 5-1 Characteristics of included studies 
Study Sample 
size  
(M/F) 
Age Diabetes 
type 
Inclusion criteria of kidney 
function 
Intervention and control 
protocol 
Duration Reported 
outcomes 
Fan, 2010 
[195] 
61 
(28/33) 
59.6 2 Albuminuria 30–300 mg/g or 
30–300 mg/24h 
T: Qi Kui granule 1 bag bid 
C: placebo  
12m UAE; FBG 
Jia, 2012 
[200] 
60 
(29/31) 
58.3 2 Proteinuria <3.5 g/24h;  
Normal Scr level  
T: Qi Wei granule 4.5g tid 
C: placebo 
3m UAE; 24hUP 
Ma, 2011a 
[204] 
414 
(186/ 228) 
56.6 NS Proteinuria ≤4.5 g/24h; 
Scr ≤190 μmol/L 
T: Arctiin granule 1 bag tid 
C: placebo   
2m UAE; 24hUP 
Ma, 2011b 
[205] 
186 
(78/108) 
55.3 NS Proteinuria ≤3.5 g/24h; 
Scr <176 μmol/L 
T1: Arctiin granule 2 bag bid + 
placebo 2 bag qd 
T2: Arctiin granule 1 bag tid + 
placebo 1 bag tid 
C: placebo 2 bag tid 
2m UAE; 24hUP 
Wei, 2012 
[207] 
56 
(24/32) 
50.6 NS Albuminuria 30-300 mg/24h; 
Scr ≤105 μmol/L 
T: Xue Zhi Kang capsule 0.6g tid 
C: placebo 
3m UAE; TC; TG; 
LDLC; HDLC 
Wei, 2016 
[208] 
41 
(32/9) 
61.8 2 Albuminuria >30 mg/g and 
Proteinuria ≤3.5 g/24h 
GFR ≥30 mL/min 
T: Gan Di capsue 3 pieces tid 
C: placebo 
6m Scr; FBG; A1C; 
TC; TG; LDLC; 
HDLC 
Xie, 2011 
[209] 
67 
(30/37) 
62.3 2 Albuminuria 30–299 μg/mg T: Liu Wei Di Huang pill 3g tid + 
Ginkgo biloba tablet 19.2mg tid 
C: LWDHW placebo + GBT 
placebo 
24m UAE; FBG; A1C; 
TC; TG; LDLC; 
HDLC; SBP; DBP 
Yang, 2014 
[210] 
142 
(80/62) 
48.5 NS Albuminuria 30–300 mg/24h; 
Normal Scr level 
T: Qi Ming granule 4.5g tid 
C: placebo 
3m UAE; FBG; TC; 
TG; LDLC; HDLC 
Zhou, 2014 
[215] 
48 
(27/21) 
58.5 2 Proteinuria ≤3.5 g/24h; 
Normal Scr level 
T: Qi Wei granule 6g tid 
C: placebo 
3m UAE; 24hUP; Scr; 
GFR; FBG; A1C; 
SBP; DBP 
Li, 2015 180 59.0 2 Albuminuria >20 μg/min or T: Tang Shen granule 8g bid + 6m UAE; 24hUP; Scr; 
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Study Sample 
size  
(M/F) 
Age Diabetes 
type 
Inclusion criteria of kidney 
function 
Intervention and control 
protocol 
Duration Reported 
outcomes 
[194] (100/80) Proteinuria 0.5–2 g/24h 
GFR 60–130 mL/min 
ACEi/ARB 
C: placebo + ACEi/ARB 
GFR; A1C; TC; 
TG; LDLC; HDLC; 
SBP; DBP; QoL 
Liu, 2015 
[203] 
60 
(NS) 
20–70 2 Albuminuria 20–200 μg/min 
or Proteinuria ≤3.5 g/24h 
GFR >60 mL/min 
T: Qi Huang capsule 1.9g tid + 
losartan 
C: placebo + losartan 
6m 24hUP; Scr 
Ni, 2013 
[206] 
224 
(112/112) 
54.7 NS Albuminuria 20–200 μg/min 
or Proteinuria ≤3.5 g/24h 
GFR 60–130 mL/min 
T: Qi Yao Xiao Ke capsule 2.4g 
tid + benazepril 
C: placebo + benazepril 
3m UAE; 24hUP; Scr; 
GFR; FBG; A1C; 
TC; TG; LDLC; 
HDLC 
Yang, 2017 
[211] 
25 
(23/2) 
59.3 2 Albuminuria 20–200 μg/min 
or 30–300 mg/24h 
T: Qi Zhu granule 1 bag bid + 
irbesartan 
C: placebo + irbesartan 
 
6m UAE; Scr; GFR 
FBG; A1C; TC; 
TG; LDLC; HDLC 
Zhang, 2006 
[212-214] 
221 
(119/102) 
61.9 NS Proteinuria <10 g/24h; 
Scr 133-354 μmol/L or Ccr 
30–70 mL/min 
 
T 1: Modified Qi Wei granule 1 
bag bid + losartan  
T 2: Modified Qi Wei granule 1 
bag bid + losartan simulant 
C: placebo + losartan 
3m 24hUP; Scr; GFR; 
QoL 
Gao, 2006 
[196] 
90 
(NS) 
35-70 2 Albuminuria 20–200 μg/min 
or 30–300 mg/24h 
T: Tang Shen Ning granule 5g tid 
+ benazepril simulant 
C: placebo + benazepril 
2m UAE; Scr; 
Gao, 2017 
[197] 
250 
(116/134) 
52.3 2 Albuminuria 30–300 mg/24h T: Tang Shen Ning granule 8g tid 
+ losartan simulant 
C: placebo + losartan 
3m UAE; Scr; FBG; 
A1C 
Han, 2014 
[198] 
104 
(NS) 
30-78 2 Proteinuria ≥0.5 g/24h 
Scr <265 μmol/L 
T1: Bao Shen pill 1 bag bid + 
Tripterygium glycosides 20mg tid 
T2: Bao Shen pill 1 bag bid 
C: BS placebo + valsartan 
1m 24hUP; Scr 
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Study Sample 
size  
(M/F) 
Age Diabetes 
type 
Inclusion criteria of kidney 
function 
Intervention and control 
protocol 
Duration Reported 
outcomes 
Jia, 2015 
[199] 
56 
(31/25) 
59.6 NS Proteinuria <10 g/24h; 
Scr <265 μmol/L 
T: San Huang Yi Shen granule 1 
bag bid + irbesartan simulant 
C: placebo + irbesartan 
3m GFR 
Li, 2012 
[201, 216] 
315 
(194/121) 
58.1 NS Proteinuria <10 g/24h; 
Scr <265 μmol/L or GFR >40 
mL/min; 
T: Modified Qi Wei granule 4.5g 
bid 
C: placebo + irbesartan 
24m Mortality; 
Composite 
endpoints; QoL 
Lin, 2000 
[202] 
119 
(46/73) 
55.3 NS Proteinuria <0.5 g/24h; 
Normal Scr level 
T: Tang Wei Kang capsule 2g tid  
C: Captopril (same appearance as 
herbal capsule) 
3m UAE; FBG; A1C; 
TC; TG; HDLC 
Abbreviation: 24hUP: 24-hour proteinuria; A1C: glycated haemoglobin; bid: twice daily; C: control group; Ccr: creatinine clearance 
rate; DBP: diastolic blood pressure; FBG: fasting blood glucose; GFR: glomerular filtration rate; HDLC: high-density lipoprotein 
cholesterol; LDLC: low-density lipoprotein cholesterol; m: months; M/F: male versus female; NS: not specified in the original reports; 
qd: once daily; QoL: quality of life; SBP: systolic blood pressure; Scr: serum creatinine concentration; T: tested group; TC: total 
cholesterol; TG: triglycerides; tid: thrice daily; UAE: urinary albuminuria excretion.  
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Table 5-2 Herbal ingredients used in included studies 
Study Formulae name Ingredients 
Fan, 2010 [195] Qi Kui granule Astragali radix; polygoni multiflori radix; abelmoschi corolla 
Jia, 2012 [200] Qi Wei granule Astragali radix; rehmanniae radix; rhei radix et rhizoma; prunellae spica; curcumae rhizoma; euonymus alatus; 
notoginseng radix et rhizoma 
Ma, 2011a [204] Arctiin granule Arctii fructus 
Ma, 2011b [205] Arctiin granule  Arctii fructus 
Wei, 2012 [207] Xue Zhi Kang capsule Fermentum rubrum* 
Wei, 2016 [208] Gan Di capsue  Scutellariae radix; astragali radix; corni fructus; rehmanniae radix phylianthi fructus; leonuri herba leonuri 
herba; bombyx batryticatus; sophorae flos (stir fry processed) 
Xie, 2011 [209] Liu Wei Di Huang pill 
Ginkgo biloba tablet 
Rehmanniae radix; corni fructus; dioscoreae rhizoma; alismatis rhizoma; moutan cortex; poria; ginkgo folium 
Yang, 2014 [210] Qi Ming granule Astragali radix; puerariae lobatae radix; rehmanniae radix; lycii fructus; cassiae semen; leonuri fructus; typhae 
pollen; hirudo 
Zhou, 2014 [215] Qi Wei granule Astragali radix; rehmanniae radix; rhei radix et rhizoma; prunellae spica; curcumae rhizoma; euonymus alatus; 
notoginseng radix et rhizoma 
Li, 2015 [194] Tang Shen granule Astragali radix; rehmanniae radix; rhei radix et rhizoma; notoginseng radix et rhizoma; euonymus alatus; corni 
fructus; aurantii fructus 
Liu, 2015 [203] Qi Huang capsule 
 
Astragali radix; rehmanniae radix; ligustri lucidi fructus; hirudo; bombyx batryticatus; eupolyphaga 
steleophaga; rhei radix et rhizoma; gymnema sylvestre*; sinomenii caulis; plantaginis semen 
Ni, 2013 [206] Qi Yao Xiao Ke capsule  Panacis quinquefolii radix; astragali radix; rehmanniae radix; dioscoreae rhizoma; corni fructus; lycii fructus; 
ophiopogonis radix; anemarrhenae rhizoma; trichosanthis radix; puerariae lobatae radix; schisandrae chinensis 
fructus schisandrae chinensis fructus; galla chinensis 
Yang, 2017 [211] Qi Zhu granule Astragali radix; ligustri lucidi fructus; atractylodis macrocephalae rhizoma; abelmoschi corolla; rosae 
laevigatae fructus dioscoreae spongiosae rhizoma; paeoniae radix rubra; coptidis rhizoma 
Zhang, 2006 
[212-214] 
Modified Qi Wei granule  Astragali radix; rehmanniae radix; prunellae spica; rhei radix et rhizoma; euonymus alatus; epimedii folium; 
corni fructus; curcumae longae rhizoma 
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Study Formulae name Ingredients 
Gao, 2006 [196] Tang Shen Ning granule  Astragali radix; rehmanniae radix; euryales semen; corni fructus; rhei radix et rhizoma; chuanxiong rhizoma 
Gao, 2017 [197] Tang Shen Ning granule  Astragali radix; euryales semen; rosae laevigatae fructus; rhei radix et rhizoma; chuanxiong rhizoma 
Han, 2014 [198] Bao Shen pill; 
Tripterygium glycosides  
Not given.  
Jia, 2015 [199] San Huang Yi Shen 
granule 
Astragali radix; curcumae longae rhizoma; rhei radix et rhizoma; chuanxiong rhizoma; angelicae sinensis 
radix; salviae miltiorrhizae radix et rhizoma; cervi cornu; anemarrhenae rhizoma; arctii fructus 
Li, 2012 [201, 
216] 
 Modified Qi Wei 
granule  
Astragali radix; rehmanniae radix; prunellae spica; rhei radix et rhizoma; euonymus alatus; epimedii folium; 
corni fructus; curcumae longae rhizoma 
Lin, 2000 [202] Tang Wei Kang capsule  Astragali radix; ligustri lucidi fructus; rhei radix et rhizoma 
Note:  All ingredients are the standardised pharmaceutical name from the Chinese Pharmacopoeia 2015. * Monascus purpureus Went. 
(Red Rice Yeast); pharmaceutical name not included in Chinese Pharmacopoeia 2015. 
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5.3.2 Quality of studies 
Generally, the quality of included studies was fair with low or unclear risk of bias, 
especially regarding blinding and outcome data completeness (Figure 5-2). Two studies 
were judged at high risk of bias with respect to blinding of patients and personnel 
because blinding may have been compromised by prescription of unequal 
numbers/amounts of medication between groups [198, 201]. Twelve studies reported 
correct procedures for random sequence generation [194, 195, 198-200, 204-206, 208, 
211, 214], whereas eight studies did not provide adequate details. For the domain of 
allocation concealment, one study did not conceal the allocation to researchers, thus 
was judged at high risk of bias [211]. Seven studies were considered to have high risk 
of selection reporting bias (mainly incomplete reporting in secondary outcomes) [195, 
196, 199, 201, 203, 208, 214], with13 studies were at unclear risk because protocols 
were not found. Other bias asseassment included baseline balance and conflict of 
interest. Two studies included pharmaceutical industry employees as co-authors 
without statements regarding their roles in the study, therefore these two trials were 
judged as high risk for potential conflicts of interest [204, 205]. Seven studies without 
baseline statistical test results or without information regarding sources of funding were 
judged to be at unclear risk [196, 198, 201, 206, 207, 209, 210]. 
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Figure 5-2 Risk of bias of included studies 
Note: The red, yellow and green dots represent high, unclear and low risk of bias of 
the included study in each domain, respectively. 
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5.3.3 Efficacy of Chinese herbal medicine  
Considering the use of RAS blockage may affect the primary outcomes, studies were 
categorised and separated into three groups according to trial application of RAS 
blockade (angiotensin-converting enzyme inhibitors [ACEi] and/or angiotensin 
receptor blockers [ARB]) in each arm prior to meta-analysis. It should be noted that 
conventional concurrent treatments of DKD recommended by guidelines were applied 
equally in both groups in all included studies, such that these conventional treatments 
are not separately mentioned henceforth. The three groups were: 
 CHM versus placebo [195, 200, 204, 205, 207-210, 215]; 
 CHM plus ACEi/ARB versus placebo plus ACEi/ARB [194, 203, 206, 211, 
214]; and 
 CHM versus placebo plus ACEi/ARB [196-199, 201, 202, 214, 216]. 
 
5.3.3.1 Mortality and progression to ESKD 
Although all-cause mortality was measured in a study [201] comparing CHM with 
matched placebo plus Irbesartan, no deaths were observed among the 315 participants 
during the two-year follow-up (Table 5-3). Within the same trial, the number of patients 
that progressed to ESKD was reported as part of a composite outcome, measured the 
number of patients with microalbuminuria progressing to macroalbuminuria, doubling 
of serum creatinine from baseline or initiating of dialysis. Compared with placebo plus 
Irbesartan, the risk of experiencing this composite outcome may be 66% lower in the 
CHM group over the two-year period (RR: 0.34, 95% CI [0.15, 0.77], p =0.01; low-
quality evidence). 
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Table 5-3 Summary of findings table 
Outcomes Anticipated absolute effects* 
 (95% CI) 
Relative 
effect 
(95% CI) 
No. of 
particip
ants 
(studies) 
Quality of the 
evidence 
(GRADE) Risk with 
placebo  
Risk with CHM 
Comparison 1: CHM versus Placebo 
Albuminuria  
follow-up: range 
2 to 12 months 
– SMD 0.92 lower 
(1.35 lower to 0.51 
lower) 
– 1021  
(8 RCTs) 
⨁⨁⨁◯  
MODERATE 
a, b  
24-hour proteinuria  
follow-up: range 
2 to 3 months 
– SMD 1.34 lower  
(2.18 lower to 0.51 
lower) 
– 699  
(4 RCTs) 
⨁⨁◯◯  
LOW a, b, c 
Serum creatinine 
(Scr)  
follow-up: range 
3 to 6 months 
The mean 
Scr was 
77.41 
μmol/L 
The mean Scr in the 
intervention group was 
5.75 μmol/L higher  
(2.06 lower to 13.57 
higher) 
– 85  
(2 RCTs) 
⨁⨁⨁◯  
MODERATE 
a, d 
Estimated 
glomerular 
filtration rate 
(eGFR)  
follow-up: mean 
3 months 
The mean 
eGFR 
was 
96.24 
mL/min 
The mean eGFR in the 
intervention group was 
10.71 mL/min lower  
(23.93 lower to 2.51 
higher) 
– 44  
(1 RCT) 
⨁⨁◯◯  
LOW a, d 
 
Comparison 2: Placebo + ACEi/ ARB versus CHM +ACEi/ARB 
Albuminuria  
follow-up: range 
3 to 6 months  
– SMD 0.56 lower  
(1.04 lower to 0.08 
lower) 
– 330  
(3 RCTs) 
⨁⨁⨁◯ 
MODERATE 
d, e 
24h-proteinuria  
follow-up: range 
3 to 6 months  
– SMD 0.15 lower  
(0.52 lower to 0.23 
higher) 
– 489  
(4 RCTs) 
⨁⨁◯◯  
LOW b, d, e  
Serum creatinine 
(Scr) 
follow-up: range 
3 to 6 months  
The mean 
Scr was 
88.13 
μmol/L  
The mean Scr in the 
intervention group was 
4.02 μmol/L lower  
(7.81 lower to 0.23 
lower) 
– 595  
(5 RCTs) 
⨁⨁⨁◯  
MODERATE 
a, c 
Estimated 
glomerular 
filtration rate 
(eGFR) 
follow-up: range 
3 to 6 months 
The mean 
eGFR 
was 
79.27 
mL/min 
The mean eGFR in the 
intervention group was 
6.28 mL/min higher  
(2.42 higher to 10.14 
higher) 
– 535  
(4 RCTs) 
⨁⨁⨁◯ 
MODERATE 
c, e 
Comparison 3: CHM versus Placebo + ACEi/ ARB 
All-cause mortality  
follow-up: mean 
24 months  
0 per 1000 0 per 1000 
(0 to 0) 
not 
estimable 
315 
(1 RCT) 
⨁⨁⨁◯  
MODERATE f  
Composite end-
points events 
follow-up: mean 
133 per 
1000 
45 per 1000 
(20 to 102) 
RR 0.34 
(0.15 to 
0.77) 
315  
(1 RCT) 
⨁⨁◯◯ 
LOW d, g 
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Outcomes Anticipated absolute effects* 
 (95% CI) 
Relative 
effect 
(95% CI) 
No. of 
particip
ants 
(studies) 
Quality of the 
evidence 
(GRADE) Risk with 
placebo  
Risk with CHM 
24 months  
Albuminuria  
follow-up: mean 
3 months  
– SMD 6.38 lower  
(9.01 lower to 3.75 
lower) 
– 499  
(3 RCTs) 
⨁◯◯◯ 
VERY LOW a, 
b, d 
24h-proteinuria  
follow-up: range 
1 to 3 months  
– SMD 0.00 lower  
(0.32 lower to 0.32 
higher) 
– 260  
(2 RCTs) 
⨁⨁⨁◯ 
LOW d, h 
Serum creatinine 
(Scr) 
follow-up: range 
1 to 3 months  
The mean 
Scr was 
105.52 
μmol/L  
The mean Scr in the 
intervention group was 
4.05 μmol/L lower  
(6.09 lower to 2.01 
lower)  
– 590  
(4 RCTs) 
⨁⨁⨁◯ 
MODERATE 
a, c 
Estimated 
glomerular 
filtration rate 
(eGFR) 
follow-up: range 
1 to 3 months 
The mean 
eGFR 
was 
97.24 
mL/min 
The mean eGFR in the 
intervention group 
was 0.57 mL/min 
lower  
(11.01 lower to 9.88 
higher) 
– 542  
(4 RCTs) 
⨁⨁◯◯ 
LOW a, b, c 
Abbreviations: CI: confidence interval; MD: mean difference; RR: risk ratio; SMD: 
standardised mean difference.  
Note: *The risk in the intervention group (and its 95% confidence interval) is based on 
the assumed risk in the comparison group and the relative effect of the intervention (and 
its 95% CI). GRADE justification: a. Unclear risk of bias of randomisation and 
allocation concealment; b. Significant heterogeneity; c. Wide confidence interval; d. 
Small sample size and wide confidence interval; e. High or unclear risk of attrition bias; 
f. Low events rate leading to imprecise estimation and small simple size; g. Number of 
patients progressing to ESRD were included in composite outcomes, not solely reported; 
h. Unclear risk of attrition bias and potential selecting report bias. 
 
5.3.3.2 Albuminuria 
Fourteen studies reported albuminuria at the end of treatment (Figure 5-3). Based on 
meta-analysis of eight studies [195, 200, 204, 205, 207, 209, 210, 215] involving 1021 
participants, use of CHM probably lowered end-of-study albuminuria compared to 
 91 
 
placebo over 2 to 12 months’ intervention (SMD -0.92, 95% CI [-1.35, -0.51], I2=87%, 
p <0.0001; moderate-quality evidence). Subgroup analysis suggested different CHM 
formulae could be the sources of heterogeneity (Appendix 3). The estimate of effect 
with the least heterogeneity was observed in the Qi Wei granule CHM subgroup [200, 
215] in which albuminuria was 70.06 mg/24h lower compared to placebo after 3 months 
(95% CI [-88.84, -51.28], I2=0%, p <0.0001). Likewise, the Arctiin granule [204, 205] 
reduced albuminuria more than placebo after 2 months’ intervention (SMD -0.38, 95% 
CI [-0.56, -0.20], I2=0%, p <0.0001). 
 
When used in combination with ACEi/ARB, a slightly lower end-of-treatment 
albuminuria level was still observed in the CHM relative to the placebo group over a 3 
to 6 months interval (SMD -0.56, 95% CI [-1.04, -0.08], I2=64%, p =0.002; moderate-
quality evidence) [194, 206, 211]. However, although lower albuminuria excretion was 
reported in the CHM group [196, 197, 202], the effect of CHM in decreasing 
albuminuria compared to ACEi/ARB was uncertain because of the very low quality of 
evidence (Table 5-3). 
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Figure 5-3 Forest plot of albuminuria outcomes 
Abbreviations: ACEi: angiotensin-converting enzyme inhibitors; ARB: angiotensin 
receptor blockers; CHM: Chinese herbal medicine. 
 
5.3.3.3 Proteinuria 
Nine studies measured end-of-treatment 24-hour proteinuria (Figure 5-4). The pooled 
estimated effect showed CHM may reduce proteinuria compared to placebo after 2 to 
3 months’ intevention, although heterogeneity was high (SMD -1.34, 95% CI [-2.18, -
0.51], I2=94%, p =0.002; low-quality evidence) [200, 204, 205, 215]. Subgroup analysis 
revealed that different formulae and proteinuria scales may have been the source of 
heterogeneity (Appendix 3). Pooled estimates of effects of Qi Wei granule [200, 215] 
and Arctiin granule [204, 205] both showed that CHM may lead to greater reductions 
in proteinuria than placebo. Subgroup of measurement unit of milligram per 24-hour 
showed proteinuria was 324.42 mg/24h lower (95% CI, [-485.15, -163.69]; I2=30%; p 
<0.0001) in the CHM group than the placebo group [204, 205, 215]. 
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When used in combination with ACEi/ARB, meta-analysis of four studies with 489 
participants [194, 206, 214] showed that CHM may make little or no difference to 
proteinuria compared to placebo after 3 to 6 months’ intervetions (SMD -0.15, 95% CI 
[-0.52,0.23], I2=72%, p =0.44; low-quality evidence). Sources of heterogeneity were 
not identified (Appendix 3). Likewise, low-quality evidence suggested that CHM may 
make no differences to end-of-treatment proteinuria compared to placebo plus 
ACEi/ARB after 1 to 3 months’ intervention (Table 5-3) [198, 214].  
 
 
Figure 5-4 Forest plot of proteinuria outcomes 
Abbreviations: ACEi: angiotensin-converting enzyme inhibitors; ARB: angiotensin 
receptor blockers; CHM: Chinese herbal medicine. 
 
5.3.3.4 Serum creatinine level 
Ten studies provided end-of-treatment data of serum creatinine (Scr) level (Figure 5-
5). Pooled estimation of two small studies [208, 215] showed that the additional CHM 
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intervention probably made little difference to Scr level compared with placebo after 3 
to 6 months (MD 5.75 μmol/L, 95% CI [-2.06, 13.57], I2=0%, p =0.15; moderate-
quality evidence). When used in combination with ACEi/ARB, end-of-treatment Scr 
level was slightly lower in the CHM than the placebo group over 3 to 6 months, but 
was not clinically significant (MD -4.02 μmol/L, 95% CI [-7.81, -0.23], I2=0%, p =0.15; 
moderate-quality evidence) [194, 203, 206, 211, 214]. Subgroup analysis found that the 
lowering Scr effect of CHM was evident in patients with abnormal baseline Scr after 3 
months’ intervention (MD -9.99 μmol/L, 95% CI [-17.71, -2.26], I2=0%, p =0.01) [206, 
214]. 
 
Slightly lower Scr levels were observed in the CHM group compared to placebo plus 
ACEi/ARB group after 1 to 3 months’ intervention, but the difference was not clinically 
significant [196-198, 214]. A similar effect was found in the subgroup analysis of Tang 
Shen Ning formula compared to placebo plus ARB in 2 to 3 months’ treatment (MD -
3.96 μmol/L, 95% CI [-6.13, -1.78], I2=6%, p =0.0004) [196, 197].  
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Figure 5-5 Forest plot of serum creatinine outcomes 
Abbreviations: ACEi: angiotensin-converting enzyme inhibitors; ARB: angiotensin 
receptor blockers; CHM: Chinese herbal medicine. 
 
5.3.3.5 Estimated glomerular filtration rate 
Of the eight studies, the GFR was estimated by either the Cockcroft-Gault equation or 
other serum creatinine-based equations (Figure 5-6). When CHM was used in 
combination with ACEi/ARB, the end-of-treatment eGFR was slightly higher in the 
CHM group compared to the placebo group after 3 to 6 months’ intervention (MD 6.28 
mL/min, 95% CI [2.42, 10.14], I2=0%, p =0.001; moderate-quality evidence) [194, 206, 
211, 214]. Subgroup analysis of specific formulae showed that the end-of-treatment 
eGFR was 5.22 mL/min higher (95% CI [0.69, 9.74], I2=0%, p =0.02) in the Tang Shen 
Fang formula plus ACEi/ARB group than the placebo plus ACEi/ARB group [194, 214]. 
It should be noted that Cockcroft-Gault equation may overestimate eGFR, leading to 
10-20% higher value in pooled estimation of eGFR than the actual eGFR and these 
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positive results should be interpreted cautionsly.  
 
One small study (44 participants) provided low-quality evidence that CHM made no 
difference to placebo in terms of eGFR after 3 months’ intervention (Table 5-3) [215]. 
When compared CHM to placebo plus ACEi/ARB, meta-analysis results indicated that 
no significant difference in eGFR over 1 to 3 months’ treatment (low-quality evidence; 
Table 5-3) [196, 197, 199, 214]. 
 
 
Figure 5-6 Forest plot of estimated glomerular filtration rate outcome 
Abbreviations: ACEi: angiotensin-converting enzyme inhibitors; ARB: angiotensin 
receptor blockers; CHM: Chinese herbal medicine. 
 
5.3.3.6 Secondary outcomes 
Meta-analysis results of secondary outcomes are summarised in Table 5-4. When 
compared to placebo, the pooled estimated effects for both fasting blood glucose (FBG) 
[195, 197, 202, 206, 208-211] and HbA1c [194, 197, 202, 206, 208, 209, 211, 215] did 
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not show additional benefit of CHM in lowering blood glucose. Likewise, summarised 
effects from three studies showed no statistical differences between the CHM and 
placebo groups for systolic and diastolic BP [194, 209, 215]. CHM resulted in lower 
levels of total cholesterol [194, 202, 206-211], triglycerides [194, 202, 206-211] and 
LDLC [194, 206-211], although HDLC levels [194, 202, 206-211] were not statistically 
significant compared to placebo. However, the results were limited by substantial 
heterogeneity and the reason was not found. Three studies [194, 212, 216] measured 
patients’ QoL by questionnaire at the end of treatment but only two studies used the 
Diabetes QoL tool and provided usable data. The pooled estimation suggested no 
statistically significant differences between the CHM and the placebo groups regarding 
QoL [194, 216]. 
 
Table 5-4 Meta-analysis results of secondary outcomes 
Outcome  Studies Participants Effect estimate 
(95% CI) 
I2 p value 
Fasting blood sugar 9 962 -0.45 [-1.15, 0.25] 93% p =0.21 
Haemoglobin A1c 8 901 0.04 [-0.17, 0.24] 59% p =0.73 
Total cholesterol 8 815 -0.96 [-1.70, -0.21] 95% p =0.01 
Triglyceride 8 815 -0.60 [-1.01, -0.19] 90% p =0.004 
LDLC 7 696 -0.51 [-0.93, -0.09] 92% p =0.02 
HDLC 8 815 0.14 [-0.04, 0.33] 93% p =0.12 
Systolic BP 3 252 0.64 [-0.90, 2.17] 0% p =0.43 
Diastolic BP 3 252 0.14 [-2.02, 2.29] 52% p =0.90 
Diabetes QoL score 2 461 0.07 [-3.87, 4.00] 54% p =0.97 
Abbreviation: BP: blood pressure; CI: confidence interval; HDLC: high-density 
lipoprotein cholesterol; LDLC: low-density lipoprotein cholesterol; QoL: quality of life. 
Note: All outcomes analysed with mean difference.  
 
5.3.4 Safety evaluation of Chinese herbal medicine therapy 
Data on adverse events was provided in 14 studies. Of these, 7 studies stated no adverse 
events (AEs) were observed during the study period [197, 199, 200, 202, 203, 208, 215]. 
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In total, 53 cases of AEs were reported in 7 studies with 1445 participants. Except for 
Li’s study [201], details of AEs in each group were reported. The most common AE of 
CHM was digestive system disorders (18 cases), including abdominal pain and diarrhea 
or sloppy stools [204, 205, 211]. Both the CHM and control groups reported a modest 
number of cases of elevated liver enzyme levels (11 cases), infection (2 cases) or 
anaemia (3 cases) [194, 198, 214]. In a three-arm study [214], one case of hypertension 
in the CHM group, one case of hypotension in the losartan group and one case of 
hyperkalaemia in the CHM plus losartan group were reported. All participants who 
experienced the above AEs recovered after discontinuation of the tested interventions. 
Three cases of serious AEs, including two cases of death and a case of acute myocardial 
infarction (AMI), were reported in Li’s trial [194]. One participant in the CHM group 
died due to subarachnoid haemorrhage while another participant died after AMI. The 
researchers reported that these serious AEs were not related to the study agent. 
 
5.3.5 Sensitivity and subgroup analysis 
Sensitivity analysis by excluded studies with substantial risk of bias regarding 
randomisation showed consistent results with the primary analysis, except for the 
comparison of CHM versus placebo plus ACEi/ARB in terms of Scr level (Appendix 
4). Subgroup analysis indicated that baseline kidney function, different CHM formulae 
and outcome measurment scale could partially explain the variant treatment effect of 
primary outcomes (Appendix 3). Publication bias was not evaluated due to the limited 
number of studies included in each outcome. 
 
5.4 Discussion 
This review included 20 RCTs involving 2719 participants and evaluated the effects 
and safety of CHM in addition to conventional therapies for DKD. As an adjunctive 
therapy, CHM may decrease proteinuria (either measured as urinary albumin or protein 
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excretion) in DKD patients compared with placebo, regardless of concomitant use of 
ACEi/ARB. When CHM and ACEi/ARB were used simultaneously, eGFR improved 
compared to ACEi/ARB alone but studies had measurement shortfalls that may have 
overestimated the effect. CHM appeared to be well tolarated in DKD patients and no 
significant adverse events causal to CHM interventions were reported. These results 
suggest potential short-term renal benefit by adding CHM to conventional 
pharmacotherapies in DKD populations. However, due to the short follow-up periods 
and small numbers of clinical events in terms of mortality and progression to ESKD the 
long-term benefit of CHM is yet to be determined. 
 
This study demonstrated that CHM may be applied as an add-on treatment for DKD to 
achieve better renal outcomes. From the clinical perspective, the short-term 
albuminuria/proteinuria reduction effect of CHM identified in this review is moderate 
when compared to placebo. In patients with chronic kidney disease (CKD), the early 
reduction in albuminuria is associated with lower risk of incident ESKD or doubling of 
Scr level, particulally in those patients with baseline albuminuria greater than 30mg/g 
[217]. Therefore, for the subgroup of DKD patients who are contraindicated for 
ACEi/ARB, CHM may offer some benefit. When used in combination with ACEi/ARB, 
the lowering albuminuria/proteinuria effect of CHM is mild to moderate from a clinical 
perspective. Considering the failure of dual RAS inhibitor therapy, CHM could be a 
potential option for those DKD patients who are on ACEi/ARB to achieve greater 
albuminuria/proteinuria reduction in the short term. The combination of CHM and 
ACEi/ARB may also be beneficial in improving eGFR, especially for patients who 
experienced acute drop of eGFR after early RAS inhibitor initiation.  
 
Findings from this review are in line with those of previous reviews focusing on single 
herbs or particular formulae. Li et al. reviewed the clinical effect of preparations of 
Astragali radix in DKD patients, finding that Astragali injection lowered Scr, increased 
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eGFR and reduced proteinuria based on data from 21 RCTs and 4 non-randomised 
controlled trials [218]. In published reviews of Ginkgo folium extract and Xue Zhi Kang 
capsules, lower FBG and HbA1c levels in the CHM group were reported [219, 220]. 
The inconsistency in terms of the glycaemic outcomes may have been due to differences 
in ingredients among the included studies. In our review, only two trials applied either 
Ginkgo folium extract or Xue Zhi Kang capsules as interventions. The glycaemic control 
effect may have been diluted by other trials using various herbal ingredients which 
targeted the kidney rather than glycaemic control. It should also be noted that the studies 
included in the previous reviews of Ginkgo folium extract and Xue Zhi Kang capsules 
resulted in significant risk of bias (including publication bias). Thus, rigorous and large-
scale clinical trials are needed to confirm the glycaemic control effects of CHM in DKD 
patients.  
 
The renal protective effect of CHM may be related to particular bioactive compounds 
contained in the herbal ingredients included in these RCTs. The most frequently used 
herb was Astragali radix. Both in vitro and in vivo studies have indicated that chemical 
components of Astragali radix, such as Astragaloside IV and Astragalus saponin I, exert 
anti-oxidant and anti-inflammatory properties in diabetic models [221, 222]. These 
chemicals can prevent and restore kidney tissue injury related to oxidative stress. 
Additionally, Astragaloside IV can reduce endoplasmic reticulum stress and increase 
podocyte integrity, which is the therapeutic target for decreasing albuminuria [223, 224]. 
The second most frequently used herb, Rehmanniae Radix, also upregulates anti-
inflammatory and antioxidant effects in diabetic rats [225]. Furthermore, anti-diabetic 
properties were observed in its constituent compound (catalpol) and ethanolic extract 
[226]. Although the glucose-lowering effect of Rehmanniae Radix was not superior to 
metformin, its use was associated with higher anti-inflammatory activity, lower 
oxidative stress levels and restoration of diabetes-induced kidney lesions. The third 
most frequent herb was Rhei Radix et Rhizoma. Active compounds of Rhei Radix et 
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Rhizoma, including anthraquinones (rhein and emodin) and phenolic acids (gallic acid 
and ferulic acid), have been shown to protect the kidneys by reducing oxidative stress, 
inflammation, fibronectin and extracellular matrix accumulation [227-229]. 
Furthermore, in vitro experiments have demonstrated that extracts of Rhei Radix et 
Rhizoma can inhibit lipid peroxidation and lower serum lipid levels, which are risk 
factors for diabetes and DKD progression [230, 231]. 
 
Renal toxicity induced by aristolochic acid (AA) has been a concern since a series of 
renal failure cases caused by AA-contaminated products were reported [232, 233]. In 
our review, the CHM used in included studies appeared to be well-tolerated and safety 
signals were not identified. This could be related to the fact that all herbal ingredients 
investigated were free from AA and some of the studies mentioned strict quality control 
processes regarding the CHM raw materials and manufacturing procedures [194, 201, 
214]. Mortality risk reduction effect of non-AA prescribed CHM was indicated in a 
CKD population study, but for DKD patients, the long-term safety of CHM requires 
further studies to confirm [234]. 
 
Although this review was conducted in a systematic and comprehensive manner, there 
are limitations that should be taken into account when interpreting the findings. Firstly, 
the number of included studies was relatively small and few studies measured and 
reported the same outcomes consistently. This caused difficulty in meta-analysis and 
introduced heterogeneity across studies and led to downgrading the quality of evidence. 
Even meta-analyses with low heterogeneity may not be reliable because there were only 
a very small number of included studies in the subgroup analyses (less than or equal to 
three studies in each subgroup). In addition, the positive effect of CHM in eGFR 
outcomes is dominated by a study using the Cockcroft–Gault equation (64.8% weight), 
leading to possible overestimation of eGFR value, as it is less precise than the guideline 
recommended equations [235]. Core outcome sets with standardised measurements are 
 102 
 
needed in future studies to rigorously assess the effect of CHM. Secondly, most of the 
studies had short follow-up periods (1–3 months) and small sample sizes, leading to 
imprecision of the estimated effect and low centainty with regards to long-term benefit 
and effect on renal function and clinical outcomes. Thirdly, more than half of the 
included studies did not provide information on randomisation and allocation 
procedures, such that the impact of potential selection bias was unclear. Although the 
CHM formulae were processed as granules or capsules in order to achieve blinding, 
quality assurance information for each CHM preparation was not provided in most of 
the studies. Further studies are strongly encouraged to report following the CONSORT 
reporting guidelines with sufficient details regarding the manufacture and quality 
control of investigated CHM [236-238]. Finally, although we did not limit the CHM 
interventions in terms of herbal composition, five included studies shared highly 
homologous CHM ingredients synthesis [194, 200, 201, 214, 215], thereby limiting the 
diversity of CHM treatments evaluated. 
 
Since the participants in most included trials were older adults with a GFR greater than 
60 mL/min, the renal protective effect of CHM in younger individuals and in advanced 
kidney disease is uncertain. Moreover, all included studies were conducted in China, 
such that the effect of CHM reported in this review may not be generalisable to other 
population groups. It should further be noted that, in most of the included studies, the 
forms of CHM used were multi-ingredient herbal formulae which were constructed 
based on traditional CM theory and experts’ clinical experience. While indicative of 
pharmacological studies, the most frequently used ingredients discussed above may not 
necessarily be relevant to the observed effects reported in this study.  
 
5.5 Conclusion 
In conclusion, combination of CHM with conventional RAS inhibitors showed promise 
as an adjunctive treatment for improving renal function and decreasing urinary albumin 
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and protein excretion in patients with DKD. The rate of occurrence of AE was low and 
the tested CHM appeared to be well-tolerated. This systematic review also provided 
potential candidate formulae and frequently used herbs for further investigation. Well-
designed RCTs following reporting guidelines with adequate sample sizes and longer 
follow-up periods are warranted to confirm the long-term efficacy and safety of CHM, 
especially with respect to patient-oriented outcomes such as mortality, disease 
progression and QoL. 
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This chapter has been published in the Journal of Ethnopharmacology. 
 
6 Astragalus Membranaceus (Huang Qi) as an Adjunctive 
Therapy for Diabetic Kidney Disease: An Updated 
Systematic Review and Meta-analysis 
 
6.1 Introduction 
Diabetic kidney disease (DKD) develops in approximately one-third of diabetic patient 
and is asymptomatic in the early stage but rapidly deteriorates [1]. It has been the 
leading cause of chronic renal failure in developed countries for decades and is 
increasingly prevalent in developing regions [72, 79, 239]. DKD causes a large 
socioeconomic burden, as diabetes and impaired renal function relate to higher risks of 
mortality and cardiovascular events [3, 78, 80]. The angiotensin-converting enzyme 
inhibitor (ACEi) and angiotensin II receptor blockers (ARB) are cornerstone therapies 
for DKD, with recent advances of renoprotection in certain sodium glucose co-
transporter 2 (SGLT2) inhibitors [1, 5, 240]. However, current pharmacotherapies are 
compromised by the potential harms of acute kidney injury, hyperkalaemia, 
hypoglycemia, diabetic ketoacidosis and lower limb amputation [241-243]. As diabetes 
increases around the world, novel therapies to limit DKD progression are needed.  
 
Chinese herbal medicine (CHM) has been extensively used in east Asia for centuries. 
In existing historical literature, descriptions highly consistent with symptoms of DKD 
as it is understood in contemporary clinical practice were commonly seen, and some 
medical terms specifically referred to DKD-like manifestations [170]. Text-mining of 
ancient texts found that Astragalus membranaceus (Fisch.) BGE. var. mongholicus 
(BGE.) Hsiao (family name: Fabaceae; common name: astragalus root or milk-vetch 
root; Chinese name: Huang qi) was frequently used for DKD-like discomfort [244]. 
According to Chinese medicine (CM) theory, A. membranaceus is capable of raising 
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yang qi and tonifying the Spleen and Lung qi, therefore facilitating urination and 
reducing oedema [245]. The chemical constitutions of A. membranaceus are diverse 
with over 100 compounds isolated from the crude herb, including flavonoids, saponins, 
polysaccharides, amino acids and some trace elements [245, 246]. A systematic review 
of 11 animal studies provided preliminary evidence that A. membranaceus preparations 
(single-herb decoction or extract) were promising in lowering glycaemia and 
albuminuria excretion, relieving glomerular hyperfiltration and reducing glomerular 
membrane thickness for early stages of DKD [247]. Clinically, A. membranaceus is still 
widely prescribed for DKD today and is recommended in several experts’ consensus-
based practice guidelines in China [167, 185] 
 
Despite A. membranaceus being used for a long time for DKD in Chinese medicine, it 
is still unclear as to the true extent of its efficacy and safety. Generally, herbal 
supplements are not recommended for patients with chronic kidney disease (CKD) in 
conventional medicine guidelines due to the lack of high-quality evidence, 
nephrotoxicity of some herbal compounds and unclear herb–drug interaction [2, 248]. 
Although benefits of A. membranaceus in improving kidney function and reducing 
albuminuria were reported in a systematic review of 25 controlled trials, the certainty 
of evidence was compromised by the low quality of included studies, high 
heterogeneity and imprecise meta-analysis results. Additionally, the previous review 
failed to assess different types of A. membranaceus preparations, to clarify the 
concurrent uses of ACEi or ARB and to sufficiently report adverse events (AEs) [218]. 
Considering the large consumption of A. membranaceus preparations in China, it is 
imperative to rigorously evaluate the efficacy and safety of A. membranaceus as 
adjunctive therapy to conventional treatments for DKD. 
 
6.2 Methods 
This systematic review followed the methods of the Cochrane Handbook of Systematic 
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Reviews and complied with the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) reporting guideline [187, 188]. The review protocol was 
registered with PROSPERO before commencement (CRD: 42017081403).  
 
6.2.1 Information sources and searches 
Five English and four Chinese databases were searched from inception to October 2017. 
Databases included MEDLINE, Embase, Cumulative Index of Nursing and Allied 
Health Literature (CINAHL), Cochrane Central Register of Controlled Trials 
(CENTRAL), Allied and Complementary Medicine Database (AMED), China 
Biomedical Literature (CBM), China National Knowledge Infrastructure (CNKI), 
Chonqing VIP (CQVIP) and Wanfang. There was no limitation on language and 
publication status. References of published systematic reviews with similar topics were 
examined for relevant studies. Clinical trial registries of the WHO, USA, China, 
European Union, Australia and New Zealand were searched for unpublished or ongoing 
trials. Terms and synonyms representing the concepts of DKD and A. membranaceus 
were used in the database searches (search strategy is shown in Appendix 5).  
 
6.2.2 Study selection and eligibility criteria 
Two reviewers independently performed the title/abstract and full-text screening 
process, and a third reviewer checked for consistency. Disagreements of screening 
results were resolved by discussion with methodologists. Randomised controlled trials 
(RCTs) that enrolled adults (aged 18 years and over) diagnosed with DKD secondary 
to primary diabetes and used A. membranaceus preparations in addition to conventional 
therapies as intervention were eligible. All forms of A. membranaceus preparations 
including boiled decoction, extracts, granules and injections were eligible. Studies that 
assessed A. membranaceus combined with other herbal ingredients or complementary 
therapies were not included. All participants received conventional therapies according 
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to clinical practice guidelines, including ACEi or ARB. 
 
The primary outcomes were all-cause mortality, number of patients progressing to end 
stage kidney disease (ESKD), change in albuminuria and proteinuria excretion, change 
in kidney function and AEs. Secondary outcomes included quality of life (QoL), 
glycaemia level, blood pressure (BP) and blood lipids profile. Studies that failed to 
report at least one of the above primary outcomes were excluded. In addition, studies 
including participants with non-diabetic albuminuria, patients already in ESKD or those 
undertaking renal replacement therapy were excluded. 
 
6.2.3 Data collection and quality assessment 
Two reviewers independently extracted data from eligible studies, using a pre-designed 
Microsoft Excel spreadsheet. Information regarding study characteristics (participants’ 
age, gender, diabetes types, baseline kidney function, DKD severity, sample size, 
follow-up period etc.), intervention protocol of A. membranaceus (administration route, 
dosage, frequency, and duration), concurrent conventional therapies (hypoglycaemia 
drugs, use of renin–angiotensin system [RAS] inhibitors etc.) and outcome data was 
collected. Consistency of extracted data was examined by a third reviewer. When 
necessary, authors of the included studies were contacted by email or telephone to 
clarify details or to acquire additional information about their trials.  
 
Two reviewers evaluated the methodological quality of included studies in parallel 
based on the Cochrane Risk of Bias Tool [192]. Methodologists were consulted when 
consensus was not reached. For individual studies, each domain of the risk of bias tool 
was graded as high, unclear or low risk of bias with justifications.  
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6.2.4 Data synthesis and analysis 
Studies fulfilling the eligibility criteria with valid outcome data were included in the 
analysis. Dichotomous data is presented as risk ratio (RR) with 95% confidence 
intervals (CI) and continuous data is presented as mean difference (MD) or standardised 
mean difference (SMD) with 95% CI. A random effects model was used in meta-
analysis. Statistical analysis was performed in RevMan 5.3 and Stata software 11.0 
(Stata Corp. College Station, Texas, USA) [191]. A p value less than 0.05 was 
considered statistically significant. 
 
Treatment effects were analysed separately based on different administration routes. 
Heterogeneity across studies was detected by using the Cochrane Q statistic and I2 test. 
An I2 greater than 50% was considered to represent substantial heterogeneity, and 
subgroup analysis and random effects univariate and multivariate meta-regression was 
conducted to explore potential sources of variants. The pre-specified subgroups were 
baseline kidney function, treatment duration and outcome measured methods, and the 
post-hoc covariate was dosage of A. membranaceus preparation. Sensitivity analysis 
including studies with low risk of bias in randomisation was conducted to assess 
robustness of the results. Publication bias was also examined by visual inspection of 
funnel plots for asymmetry and Egger’s linear regression test for outcomes with ten or 
more included studies.  
 
6.3 Results 
6.3.1 Study selection 
There were 7872 citations retrieved from databases and an extra 143 citations collected 
from the reference lists of published systematic reviews (Figure 6-1). Among the 436 
full-text articles screened, a total of 66 eligible studies were identified [249-314]. The 
most common reasons for exclusion were non-randomized controlled study design 
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(35.5%), neither ACEi nor ARB used (23.8%) and combined use of other investigated 
agents (11.7%). All included studies were performed in China and published in Chinese 
language medical journals from 2000 to 2017.  
 
 
Figure 6-1 PRISMA flowchart 
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6.3.2 Study characteristics 
Details of study characteristics are presented in Table 6-1. A total of 4785 DKD 
participants were included in the 66 eligible studies, with a mean age of 53.5 years 
(range from 18 to 84). The numbers of male and female participants were similar (2,725 
versus 2072, respectively). Twenty-seven studies only enrolled participants with type 2 
diabetes [249, 253, 256-259, 263, 264, 269, 270, 272, 278, 280, 282, 283, 285, 290, 
295, 297, 298, 301, 303, 307, 311], two studies enrolled both type 1 and type 2 diabetic 
patients [296, 312] and other studies did not specify type but only that participants had 
a diagnosis of diabetes [250-252, 254, 255, 260, 262, 265-268, 271, 273, 274, 276, 277, 
279, 281, 284-289, 291, 293, 294, 299, 300, 302, 304-306, 308-310, 313, 314]. Thirty-
two studies recruited DKD patients in the early stage (micro-albuminuria) [249-252, 
256-261, 264, 267-271, 275, 276, 282, 285, 286, 291, 295, 297, 298, 301, 303, 304, 306, 
309, 311, 313], while six studies also included those with overt nephropathy (macro-
albuminuria) [253, 289, 290, 295, 312]. Five studies included DKD patients presented 
that with mild to moderate declined kidney function [255, 272, 278, 283, 299].  
 
In most of the studies (61 RCTs), A. membranaceus preparation was administered in 
the form of intravenous drip injection, which is a sterilised water extract of A. 
membranaceus [249-257, 259-288, 290-294, 296-300, 302-309, 311-314]. The dose of 
A. membranaceus injection varied from 20 to 60 mL per day and 40 mL was the most 
common dose. Oral A. membranaceus preparations were applied in five studies, 
including the forms of tablet [258], granule [295], decoction [289, 310] and extract 
liquid [301]. Treatment duration was on average four weeks, ranging from one to 12 
weeks. Both participants of intervention and controlled groups received matched 
conventional therapies of DKD, including glycaemic and BP control, dyslipidaemia 
regulation, and either ACEi or ARB. Most of the studies reported at least one laboratory 
test outcome of albuminuria, proteinuria or kidney function, but none of them measured 
the clinical outcomes of mortality or number of patients progressing to ESKD.
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Table 6-1 Study characteristics 
Study 
Diabete
s type 
Baseline albuminuria and 
renal function 
Participants 
(male/female) 
Age mean 
(range) 
A. membranaceus 
preparations, dose & 
frequency 
RAS inhibitors, dose & 
frequency 
Treatment 
duration 
Chen, 2010 [251] NS microalbuminuria 112(58/54) 46.73 (NS) injection, 20 mL, qd Irbesartan 150 mg, qd 28 days 
Chen, 2015 [252] NS NS 100(59/41) 63.19 (38-78) injection, 30 mL, qd Telmisartan (dose not given) 2 weeks 
Chen, 2008 [253] T2DM macroalbuminuria 60(34/26) 56.5 (51-78) injection, 20 mL, qd Benazepril 10 mg, qd 4 weeks 
Chen, 2012 [254] NS microalbuminuria 78(35/43) 47.71 (NS) injection, 40 mL, qd Benazepril 10 mg, qd 6 weeks 
Cong, 2013 [255] NS 
mild-moderate renal 
function impaired 
98(60/38) 43.3 (18-65) injection, 40 mL, qd 
Enalapril 10 mg, qd or 
Valsartan 80 mg, bid 
4 weeks 
Cui, 2011 [257] T2DM 
microalbuminuria; Normal 
renal function 
60(34/26) 50.6 (24-68) injection, 30 mL, qd Benazepril 10 mg, qd or bid 12 weeks 
Cui, 2009 [256] T2DM microalbuminuria 72(49/23) 51.2 (35-70) injection, 50 mL, qd Captopril 25 mg, tid 4 weeks 
Dou, 2014 [258] T2DM 
microalbuminuria; Normal 
renal function 
48(25/23) 52.5 (NS) tablet, 4 pieces, bid Valsartan 80 mg, qd 12 weeks 
Geng, 2010 [259] T2DM microalbuminuria 60(26/34) 58 (39-73) injection, 60 mL, qd Benazepril 10 mg, qd 4 weeks 
Hu, 2010 [260] NS 
microalbuminuria; Normal 
renal function 
40(27/13) NS (51-72) injection, 40 mL, qd Valsartan 80 mg, qd 4 weeks 
Huan, 2010 [261] T2DM microalbuminuria 40(21/19) 68.95 (54-82) injection, 30 mL, qd Losartan 100 mg, qd 4 weeks 
Huang, 2013 [262] NS NS 100(NS) 67.05 (43-82) injection, 20 mL, qd Losartan 50 mg, qd 4 weeks 
Huang, 2004 [263] T2DM NS 58(34/24) 57.71 (42-74) injection, 40 mL, qd Benazepril 10-30 mg, qd 4 weeks 
Jiang, 2005 [265] NS Normal renal function 62(34/28) 57.11 (43-74) injection, 30 mL, qd Benazepril 10 mg, qd 1 month 
Jiang, 2010 [264] T2DM microalbuminuria 98(47/51) 62.98 (NS) injection, 30 mL, qd Telmisartan 80 mg, qd 3 months 
Kong, 2015 [266] NS NS 78(37/41) 53 (NS) injection, 20 mL, qd Benazepril 10 mg, qd 3 weeks 
Li, 2008 [268] NS microalbuminuria 78(42/36) 60.6 (38-76) injection, 30 mL, qd Captopril 6.25-50 mg, qd 1 month 
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Study 
Diabete
s type 
Baseline albuminuria and 
renal function 
Participants 
(male/female) 
Age mean 
(range) 
A. membranaceus 
preparations, dose & 
frequency 
RAS inhibitors, dose & 
frequency 
Treatment 
duration 
Li, 2017 [269] T2DM microalbuminuria 110(65/45) NS (48-73) injection, 50 mL, qd Irbesartan 150 mg, qd 1 month 
Li, 2007 [267] NS 
microalbuminuria; Normal 
renal function 
76(49/27) NS (48-71) injection, 40 mL, qd Captopril 25 mg, tid 2 weeks 
Li, 2011 [270] T2DM 
microalbuminuria; Normal 
renal function 
60(48/42) 60 (40-83) injection, 60 mL, qd Irbesartan 150-300 mg, qd 6 weeks 
Li, 2010 [271] NS microalbuminuria 70(44/26) 57.52 (31-72) injection, 50 mL, qd Telmisartan 40 mg, qd 4 weeks 
Liang, 2002 [272] T2DM 
mild-moderate renal 
function impaired 
59(42/17) 53.82 (50-70) injection, 30 mL, qd Benazepril 5-20 mg, qd 4 weeks 
Liu, 2004 [273] NS NS 36(21/15) NS (23-70) injection, 20 mL, qd Captopril 12.5 mg, tid 4 weeks 
Liu, 2013 [274] NS NS 56(32/24) 59.6 (47-65) injection, 40 mL, qd Valsartan 80 mg, qd 30 days 
S. Liu, 2015 [275] T2DM 
microalbuminuria; Serum 
creatinine level < 133 
µmol/L 
56(29/27) 67.25 (NS) injection, 40 mL, qd Irbesartan 150 mg, qd 4 weeks 
Liu, 2010 [277] NS Normal renal function 43(25/18) 62.5 (NS) injection, 40 mL, qd Irbesartan 150 mg, qd 15 days 
X. Liu, 2015 [276] NS microalbuminuria 72(41/31) 53.9 (NS) injection, 50 mL, qd Benazepril 10 mg, qd 30 days 
Liu and Yu, 2004 
[278] 
T2DM 
Serum creatinine level < 
265 µmol/L 
56(32/24) 72 (56-84) injection, 40 mL, qd Valsartan 80 mg, qd 4 weeks 
Ma, 2006 [279] NS NS 168(98/70) 53.2 (40-76) injection, 40 mL, qd Enalapril 10 mg, qd 4 weeks 
Ma, 2016 [280] T2DM NS 86(49/37) 43.65 (35-76) injection, 40 mL, qd Valsartan 80 mg, qd 1 week 
Qi, 2017 [281] NS NS 138(68/70) 39.49 (30-60) injection, 30 mL, qd Captopril 12.5 mg, bid 4 weeks 
Qiu, 2011 [282] T2DM microalbuminuria 120(70/50) 47.98 (32-65) injection, 50 mL, qd Valsartan 80 mg, bid 4 weeks 
Shen, 2006 [283] T2DM 
mild-moderate renal 
function impaired 
56(34/22) 56.5 (40-73) injection, 40 mL, qd Benazepril 10-30 mg, qd 4 weeks 
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Baseline albuminuria and 
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(male/female) 
Age mean 
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A. membranaceus 
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frequency 
RAS inhibitors, dose & 
frequency 
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Shi, 2015 [284] NS NS 84(48/36) 42.98 (34-78) injection, 40 mL, qd Valsartan 80 mg, qd 1 week 
Sun, 2014 [285] T2DM microalbuminuria 76(40/36) 52.24 (39-75) injection, 20 mL, qd Telmisartan 40 mg, qd 2 weeks 
Tang, 2016 [286] NS microalbuminuria 144(87/57) 52.31 (41-68) injection, 20 mL, qd Valsartan 80 mg, qd 4 weeks 
Tian, 2009 [287] NS NS 80(39/41) 49.75 (NS) injection, 50 mL, qd Enalapril 10 mg, qd 2 months 
Tuo, 2011 [288] NS NS 51(47/51) 54.6 (32-76) injection, 40 mL, qd Quinapril 10 mg, qd 4 weeks 
Wang, 2012 [289] NS micro-macroalbuminuria 26(14/12) NS (42-70) decoction, 30 grams, bid Enalapril 5 mg, bid 30 days 
Wang, 2003 [290] T2DM micro-macroalbuminuria 62(28/34) NS (49-78) injection, 30 mL, qd Losartan 50 mg, qd 12 weeks 
Wang, 2008 [291] NS 
microalbuminuria; Normal 
renal function 
69(39/30) NS (39-71) injection, 40 mL, qd Irbesartan 150 mg, qd 1 month 
Wang, 2010 [292] T2DM NS 48(26/22) 42.6 (25-68) injection, 20 mL, qd ACEi or ARB 2 weeks 
Wen, 2004 [293] NS NS 57(40/17) 54.96 (38-72) injection, 30 mL, qd Captopril 12.5 mg, bid or tid 4 weeks 
Wu, 2005 [294] NS NS 53(58/34) 53 (40-68) injection, 20 mL, qd Captopril 25 mg, tid 3 weeks 
Xiang, 2016 [295] T2DM microalbuminuria 67(31/36) 57.96 (NS) granules, 4 grams, bid Valsartan 80 mg, qd 3 months 
G. Xu, 2008 [296] 
T1 & 
T2DM 
macroalbuminuria 52(28/24) 53.16 (26-72) injection, 20 mL, qd Telmisartan 80 mg, qd 6 weeks 
X. Xu, 2008 [297] T2DM microalbuminuria 80(47/33) 49.22 (39-70) injection, 60 mL, qd Losartan 50 mg, qd 4 weeks 
Xu, 2009 [298] T2DM microalbuminuria 56(27/25) 49.2 (34-68) injection, 40 mL, qd Valsartan 80 mg, qd 4 weeks 
R. Yang, 2006 [299] NS 
micro-macroalbuminuria; 
34 cases renal 
insufficiency 
92(56/36) 54.04 (35-68) injection, 20 mL, qd Captopril 12.5 mg, tid 6 weeks 
Y. Yang, 2006 [300] NS NS 62(43/19) NS (56-82) injection, 40-50 mL, qd Losartan 50-100 mg, qd 4 weeks 
Yao, 2015 [301] T2DM microalbuminuria 60(40/20) 51.2 (35-70) extract liquid, 20 mL, qd Captopril 25 mg, tid 8 weeks 
Zeng, 2010 [249] T2DM microalbuminuria 52(31/21) 50.55 (35-74) injection, 40 mL, qd Enalapril 10 mg, qd 4 weeks 
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Zeng, 2007 [250] NS 
microalbuminuria; Normal 
renal function 
80(46/34) 56.23 (47-71) injection, 20 mL, qd Benazepril 10 mg, qd 45 days 
D. Zhang, 2014 [302] NS NS 60(33/27) 57 (40-73) injection, 40 mL, qd Benazepril 10 mg, qd 3 weeks 
Zhang, 2007 [303] T2DM microalbuminuria 50(28/22) 58.2 (NS) injection, 30 mL, qd Candesartan 4 mg, qd 30 days 
Q.Zhang, 2014 [304] NS microalbuminuria 56(33/23) 51.33 (41-70) injection, 60 mL, qd Losartan 50 mg, qd 4 weeks 
Zhang, 2009 [306] NS 
microalbuminuria; Normal 
renal function 
68(39/29) NS (51-72) injection, 30 mL, qd Valsartan 80 mg, qd 4 weeks 
Zhang, 2000 [305] NS NS 35(16/19) NS (21-63) injection, 20 mL, qd Captopril 12.5 mg, tid 4 weeks 
Zhang, 2001 [307] T2DM NS 60(41/19) 56 (42-76) injection, 40 mL, qd Benazepril 5 mg, qd 4 weeks 
Zhang, 2017 [308] NS NS 178(123/55) 54.95 (32-80) injection, 20 mL, qd Valsartan 80 mg, qd 3 weeks 
Zhang, 2012 [309] NS microalbuminuria 60(29/31) 51.65 (NS) injection, 20 mL, qd Valsartan 80 mg, qd 3 weeks 
Zhao, 2011 [310] NS NS 61(35/26) 53.02 (38-63) decoction, 60 grams, qd Benazepril 10 mg, qd NS 
Zhao, 2013 [311] T2DM microalbuminuria 112(65/47) 45.6 (31-59) injection, 40 mL, qd Irbesartan 150 mg, qd 1 month 
Zhao, 2003 [312] 
T1 & 
T2DM 
macroalbuminuria 48(29/19) 53.6 (26-72) injection, 20 mL, qd Enalapril 10 mg, qd 45 days 
Zheng, 2013 [313] NS microalbuminuria 51(28/23) 44.86 (25-72) injection, 60 mL, qd Losartan 50 mg, qd 4 weeks 
Zhong, 2002 [314] NS NS 91(42/49) NS (24-72) injection, 30 mL, qd Benazepril 5 mg, qd 1 month 
Abbreviations: bid: twice a day; mg: milligram; mL: millilitre; NS: not specified; qd: once a day; T1DM: type 1 diabetes mellitus; T2DM: 
type 2 diabetes mellitus; tid: thrice a day. 
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6.3.3 Quality assessment 
The overall methodology quality of included studies was low, because of unmasked 
participants and personnel, unclear randomised and allocated procedures, and potential 
risk of selective reporting (Table 6-2). None of the included studies used blinding 
methods or placebo control to reduce performance bias. Details of approaches to 
generate a random sequence were only provided in nine studies [252, 256, 259, 276, 
284, 286, 299, 304, 313] and 65 out of 66 eligible studies did not report how they 
concealed allocation sequence. All studies were judged at low risk of bias in terms of 
blinding of assessment because of the nature of laboratory test outcomes. Over 70% of 
studies were judged at low risk of attrition bias because of no withdrawals or losses to 
follow-up during the study period. 
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Table 6-2 Summary of risk-of-bias assessment of included studies 
 
Risk of Bias Domain Low risk Justification Unclear risk Justification High risk Justification 
Random sequence generation 13.6% (9) 
Random number chart or 
coin tossing 
86.4% (57) Details not given 0 – 
Allocation concealment 
 
0 – 98.5% (65) Not mentioned 1.5% (1) Coin toss 
Blinding of participants and 
personnel 
0 – 0 – 100% (66) Blinding not used 
Binding of outcome assessment 100% (66) 
Laboratory outcomes 
unlikely influenced by not 
blinding 
0 – 0 – 
Incomplete outcome data 72.7% (48) 
No withdrawals or losses 
to follow-up 
27.3% (18) 
Attrition number not 
mentioned 
0 – 
Selective reporting 0 – 97.0% (64) Protocol not found 3.0% (2) 
Missing outcome 
data 
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6.3.4 Effects of A. membranaceus on albuminuria and proteinuria 
Change of albuminuria was measured in 32 studies using A. membranaceus injection 
[249, 250, 254, 256, 257, 259, 263-265, 267, 270, 271, 275, 276, 279, 280, 282-285, 
287, 288, 291, 292, 297, 298, 303, 304, 307, 309, 312, 313] and 4 studies using oral A. 
membranaceus preparation [258, 295, 301, 310]. The pooled estimation indicated that 
additional use of either intravenous (SMD: -2.05 [-2.49, -1.61], I2=94%) or oral A. 
membranaceus preparations (SMD: -1.27 [-1.82, -0.73], I2=73%) reduced albuminuria 
more than conventional therapies alone (Figure 6-2).  
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Figure 6-2 Forest plot of albuminuria outcome 
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As for proteinuria, the meta-analyses result of 26 studies [251, 253, 254, 259, 262, 268, 
269, 272-274, 277, 278, 283, 286, 288, 290, 292, 294, 296, 299, 302, 305, 309, 311, 
312, 314] also suggested lower proteinuria in the A. membranaceus injection group 
(SMD: -1.85 [-2.34, -1.37], I2=95%), albeit with substantial heterogeneity (Figure 6-
3).  
 
Sensitivity analysis of low risk-of-bias studies found consistent results of both 
albuminuria (SMD: -2.87 [-4.25, -1.50], I2=96%) [256, 259, 276, 284, 304, 313] and 
proteinuria (SMD: -2.79 [-4.31, -1.27], I2=95%) outcomes [259, 286, 299]. But the 
sources of heterogeneity were not identified by subgroup analysis of baseline kidney 
function, treatment duration, outcome measurement methods or different doses of A. 
membranaceus injection (Appendix 6). Univariate meta-regression analysis showed 
that baseline albuminuria excretion partially contributed to the heterogeneity of 
albuminuria outcome (Adjusted R2 = 18.37%, p = 0.009). Likewise, baseline proteinuria 
excretion was part of the source of heterogeneity for proteinuria outcome (adjusted R2= 
22.34%, p= 0.013). Other sources of heterogeneity were not identified. 
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Figure 6-3 Forest plot of proteinuria outcome 
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6.3.5 Effects of A. membranaceus on kidney function 
Kidney function was reflected by the measurement of serum creatinine concentration 
(Scr) and glomerular filtration rate (GFR) in included studies. Of 36 studies employing 
A. membranaceus injection [249, 251-253, 255-257, 261, 264-272, 274-276, 278, 279, 
282, 284-286, 290, 292, 297, 298, 302, 304, 307, 308, 311, 313], the end-of-study 
estimated Scr was −14.78 µmol/L (95% CI [-19.22, -10.33]) lower in the A. 
membranaceus group than the conventional therapies group, although heterogeneity 
was significant (I2=97%, Figure 6-4). In terms of GFR, three studies measured it using 
creatinine clearance [277, 287, 312], while one study estimated it based on Scr [296]. 
Although the GFR of the A. membranaceus group tended to be higher, the effect of add-
on A. membranaceus injection on GFR was uncertain (223 participants; MD: 6.64 
mL/min [-2.11, 15.39], I2=74%).  
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Figure 6-4 Forest plot of serum creatinine concentration outcome 
 
The decreasing Scr effect of A. membranaceus injection was consistent in sensitivity 
analysis (567 participants; MD: -8.31 µmol/L [-10.38, -6.24], I2=69%) %) [252, 256, 
276, 284, 286, 304, 313]. The substantial heterogeneity was not explained by pre-
defined subgroup analysis (Appendix 6). Meta-regression of Scr suggested that 
baseline Scr variants could be the main source of heterogeneity (adjusted R2 =94.08%, 
p <0.0001), in which greater Scr reduction was associated with higher baseline Scr 
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values (Figure 6-5). 
 
 
Figure 6-5 Meta-regression of serum creatinine concentration outcome  
Abbreviations: scrbm: baseline serum creatinine concentration; WMD: weight mean 
differences. Note: the meta-regression outcome of serum creatinine concetration was 
based on the baseline serum creatinine level in each study.  
 
6.3.6 Effects of A. membranaceus on DKD risk factors 
Meta-analysis showed that FBG and HbA1c levels of the additional A. membranaceus 
injection group was lower than the conventional therapies alone group, but no statistical 
differences regarding postprandial blood glucose were observed (Table 6-3). Patients 
receiving additional A. membranaceus injection had lower blood lipid concentration, 
except for non-significant changes in HDLC (Table 6-3). In terms of BP, there were no 
evidence of effect of adjunctive use of A. membranaceus compared to use ACEi or ARB 
alone (Table 6-3).  
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Table 6-3 Meta-analysis results of secondary outcomes 
Outcome (Unit) Administration 
route 
Study Participants Statistical method Effect estimate 
[95% CI] 
I2 p value 
Fasting Blood Glucose 
(mmol/L) 
Intravenous drip 23 1497 Mean Difference  -0.54 [-0.83, -0.24] 94% p =0.0004 
Oral 3 176 Mean Difference  -0.06 [-0.31, 0.19] 0% p =0.65 
Postprandial blood glucose Intravenous drip 4 318 Mean Difference  0.03 [-0.40, 0.46] 0% p =0.89 
Glycated haemoglobin 
(HbA1c, %) 
Intravenous drip 9 522 Mean Difference  -0.20 [-0.39, -0.02] 31% p =0.03 
Oral 2 115 Mean Difference  -0.05 [-0.37, 0.27] 0% p =0.74 
Total cholesterol (mmol/L) Intravenous drip 15 1008 Mean Difference  -1.35 [-1.86, -0.84] 96% p <0.0001 
Oral 1 61 Mean Difference  -0.26 [-0.71, 0.19] NA  p =0.26 
Triglycerides (mmol/L) Intravenous drip 15 1056 Mean Difference  -0.82 [-1.04, -0.60] 91% p <0.0001 
Oral 1 61 Mean Difference  0.05 [-0.35, 0.45] NA  p =0.80 
LDLC (mmol/L) Intravenous drip 1 84 Mean Difference  -2.65 [-3.23, -2.07] NA p <0.0001 
HDLC (mmol/L) Intravenous drip 3 246 Mean Difference  0.55 [-0.07, 1.16] 97%  p =0.08 
Systolic BP Intravenous drip 18 1273 Std. Mean Difference  -0.07 [-0.21, 0.06] 28% p =0.27 
Oral 1 60 Std. Mean Difference  0.00 [-0.51, 0.51] NA p =1.00 
Diastolic BP Intravenous drip 18 1273 Std. Mean Difference  -0.11 [-0.25, 0.03] 33% p =0.11 
Oral 1 60 Std. Mean Difference  -0.09 [-0.59, 0.42] NA p =0.74 
Abbreviations: BP: blood pressure; CI: confidence interval; HDLC: high-density lipoprotein cholesterol; LDLC: low-density lipoprotein 
cholesterol; mmol/L: millimoles per litre; NA: not applicable; Std: standard.  
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6.3.7 Safety outcomes 
Safety outcomes were reported in 20 out of 66 included studies. Fifteen studies stated 
no AEs during the treatment period [256, 257, 261, 262, 265, 270, 276, 278, 287, 288, 
294, 295, 297, 301, 309]. The most common AEs reported in five studies were dry 
cough (18 cases), Scr elevated more than 30% from baseline (15 cases) and dizziness 
(13 cases) [250, 263, 282, 283, 290]. Three cases of angioedema and a case of 
hyperkalaemia were observed in two studies [282, 290]. All AEs were relieved 
spontaneously and there was no difference of incidence across the groups.  
 
6.3.8 Publication Bias 
Publication bias was suspected in relation to outcomes of albuminuria (p <0.001) and 
proteinuria (p <0.001), but not detected in Scr (p =0.287). Funnel plots of both 
albuminuria and proteinuria outcomes were asymmetric, suggesting a lack of studies 
with negative results (Figure 6-6).  
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Figure 6-6 Funnel plot of albuminuria, proteinuria and serum creatinine outcomes 
Note: Panel A. albuminuria outcome; Panel B. proteinuria outcome; Panel C. serum creatinine outcome 
A B 
C 
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6.4 Discussion 
6.4.1 Summary of findings 
This systematic review and meta-analysis indicated that adjunctive use of A. 
membranaceus preparations with conventional therapies was probably beneficial in the 
short-term reduction of urinary albumin/protein excretion and lowering Scr level for 
adult DKD patients. Additionally, the combination of A. membranaceus preparations 
and current pharmacotherapies appeared to be tolerated. However, considering the 
overall low quality of clinical trials, large variant of effect size and potential publication 
bias, application of A. membranaceus preparations should be with caution. 
 
From clinical perspective, the magnitude of urinary albumin/protein reduced by A. 
membranaceus injection was moderate. Based on the results of different measurement 
subgroups, additional uses of A. membranaceus injection resulted in -50.21 mg/day 
(−30.86 ug/min) reduction of albuminuria and −59.64 mg/day (−0.43 g/day) decrease 
of proteinuria. Compared to a previous systematic review, the estimated effect size of 
proteinuria was similar (SMD: -1.85 versus -1.78, respectively). The albuminuria 
outcome could not be compared due to missing measurement units [218]. The moderate 
anti-albuminuria effect was also observed in studies using oral A. membranaceus 
preparations, but the effect on proteinuria was uncertain due to a limited number of 
studies. As albuminuria/proteinuria are established indicators of DKD progression, 
cardiovascular events and deaths, the anti-albuminuria/proteinuria effect of A. 
membranaceus preparations might be helpful in improving these patient-important 
outcomes [315, 316]. 
 
The Scr-lowering effect of A. membranaceus injection was also considerable from the 
clinical point of view, but the effect of oral A. membranaceus preparations was unclear 
since only one small study was included. The Scr-lowering effect of A. membranaceus 
injection was more apparent in the study subgroup of DKD participants with mild to 
moderate declined kidney function. This finding was confirmed by the meta-regression 
analysis that the higher the baseline Scr level, the greater reduction of end-of-trial Scr. 
Since sudden elevated Scr is a common side effect leading to discontinuation of 
ACEi/ARB, A. membranaceus injection could be a complementary therapy particularly 
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for advanced DKD patients intolerant to RAS inhibitors in initial stages.  
 
The add-on effect of A. membranaceus preparations on GFR was uncertain based on 
current meta-analysis results. In a previous review, GFR measured as creatinine 
clearance was 14.02 mL/min higher in the A. membranaceus group than the 
conventional therapies alone group [218]. The inconsistency of GFR outcomes could 
be partly explained by different baseline kidney function. The pooled estimation in the 
previous review was dominated (weight 96%) by a trial of DKD participants with 
moderately impaired renal function, in contrast to the baseline GFR of included studies 
in our review which were all over 60 mL/min. Moreover, the use of RAS inhibitors in 
each arm was not clarified in the previous review, therefore the increased GFR could 
have resulted from the acute effect of ACEi/ARB rather than the therapeutic effect of 
A. membranaceus injections. 
 
Although all included studies used single-herb preparations of A. membranaceus as 
intervention, the bioactive constituents and action mechanisms corresponding to the 
therapeutic effect were not fully clarified. The preparations are extracts of A. 
membranaceus raw herb rather than isolated chemical entities, and contain multi-
components and have synergistic functions. Some action mechanisms have been 
proposed by studies focusing on specific A. membranaceus constituents. For example, 
attenuated podocyte apoptosis by administration of astragaloside IV was observed in 
two different diabetic mouse models [317, 318]. An in vitro study showed that 
astragaloside IV also reversed the high glucose-induced adhesion dysfunction in mouse 
podocyte [319]. As podocyte injuries play a major role in urinary protein leakage, the 
anti-proteinuria properties of A. membranaceus may be partially mediated by the 
podocyte protective effect of astragafloside IV. In addition, in vitro experiments 
suggested that Astragalus saponin I suppressed the oxidative and inflammatory activity 
in high-glucose mesangial cells, thus reducing the accumulation of extracellular matrix 
[320]. Such chemicals contained in A. membranaceus preparations attenuated renal 
injuries secondary to diabetes via multiple targets and multiple pathways, 
supplementary to the RAS inhibitory pathway of ACEi/ARB.  
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6.4.2 Limitations  
This review was intended to be comprehensive and unbiased by performing an 
exhaustive search and pre-defined protocol focusing on the effect of A. membranaceus 
preparations on top of conventional therapies. But limitations existed when interpreting 
and generalising the findings. Firstly, the confidence in the beneficial effect of A. 
membranaceus preparations was compromised due to the unblinded study designs, 
unexplained heterogeneity and potential publication bias. Additionally, the effect of A. 
membranaceus preparations could be exaggerated as larger effects were observed in 
clinical trials published in Chinese compared to those in English [321]. Secondly, there 
was not enough data to completely confirm the safety of A. membranaceus preparations. 
More detailed evaluation and reporting of chemical profiles and AE is required since 
severe allergic reactions have been observed after high-dose oral preparations or 
injections [245]. Thirdly, the long-term effect of A. membranaceus preparations (over 
3 months), particularly for patient-important outcomes, was inconclusive due to the 
lack of evidence.  
 
Clinically, oral A. membranaceus preparations may be preferred over injection for its 
convenience and non-invasive nature. Unfortunately, the effect and safety of oral A. 
membranaceus preparations were less certain due to the limited number of studies and 
various forms of products. For the same reasons, we failed to compare the injected A. 
membranaceus preparations with oral ones to determine which forms achieved better 
therapeutic outcomes. In addition, all included studies were conducted in China with 
adult Chinese participants. Treatment effect may vary when applied to children or other 
ethnic groups.   
 
6.4.3 Implications for future research  
Further studies are needed to better understand the therapeutic effect and safety profile 
of A. membranaceus preparations. Application of placebo is highly recommended to 
reduce the risk of performance bias. RCT with adequate sample sizes and long follow-
up periods in addition to measuring clinically relevant outcomes are warranted. The 
hard outcomes, such as mortality, disease progression and QoL, are more relevant to 
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patients and more informative in clinical decision-making than the surrogate laboratory 
outcomes. Furthermore, well-designed clinical trials of oral A. membranaceus 
preparations are preferred.  
 
In terms of study reporting, it is encouraged to provide information about the 
manufacturing and quality control processes of A. membranaceus preparations. 
Considering the fact that chemical constitutents are affected by the raw material source, 
cultivation methods and manufacturing approach, consistent high-quality A. 
membranaceus preparations are necessary. Lastly, clinical trials with “negative 
outcomes” should also be reported [237, 238, 322]. The included studies evaluating A. 
membranaceus for DKD are overall very positive, but it is likely that negative result 
studies have been undertaken but not reported.  
 
6.5 Conclusion 
This updated systematic review and meta-analysis suggests that adjunctive use of A. 
membranaceus preparations probably reduced albuminuria, proteinuria and serum 
creatinine levels compared to conventional therapies alone in people with DKD. 
Adverse herb–drug interactions were not found. The overall quality of evidence was 
low and the findings should be interpreted with caution. Well-designed RCTs are 
needed to confirm the long-term efficacy and safety of A. membranaceus preparations, 
particularly with respect to outcomes of mortality, disease progression and QoL. 
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7 A Network Pharmacology Approach to Explore the Active 
Compounds and Possible Mechanisms of Huang qi in 
Diabetic Kidney Disease 
 
7.1 Introduction 
Over the past 20 years, traditional drug development has failed to yield a sufficient 
number of new drugs despite increasing investment [323, 324]. This brings into 
question the ongoing validity of conventional drug discovery processes and the 
pharmaceutical industry. The overriding reason for research and design (R&D) failure 
is lack of efficacy and safety revealed in the clinical trial stages [325, 326]. In the field 
of diabetic kidney disease (DKD), two widely known cases of drug failure during 
development are documented, namely, sulodexide and bardoxolone methyl. Sulodexide 
showed a lack of efficacy when compared to placebo during clinical testing, while 
bardoxolone methyl was associated with higher rates of cardiovascular events [155, 
160]. It led to early termination of their Phase III (in human efficacy assessment) trials. 
Considering the huge effort invested before entering the clinical trial phase, this kind 
of failure is a major setback to both industry and the academic field.  
 
Reducing the discrepancy between promising pre-clinical trends and subsequent 
disappointing clinical results is pivotal for new drug development. Conventional drug 
discovery involves compounds highly selective to disease-specific targets chosen as 
potential candidates for drug development research. However, recent advances in 
systems biology reveal that biological systems are complex and robust. The network 
relationships of genes, gene products and other biological components are important 
organism features and a single compound–target drug can be counteracted by after-
effects of other pathways in the same network. The complex nature of biological 
systems and multi-factorial characteristics of chronic diseases like DKD require novel 
methods for new drug discovery and development [327, 328].  
 
In the face of these challenges, a novel drug discovery paradigm named “network 
pharmacology” was advocated in 2008 by Hopkins [10]. This novel drug design and 
discovery approach was based on the development of chemistry, systems biology and 
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network analysis techniques. Different from the traditional “one target, one drug” mode, 
network pharmacology was developed to address the limitations in the traditional drug 
discovery pipeline that focus on selective ligands to act on individual drug targets. In 
contrast to the conventional approach, potential therapy in network pharmacology was 
assumed to modify the hub target in the disease network or regulate multiple targets 
simultaneously, leading to restoration of the biology network back to normal status. 
  
One application of the network pharmacology approach is in the assessment of 
mechanisms of herbal medicine. Due to the complex chemical compositions of medical 
plants, multiple targets and pathways may be affected by a single herb. The bioactive 
compounds and action mechanisms corresponding to the therapeutic effects of Chinese 
herbal medicine (CHM) are difficult to fully elucidate using traditional research 
techniques because they have multiple components and multiple targets. The advent of 
network pharmacology approach may help to shed light on CHM and assist with the 
therapeutic development, as the molecular basis of herbal products can be studied in a 
systematic way [11]. Due to its unique advantages, the network pharmacology approach 
has been increasing applied in the context of Chinese medicine (CM)  and specific tools 
tailored for CM have been developed [329].   
 
This chapter reports on a network pharmacology approach that was used to decipher 
the action mechanisms of the selected herb, huang qi 黄芪 (Astragalus Membranaceus), 
in the treatment of DKD. This herb was selected because it is the most commonly 
studied herb in clinical trials of DKD and has been consistently used in historical CM 
literature, indicating it is the most promising herb for the treatment of DKD. The 
findings of this network pharmacology study provide insight into bioactive compounds 
and a corresponding action mechanism hypothesis related to DKD for future 
experimental confirmation.  
 
7.2 Methods 
The methods used in this study are adapted from the research framework of CM 
network pharmacology proposed by Li et al. [11]. Briefly, herbal chemicals are 
collected and then predicted or searched for corresponding herbal targets. The herbal 
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DKD targets are assembled and constructed into separate protein–protein interaction 
(PPI) networks. The herbal and DKD networks are combined and intersections shown 
in a network configuration. The network undergoes analysis, and active chemicals and 
action mechanisms are revealed. The main steps are shown in Figure 7-1. 
 
 
Figure 7-1 Flowchart of network pharmacology study process 
Abbreviations: DKD: diabetic kidney disease; PPI: protein-protein interaction. 
 
 
7.2.1 DKD target collection 
DKD-related targets were collected from four databases: Online Mendelian Inheritance 
in Man (OMIN), Genetic Association Databases (GAD), Therapeutic Target Database 
(TTD) and DrugBank (Table 7-1). These four databases are recognised as the most 
important when collecting disease targets. Together, they provide enough known target 
information related to specific diseases to use in network analysis [330, 331]. The 
OMIN and GAD databases are repositories of data associated with known genes–
diseases, while the TTD and DrugBank databases provide “druggable” targets for 
specific diseases. In all databases, “diabetic nephropathy” and “diabetic kidney disease” 
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were used as search terms. The retrieved sources, target names and gene symbols of 
each DKD target were collected in a Microsoft Excel spreadsheet. The DKD targets 
that were duplicates and identified in more than one database were removed. The 
remaining targets were examined to exclude non-homogeneous species targets. 
 
Table 7-1 Databases for DKD target collection 
Database (Website) Introduction Update 
Frequency 
Online Mendelian Inheritance in 
Man, OMIN [332] 
www.omim.org 
Primary information repository of over 
15,500 genes and 7,800 genetic 
phenotypes, with a focus on the gene-
phenotype relationship 
Initiated in the 
early 1960s and 
updated daily 
Genetic Association Databases, 
GAD [331] 
geneticassociationdb.nih.gov 
Provides genetic association information 
of complex diseases 
Last updated in 
September 2014 
Therapeutic Target Database, 
TTD [333] 
db.idrblab.org/ttd/ 
Provides information about known and 
explored therapeutic targets, with 
correlated disorders and drugs data  
Updated annually 
DrugBank [334] 
www.drugbank.ca 
Provides chemical data on 11,680 drugs 
and 5,129 protein sequences 
corresponding to these drugs   
The latest version 
5.0 was released in 
2018 
 
 
7.2.2 Herbal chemical collection 
7.2.2.1 Database 
The chemical composition of huang qi was collected from two databases: the 
Traditional Chinese Medicine Database @Taiwan (TCM Database @Taiwan) and the 
Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform 
(TCMSP) [335, 336]. Since the same chemical compounds may have various synonyms 
in different data sources, the herbal compounds collected from TCM 
Database@Taiwan and TCMSP were standardised with unique labels. The PubChem 
and ChEMBL (version 24) public repositories were used as references [337, 338]. 
 
The TCM Database @Taiwan includes not only herbs but also medical minerals and 
animal products recorded in classical literature and dictionaries, claiming to be the 
largest and most comprehensive non-commercial database in the field of CM. A total 
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of 32,364 compounds originating from 453 different Chinese medicinals are indexed. 
All compounds were gathered manually from published literature, with molecule 
structures illustrated for docking purposes [336], therefore ensuring herbal compounds 
and chemical structures can be obtained from the TCM Database @Taiwan.  
 
As for the TCMSP, it provides three types of information: (1) herbal compounds with 
absorption, distribution, metabolism and excretion (ADME) related properties; (2) 
integrated compounds, targets and disease information sourced from PubChem, 
DrugBank and other databases; (3) computed compounds–target relationships and 
target–disease relationships. In total, the TCMSP includes 499 herbs indexed in the 
Chinese Pharmacopoeia (2010 version), 29,834 compounds contained in these herbs, 
3311 targets and 837 associated diseases. One of the advantages of the TCMSP is that 
ADME information is provided, so herbal chemicals with greater druggable possibility 
can be filtered out for further study [335]. 
 
PubChem is the largest open-access archive of chemical information, established by the 
US National Institutes of Health in 2004. It consists of three linked databases 
(Substance, Compound and BioAssay databases). In the PubChem Compound database, 
an aggregated view of a particular compound is provided after standardisation of 
substance descriptions from different data sources [337]. As of August 2018, there were 
over 96 million records of compounds with unique chemical structures which were 
mainly identified by high-throughput screening experiments [337]. On the Compound 
webpage, information about specific compounds includes, but is not limited to, names 
and identifiers, chemical and physical properties, chemical structure, bioactivities and 
related literature (Figure 7-2).  
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Figure 7-2 Snapshot of PubChem Compound summary page for berberine 
 
The other compound source is ChEMBL. This is a freely accessible large-scale 
bioactivity database maintained by the European Bioinformatics Institute. It includes 
extracted and curated bioactivity data from published literature at regular time intervals, 
with a manual annotation process to ensure data quality [338]. In the latest version of 
ChEMBL (version 24), it covers over 1.8 million distinct compounds, 15 million 
bioactivity records and 12,091 targets extracted from nearly 70 thousand publications 
and corresponding databases. Although there are more compounds recorded in 
 137 
 
PubChem, ChEMBL provides a larger proportion of active compounds with dose–
response properties validated in published literature [339]. Likewise, there are overlaps 
and differences regarding the target datasets of PubChem and ChEBML. Thus, the two 
open repositories are complementary to each other and used together in this research. 
 
7.2.2.2 Chemicals collection procedure 
The Chinese names of huang qi were used as search terms. In the TCM Database 
@Taiwan, since the compound records were manually extracted from chemistry 
experiment results, all retrieved herbal compounds were considered reliable, therefore 
could be directly included in the huang qi chemical profile. In contrast, herbal 
compounds identified in the TCMSP went through an additional ADME screening step 
to search for chemicals with potential bioactivity. Herbal compounds with oral 
bioavailability (OB) higher than 30% and drug-likeness (DL) larger than 0.18 were 
eligible for selection [340, 341].  
 
Herbal compounds gathered from the TCM Database @Taiwan and eligible 
compounds from the TCMSP were recorded in a Microsoft Excel spreadsheet as the 
huang qi chemical profile. Molecular names of herbal compounds were standardised in 
accordance with PubChem or ChEMBL databases. Additional compound identifiers 
and chemical information such as Chemical Abstracts Service (CAS) registry number, 
International Chemical Identifier (InChIKeys), molecular formulae and simplified 
molecular input line entry specification (SMILES) notation were collected and recorded 
in the spreadsheet.  
 
7.2.3 Herbal target collection and prediction 
Targets corresponding to the herbal chemicals were generated by two approaches: 
bioactivity database searching and in silico prediction. Bioactive database searching 
was efficient for finding experimental verified targets, while the in silico prediction was 
useful for exploring potentially related targets. Therefore, both methods were used to 
collect targets possibly related to the therapeutic effect of herbal compounds. 
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7.2.3.1 Known herbal target collection 
The PubChem BioAssay database and ChEBML contain structural bioactive data from 
published literature thus they were used as sources of targets validated by laboratory 
experiments [338, 342]. By inputting the compounds’ identifiers, the bioactivity data of 
interaction targets can be downloaded from the compounds’ webpages. Only targets 
labelled “Active” in PubChem databases and those with bioactivities larger than 3000 
in ChEBML were included in the huang qi target profile. Non-homogeneous species 
targets were excluded.  
 
7.2.3.2 Potential herbal target prediction 
The in silico technique was used to predict potential target interaction with given herbal 
compounds. This prediction was based on the chemical similarity theory that chemicals 
with similar molecular structures were likely to act on the same targets [343]. As a 
result, molecular interaction relationships of uncharacterised compounds can be 
assumed. The web server of SwissTargetPrediction (www.swisstargetprediction.ch) 
was used to predict the potential targets of herbal compounds. Over 280 thousand 
ligands and 2686 target are contained in SwissTargetPrediction for chemical similarity 
comparison and target prediction [344].  
 
The SMILES notation of each herbal compound was entered into the 
SwissTargetPrediction web interface, then a 2D structure was automatically 
synchronised (Figure 7-3). After setting target prediction limited to human organisms, 
the computation was performed. Except for the targets predicted based on homology, 
all putative targets were added to the huang qi target profile.  
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Figure 7-3 Example working interface of SwissTargetPrediction 
 
7.2.3.3 Herbal target profile construction 
Both huang qi known targets and putative targets were assembled and recorded in a 
spreadsheet. The targets’ name and identifiers were standardised based on the official 
gene symbols in the Universal Protein Resource (UniProt) knowledge base 
(www.uniprot.org), which covers over 60 million protein sequences and associated 
annotation [345]. Duplicate targets were removed. 
 
7.2.4 Construction of Herb–DKD protein–protein interaction network  
In a living organism, intentional physical contact between proteins are essential in both 
biological processes and disease status, and is defined as protein–protein interaction 
(PPI) [346]. These PPI relationships can be detected by experiment and the proven PPIs 
have been manually curated in primary databases by different research groups. In this 
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study, five primary databases were searched to explore human PPIs of collective targets, 
including the Biological General Repository for Interaction Datasets (BioGRID), the 
Biomolecular Interaction Network Database (BIND), the Molecular INTeraction 
Database (MINT), the Human Protein Reference Database (HPRD) and the Database 
of Interacting Proteins (DIP) [347-351]. The plugin app of Cytoscape software named 
BisoGenet was used to retrieve data from these databases simultaneously [352].  
 
The complex PPI relationships of huang qi and DKD targets were visualised as a 
network by Cytoscape software (version 3.6.1) [353]. The PPI networks of huang qi 
targets and DKD were built separately. In a PPI network, a node represents a target and 
the edge represents an interaction link between nodes. To explore the action mechanism 
of huang qi in terms of DKD pathogenesis, the herbal PPI network and DKD PPI 
network were merged to find overlapping targets. As a result, a herb–DKD network of 
shared targets was constructed.  
 
7.2.5 Network and enrichment analysis  
7.2.5.1 Network analysis of key targets 
Based on graph theory, the importance of each node in a network can be evaluated by 
centrality indices from a topological point of view. Four basic centrality measures were 
calculated to identify key targets in the herb–DKD PPI network, including degree 
centrality (DC), betweenness centrality (BC), closeness centrality (CC) and eigenvector 
centrality (EC). The topological meanings of these centrality indices are listed in Table 
7-2 with interpretations in a biological context. The CytoNCA app in the Cytoscape 
software was used for central indices calculation [354]. Targets with DC, BC, CC and 
EC quantitative values ranked in the top 10 per cent among the whole herb–DKD targets 
list were defined as key targets and selected for further analysis.  
  
 141 
 
Table 7-2 Definition of central indices  
Index Definition Biological interpretation 
Degree 
centrality  
The number of nodes directly 
connected to a given node, 
corresponding to the number of 
adjacent links 
Target with higher degree centrality 
links to more targets, suggesting a 
central regulatory role 
Betweenness 
centrality 
The number of times a given node 
bridges the shortest path between two 
other nodes 
Target with higher betweenness 
centrality communicates more distant 
targets, indicating an organising 
regulatory role 
Closeness 
centrality 
The average length of the shortest 
path between the node and all other 
nodes in the network  
Target with higher closeness 
centrality is closer to all other targets, 
suggesting a central regulatory role 
Eigenvector 
centrality 
The number of high degree centrality 
nodes connected to a given node 
Target with higher eigenvector 
centrality interacts with more central 
targets 
References:[355, 356].  
 
7.2.5.2 Enrichment analysis of key targets 
To understand the biological role of the key targets, gene ontology and pathway 
functional enrichment analysis were performed. Gene ontology (GO) is a dynamic, 
structured, well-defined, controlled vocabulary produced by biologists to describe 
knowledge of gene and gene products in organisms [357]. In addition to descriptions 
of gene functions, the relations between gene functions are also provided. However, 
due to the complexity of biological systems, one gene or gene product may be involved 
in different biological processes, and therefore labelled with many inter-linked GO 
terms. For a given gene set, enrichment analysis can identify the GO terms where these 
genes are markedly present. Similarly, the over-represented pathways of specific gene 
sets can be revealed by pathway enrichment analysis.  
 
The GO and pathway enrichment analysis were conducted in the FunRich Functional 
Enrichment Analysis Tool (version 3.1.3) [358, 359]. The gene symbols of the key 
targets of the herb–DKD PPI network were entered in the software, with default 
analysis gene background. Default parameters were used for enrichment analysis, with 
an adjusted Bonferroni p-value <0.01 considered the significance cut-off. The 
relationships and cross-talk among the top 10 enriched pathways were further analysed 
based on the sub-pathway searching results in the PathwayCommons database 
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(www.pathwaycommons.org/pc/home.do) [360].  
 
7.3 Results 
7.3.1 Characteristics of DKD targets 
Searching in OMIN, GAD, TTD and DrugBank databases retrieved a total of 118 
human targets related to DKD. After duplicate removal, 103 DKD-related targets 
remained (Table 7-3). Among these DKD-related targets, angiotensin-converting 
enzyme (ACE) appeared in all four databases. Mitochondrial superoxide dismutase 
(SOD2), advanced glycosylation end product-specific receptor (AGER), C-C 
chemokine receptor 2 (CCR2), C-C chemokine receptor 5 (CCR5), transforming 
growth factor beta receptor 1 (TGFBR1), Type-1 angiotensin II receptor (AGTR1), 
Vascular endothelial growth factor A (VEGFA) and methylenetetrahydrofolate 
reductase (MTHFR) were identified in two different databases.  
 
Table 7-3 Known DKD targets 
Uniprot entry Gene symbol DKD rarget name 
P08183 ABCB1 Multidrug resistance protein 1  
Q92887 ABCC2 Canalicular multispecific organic anion transporter 1  
Q9UNQ0 ABCG2 ATP-binding cassette sub-family G member 2  
P12821 ACE Angiotensin-converting enzyme  
Q15848 ADIPOQ Adiponectin  
Q9H2P0 ADNP Activity-dependent neuroprotector homeobox protein  
P18825 ADRA2C Alpha-2C adrenergic receptor  
P08588 ADRB1 Beta-1 adrenergic receptor  
P07550 ADRB2 Beta-2 adrenergic receptor  
Q15109 AGER Advanced glycosylation end product-specific receptor  
P01019 AGT Angiotensinogen  
P30556 AGTR1 Type-1 angiotensin II receptor  
P02768 ALB Serum albumin 
Q6Q788 APOA5 Apolipoprotein A-V  
P02656 APOC3 Apolipoprotein C-III  
P02649 APOE Apolipoprotein E  
P56817 BACE1 Beta-secretase 1  
P06276 BCHE Cholinesterase  
P46663 BDKRB1 B1 bradykinin receptor  
P04040 CAT Catalase  
P41597 CCR2 C-C chemokine receptor type 2  
P51681 CCR5 C-C chemokine receptor type 5  
P23141 CES1 Liver carboxylesterase 1  
 143 
 
Uniprot entry Gene symbol DKD rarget name 
P29279 CTGF Connective tissue growth factor  
P05177 CYP1A2 Cytochrome P450 1A2  
P10632 CYP2C8 Cytochrome P450 2C8  
P11712 CYP2C9 Cytochrome P450 2C9  
P33261 CYP2C19 Cytochrome P450 2C19  
P10635 CYP2D6 Cytochrome P450 2D6  
P08684 CYP3A4 Cytochrome P450 3A4  
P20815 CYP3A5 Cytochrome P450 3A5  
O15528 CYP27B1 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial  
P43146 DCC Netrin receptor DCC  
P05305 EDN1 Endothelin-1  
P25101 EDNRA Endothelin-1 receptor  
P01588 EPO Erythropoietin  
P09488 GSTM1 Glutathione S-transferase Mu 1  
Q30201 HFE Hereditary hemochromatosis protein  
P20823 HNF1A Hepatocyte nuclear factor 1-alpha  
P00738 HP Haptoglobin  
P05362 ICAM1 Intercellular adhesion molecule 1  
P08833 IGFBP1 Insulin-like growth factor-binding protein 1  
P01584 IL1B Interleukin-1 beta  
P18510 IL1RN Interleukin-1 receptor antagonist protein  
P08887 IL6R Interleukin-6 receptor subunit alpha  
P05106 ITGB3 Integrin beta-3  
P23458 JAK1 Tyrosine-protein kinase JAK1  
O60674 JAK2 Tyrosine-protein kinase JAK2  
P05412 JUN Transcription factor AP-1  
P11150 LIPC Hepatic triacylglycerol lipase  
P01374 LTA Lymphotoxin-alpha  
P09960 LTA4H Leukotriene A-4 hydrolase  
Q99683 MAP3K5 Mitogen-activated protein kinase kinase kinase 5  
P53778 MAPK12 Mitogen-activated protein kinase 12  
Q9UBB5 MBD2 Methyl-CpG-binding domain protein 2  
P02686 MBP Myelin basic protein  
P08473 MME Neprilysin  
P03956 MMP1 Interstitial collagenase  
P08253 MMP2 72 kDa type IV collagenase  
P14780 MMP9 Matrix metalloproteinase-9  
P42898 MTHFR Methylenetetrahydrofolate reductase  
Q96PU5 NEDD4L E3 ubiquitin-protein ligase NEDD4-like  
P35228 NOS2 Nitric oxide synthase, inducible  
P29474 NOS3 Nitric oxide synthase, endothelial  
P08235 NR3C2 Mineralocorticoid receptor  
P16860 NPPB Natriuretic peptides B  
O95427 PIGN GPI ethanolamine phosphate transferase 1  
P27169 PON1 Serum paraoxonase/arylesterase 1  
P37231 PPARG Peroxisome proliferator-activated receptor gamma  
P23219 PTGS1 Prostaglandin G/H synthase 1  
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Uniprot entry Gene symbol DKD rarget name 
Q13464 ROCK1 Rho-associated protein kinase 1  
P34741 SDC2 Syndecan-2  
P05121 SERPINE1 Plasminogen activator inhibitor 1  
P05120 SERPINB2 Plasminogen activator inhibitor 2  
Q9UIV8 SERPINB13 Serpin B13  
Q6FHJ7 SFRP4 Secreted frizzled-related protein 4  
Q9NRM0 SLC2A9 Solute carrier family 2, facilitated glucose transporter member 9  
P23975 SLC6A2 Sodium-dependent noradrenaline transporter  
P46059 SLC15A1 Solute carrier family 15 member 1  
Q16348 SLC15A2 Solute carrier family 15 member 2  
Q4U2R8 SLC22A6 Solute carrier family 22 member 6  
Q9Y694 SLC22A7 Solute carrier family 22 member 7  
Q8TCC7 SLC22A8 Solute carrier family 22 member 8  
Q96S37 SLC22A12 Solute carrier family 22 member 12  
P46721 SLCO1A2 Solute carrier organic anion transporter family member 1A2  
Q9Y6L6 SLCO1B1 Solute carrier organic anion transporter family member 1B1  
Q9NPD5 SLCO1B3 Solute carrier organic anion transporter family member 1B3  
Q6EEV6 SUMO4 Small ubiquitin-related modifier 4  
P22309 UGT1A1 UDP-glucuronosyltransferase 1-1  
P35503 UGT1A3 UDP-glucuronosyltransferase 1-3  
Q9HAW8 UGT1A10 UDP-glucuronosyltransferase 1-10  
P16662 UGT2B7 UDP-glucuronosyltransferase 2B7  
O75795 UGT2B17 UDP-glucuronosyltransferase 2B17  
Q9UKP6 UTS2R Urotensin-2 receptor  
P15692 VEGFA Vascular endothelial growth factor A  
P01137 TGFB1 Transforming growth factor beta-1 proprotein  
P36897 TGFBR1 TGF-beta receptor type-1  
P37173 TGFBR2 TGF-beta receptor type-2  
P01375 TNF Tumor necrosis factor  
Q86Y38 XYLT1 Xylosyltransferase 1  
Q9H1B5 XYLT2 Xylosyltransferase 2  
Q8N4Q0 ZADH2 Prostaglandin reductase 3  
 
7.3.2 Chemical and target profile of huang qi 
There were 22 compounds from huang qi identified in the TCM Database @Taiwan 
and 87 compounds in the TCMSP. After ADME property screening and cross-checking 
against PubChem/ChEMBL databases, 38 compounds remained as potential bioactive 
chemicals of huang qi.  
 
The chemical information of the 38 compounds is summarised in Table 7-4. The 
potential bioactive compounds include flavonoids, terpenes, saponins and alkaloids. 
The molecular weights of compounds range from 117 to 947 g/mol and the molecular 
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masses of 26 compounds were no greater than 500 g/mol. The oral bioavailability (OB) 
and drug-likeness (DL) data are available for 29 compounds. Among the bioactive 
compounds identified from TCM Database @Taiwan, four compounds had an OB less 
than 30% and the DL of five compounds was smaller than 0.18.  
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Table 7-4 Chemical information of bioactive compounds of huang qi 
PubChem ID Compoundname Chemical classification 
Molecular 
formula 
Molecular 
weight 
(g/mol) 
Oral 
bioavailability  
(%) 
Drug-
likeness 
No. of 
targets 
5280343 Quercetin Flavonoids C15H10O7 302.238 46.43 0.28 194 
5280863 Kaempferol Flavonoids C15H10O6 286.239 41.88 0.24 89 
5280378 Formononetin Flavonoids C16H12O4 268.268 69.67 0.21 40 
64971 Betulinic Acid Triterpenoids  C30H48O3 456.711 55.38 0.78 38 
6037 Folic Acid Vitamin B family  C19H19N7O6 441.404 68.96 0.71 35 
5280448 Calycosin Flavonoids C16H12O5 284.267 47.75 0.24 22 
5281654 Isorhamnetin Flavonoids C16H12O7 316.265 49.6 0.31 20 
2837663 
8-(2,3-Dihydroxy-3-methylbutoxy)-4-methoxy-1-
methylquinolin-2-one 
Alkaloids  C16H21NO5 307.346 NA  NA  14 
247 Betaine Alkaloids C5H11NO2 117.148 24.8 0.55 13 
143 Calcium Folinate Vitamin B family  C20H23N7O7 473.446 23.6 0.74 13 
21160900 Chrysanthemaxanthin Terpenoids  C40H56O3 584.885 38.72 0.58 13 
23135 Candicine Alkaloids C11H18NO+ 180.271 38.7 0.04 13 
5316874 Pinosylvin Dimethyl Ether Stilbenoids  C16H16O2 240.302 NA   NA 12 
457801 gamma-Sitosterol Triterpenoids C29H50O 414.718 NA  NA  11 
15976101 (24S)-24-Propylcholesta-5-ene-3beta-ol Triterpenoids C30H52O 428.745 36.23 0.78 10 
5316760 3,9-Dimethoxy-6H-[1] benzofuro [3,2-c]chromene-1,7-diol Pterocarpene  C17H14O6 314.293 39.05 0.48 10 
5317378 Kumujancine Alkaloids C13H10N2O2 226.235 NA  NA  10 
71306915 Astragaloside-II Saponins  C41H66O15 798.964 46.06 0.13 8 
21680050 2-Hydroxy-3-methoxystrychnine Alkaloids  C22H24N2O4 380.444 NA   NA 8 
73299 Hederagenin Triterpenoids  C30H48O4 472.71 36.91 0.75 8 
160767 Isoflavanone Flavonoids C15H12O2 224.259 109.99 0.3 8 
14077830 Astrapterocarpan Flavonoids C17H16O5 300.31 64.26 0.42 7 
108213 Bifendate Heterocyclic compounds C20H18O10 418.354 31.1 0.67 7 
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PubChem ID Compoundname Chemical classification 
Molecular 
formula 
Molecular 
weight 
(g/mol) 
Oral 
bioavailability  
(%) 
Drug-
likeness 
No. of 
targets 
5318035 DSTCZBGJCUOFLM-COECVNONSA-N Terpenoid  C36H58O6 586.854 NA  NA  7 
15689653 Isomucronulatol 7,2'-di-O-glucoside Flavonoid glucosides  C29H38O15 626.608 49.28 0.62 7 
5318869 Jaranol Flavonoids C17H14O6 314.293 50.83 0.29 7 
13943297 n-Benzyloxycarbonyl-1-aminocyclopropanecarboxylic acid Saponins C41H68O14 784.981 17.74 0.15 7 
10380176 NQRBAPDEZYMKFL-NSHDSACASA-N Flavonoids  C17H18O5 302.326 67.67 0.26 7 
9986231 Suffruticoside A Paeonol glycosides  C27H32O16 612.537 13.9 0.2 7 
13996685 Astragaloside I Saponins C45H72O16 869.055 46.79 0.11 6 
441905 Astragaloside III Saponins C41H68O14 784.981 31.83 0.1 6 
71448939 Astragaloside V Saponins  C47H78O19 947.122 NA  NA  6 
71448940 Astragaloside VI Saponins C47H78O19 947.122 NA  NA  6 
14241100 Astragaloside VII Saponins C47H78O19 947.122 NA  NA  6 
15689655 3,9-Di-O-methylnissolin Flavonoids C18H18O5 314.337 53.74 0.48 5 
15689652 7-O-Methylisomucronulatol Flavonoids  C18H20O5 316.353 74.69 0.3 4 
101679160 Astrapterocarpan Glucoside Flavonoid glucosides  C23H26O10 462.451 36.74 0.92 4 
15689654 SRVGYVIWVOOXQO-BKCJKFSYSA-N Flavonoids  C29H38O16 642.607 41.72 0.69 4 
Abbreviation: NA: not available (data not found).  
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Of the 38 potential bioactive compounds, 16 had experiments that verified targets 
according to the PubChem BioAssay and ChEBML databases. After removal of duplicates 
and non-human targets, 303 targets corresponding to the huang qi bioactive compounds 
were identified from the two databases. In addition, 138 potential targets were obtained by 
the in silico prediction. The Venn diagram (Figure 7-4) shows that 71.6% of the herbal 
targets can be found in only one of the sources, indicating the supplementary relationship 
of the target collection methods. In total, the huang qi target profile contains 327 unique 
targets.  
 
 
Figure 7-4 Venn diagram of huang qi targets from different sources 
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The number of targets gained from each of the 38 bioactive compounds varied from 4 to 
194 (Table 7-4). Nearly 90% of compounds (32 out of 36) were thought to interact with 
less than 20 targets. Quercetin and kaempferol contributed many more targets than other 
compounds, with 194 and 89 related targets, respectively. The complex relationships 
between the 38 bioactive compounds and their interactive targets were then represented in 
a network manner (Figure 7-5). Notably, there were shared targets across different 
compounds and unique targets corresponding to specific compounds.  
 
 
Figure 7-5 Huang qi compounds–targets network  
Note: Yellow nodes represent bioactive compounds, blue nodes represent related targets, 
edges represent association relationships. 
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7.3.3 Network analysis of huang qi–DKD PPI network 
7.3.3.1 Characteristics of huang qi–DKD PPI network 
The PPI network for DKD was constructed based on 103 disease-related targets in the 
Cytoscape software, resulting in a DKD-specific PPI network with 2738 nodes and 53,925 
edges. The PPI network for huang qi was generated by using the 327 putative targets by 
the same method, and a herbal PPI network with 8817 nodes and 195,294 edges was 
obtained. Then, a huang qi–DKD shared targets network was built, which consisted of 2269 
nodes and 50,304 edges. Over 83% of targets in the disease PPI network were covered by 
the herbal PPI network. 
 
7.3.3.2 Key targets of huang qi–DKD PPI network 
The network analysis of the huang qi–DKD shared PPI network revealed that the top 10% 
cut-off values of centrality indices were 107 for DC, 0.00139859 for BC, 0.4606947 for 
CC and 0.03383857 for EC. Consequently, 118 key targets from the huang qi–DKD PPI 
network with all centrality indices higher than the cut-off values were identified (Table 7-
5). The four centrality indices of each key target are provided in Appendix 7. 
 
Table 7-5 Key targets of huang qi–DKD PPI network 
Uniprot entry Gene symbol Huang qi–DKD key target name 
P00519 ABL1 Tyrosine-protein kinase ABL1  
P60709 ACTB Actin, cytoplasmic 1  
P07550 ADRB2 Beta-2 adrenergic receptor  
P31749 AKT1 RAC-alpha serine/threonine-protein kinase  
P05067 APP Amyloid-beta A4 protein  
P10275 AR Androgen receptor  
P49407 ARRB1 Beta-arrestin-1  
P32121 ARRB2 Beta-arrestin-2  
O14965 AURKA Aurora kinase A  
P38398 BRCA1 Breast cancer type 1 susceptibility protein  
Q9Y297 BTRC F-box/WD repeat-containing protein 1A  
P0DP23 CALM1 Calmodulin-1 
P0DP24 CALM2 Calmodulin-2 
P0DP25 CALM3 Calmodulin-3 
Q86VP6 CAND1 Cullin-associated NEDD8-dissociated protein 1  
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Uniprot entry Gene symbol Huang qi–DKD key target name 
P22681 CBL E3 ubiquitin-protein ligase CBL  
Q9H0W5 CCDC8 Coiled-coil domain-containing protein 8 
Q16543 CDC37 Hsp90 co-chaperone Cdc37  
P06493 CDK1 Cyclin-dependent kinase 1  
P38936 CDKN1A Cyclin-dependent kinase inhibitor 1  
Q00610 CLTC Clathrin heavy chain 1  
Q92905 COPS5 COP9 signalosome complex subunit 5  
Q92793 CREBBP CREB-binding protein  
P68400 CSNK2A1 Casein kinase II subunit alpha  
Q8NEV1 CSNK2A3 Casein kinase II subunit alpha 3  
P35222 CTNNB1 Catenin beta-1  
Q13617 CUL2 Cullin-2  
Q93034 CUL5 Cullin-5  
Q14999 CUL7 Cullin-7  
O75530 EED Polycomb protein EED  
P68104 EEF1A1 Elongation factor 1-alpha 1  
P00533 EGFR Epidermal growth factor receptor  
Q09472 EP300 Histone acetyltransferase p300  
P03372 ESR1 Estrogen receptor  
Q01844 EWSR1 RNA-binding protein EWS  
Q9NRD1 FBXO6 F-box only protein 6  
P21333 FLNA Filamin-A  
P02751 FN1 Fibronectin  
P35637 FUS RNA-binding protein FUS  
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase  
P62993 GRB2 Growth factor receptor-bound protein 2  
P16104 H2AFX Histone H2AX  
Q13547 HDAC1 Histone deacetylase 1  
Q92769 HDAC2 Histone deacetylase 2  
Q9UQL6 HDAC5 Histone deacetylase 5  
Q9UBN7 HDAC6 Histone deacetylase 6  
 
 
 
 
 
P68431 
HIST1H3A; 
HIST1H3B; 
HIST1H3C; 
HIST1H3D; 
HIST1H3E; 
HIST1H3F; 
HIST1H3G; 
HIST1H3H; 
HIST1H3I; 
HIST1H3J 
 
 
 
 
 
Histone H3.1  
P09651 HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1  
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Uniprot entry Gene symbol Huang qi–DKD key target name 
P61978 HNRNPK Heterogeneous nuclear ribonucleoprotein K  
Q00839 HNRNPU Heterogeneous nuclear ribonucleoprotein U  
P07900 HSP90AA1 Heat shock protein HSP 90-alpha  
P08238 HSP90AB1 Heat shock protein HSP 90-beta  
P34932 HSPA4 Heat shock 70 kDa protein 4  
P11021 HSPA5 Endoplasmic reticulum chaperone BiP  
P11142 HSPA8 Heat shock cognate 71 kDa protein  
P38646 HSPA9 Stress-70 protein, mitochondrial  
P04792 HSPB1 Heat shock protein beta-1  
P10809 HSPD1 60 kDa heat shock protein, mitochondrial  
Q7Z6Z7 HUWE1 E3 ubiquitin-protein ligase HUWE1  
Q14164 IKBKE Inhibitor of nuclear factor kappa-B kinase subunit epsilon  
Q9Y6K9 IKBKG NF-kappa-B essential modulator  
Q12906 ILF3 Interleukin enhancer-binding factor 3  
P46940 IQGAP1 Ras GTPase-activating-like protein IQGAP1  
P05412 JUN Transcription factor AP-1  
Q92993 KAT5 Histone acetyltransferase KAT5  
Q13233 MAP3K1 Mitogen-activated protein kinase kinase kinase 1  
P28482 MAPK1 Mitogen-activated protein kinase 1  
P49736 MCM2 DNA replication licensing factor MCM2  
Q00987 MDM2 E3 ubiquitin-protein ligase Mdm2  
P01106 MYC Myc proto-oncogene protein  
P35579 MYH9 Myosin-9  
P19338 NCL Nucleolin  
P19838 NFKB1 Nuclear factor NF-kappa-B p105 subunit  
P06748 NPM1 Nucleophosmin  
P04150 NR3C1 Glucocorticoid receptor  
P04629 NTRK1 High affinity nerve growth factor receptor  
O75147 OBSL1 Obscurin-like protein 1 
Q504Q3 PAN2 PAN2-PAN3 deadenylation complex catalytic subunit PAN2  
P09874 PARP1 Poly [ADP-ribose] polymerase 1  
P12004 PCNA Proliferating cell nuclear antigen  
P30153 PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform  
P78527 PRKDC DNA-dependent protein kinase catalytic subunit  
O60260 PRKN E3 ubiquitin-protein ligase parkin  
P25788 PSMA3 Proteasome subunit alpha type-3  
P63244 RACK1 Receptor of activated protein C kinase 1  
Q04206 RELA Transcription factor p65  
Q99496 RNF2 E3 ubiquitin-protein ligase RING2  
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Uniprot entry Gene symbol Huang qi–DKD key target name 
P62979 RPS27A Ubiquitin-40S ribosomal protein S27a  
Q9UBS0 RPS6KB2 Ribosomal protein S6 kinase beta-2  
P29353 SHC1 SHC-transforming protein 1  
Q96EB6 SIRT1 NAD-dependent protein deacetylase sirtuin-1  
Q9NRC8 SIRT7 NAD-dependent protein deacetylase sirtuin-7  
Q15796 SMAD2 Mothers against decapentaplegic homolog 2  
P84022 SMAD3 Mothers against decapentaplegic homolog 3  
P51532 SMARCA4 Transcription activator BRG1  
Q9HCE7 SMURF1 E3 ubiquitin-protein ligase SMURF1  
P08047 SP1 Transcription factor Sp1 
Q13501 SQSTM1 Sequestosome-1  
P12931 SRC Proto-oncogene tyrosine-protein kinase Src  
Q9UNE7 STUB1 E3 ubiquitin-protein ligase CHIP  
Q13148 TARDBP TAR DNA-binding protein 43  
P04637 TP53 Cellular tumor antigen p53  
Q9Y4K3 TRAF6 TNF receptor-associated factor 6  
Q71U36 TUBA1A Tubulin alpha-1A chain  
P07437 TUBB Tubulin beta chain  
P0CG48 UBC Polyubiquitin-C [Cleaved into: Ubiquitin] 
P63279 UBE2I SUMO-conjugating enzyme UBC9  
P11441 UBL4A Ubiquitin-like protein 4A  
P55072 VCP Transitional endoplasmic reticulum ATPase  
P40337 VHL von Hippel-Lindau disease tumor suppressor  
P08670 VIM Vimentin 
O14980 XPO1 Exportin-1  
P12956 XRCC6 X-ray repair cross-complementing protein 6  
P31946 YWHAB 14-3-3 protein beta/alpha  
P62258 YWHAE 14-3-3 protein epsilon  
P61981 YWHAG 14-3-3 protein gamma  
P27348 YWHAQ 14-3-3 protein theta  
P63104 YWHAZ 14-3-3 protein zeta/delta  
 
 
7.3.4 Enrichment analysis of key targets 
All 127 key targets obtained from network analysis of the huang qi–DKD PPI network 
were included for GO and pathway enrichment analysis in the FunRich tool. But one target 
(Receptor of activated protein C kinase 1, RACK1) was not indexed in the FunRich default 
databases, therefore it was excluded from enrichment analysis. 
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7.3.4.1 GO enrichment analysis 
The GO enrichment analysis showed that the 126 key targets of the huang qi–DKD PPI 
network were enriched in three biological processes and four molecular functions (Table 
7-6). All enriched biological processes and the molecular functions of ubiquitin-specific 
protease activity are related to metabolic processes. The other three enriched molecular 
functions are associated with DNA and protein binding.   
 
Table 7-6 Enriched biological process and molecular function of key targets 
 GO Term 
No. of genes 
input/ in 
background 
Percentages 
of genes 
Fold 
enrichment 
p-value 
(Bonferroni 
method) 
Biological 
process 
Protein metabolism 30/1323 24.2 3.315129 6.51E-07 
Regulation of 
nucleobase, nucleoside, 
nucleotide and nucleic 
acid metabolism 
38/2828 30.6 1.96433 0.00332 
Regulation of gene 
expression, epigenetic 
5/66 4.0 11.0924 0.015752 
Molecular 
function 
Receptor signalling 
complex scaffold 
activity 
10/322 8.1 4.543455 0.016648 
Ubiquitin-specific 
protease activity 
17/377 13.7 6.594365 1.82E-07 
DNA binding 17/654 13.7 3.801382 0.000513 
Chaperone activity 8/126 6.5 9.290713 0.000548 
 
 
7.3.4.2 Pathway enrichment analysis 
As for the biological pathway analysis, the 126 key targets of the huang qi–DKD PPI 
network were found to be enriched in 174 pathways. The top 10 most significantly enriched 
biological pathways are shown in Figure 7-7, ranked by ascending logarithmic p-values. 
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 Figure 7-6 Top 10 enriched pathway of key targets 
Abbreviations: AP: activator protein; TGF-β: transforming growth factor beta; TRAIL: 
tumour necrosis factor-related apoptosis inducing ligand; VEGF(R): vascular endothelial 
growth factor (receptor). 
 
Among the pathways highlighted, cross-talk and internal linkage exist (Figure 7-8). Based 
on the relations, two groups can be distinguished among the top 10 enriched pathways. The 
first group includes the up-stream pathways of the integrin-linked kinase (ILK) signalling 
pathway, glypican pathway and activator protein (AP) 1 transcription factor network which 
impact on the downstream transforming growth factor beta (TGF-β) receptor signalling 
pathway and subsequent Smad 2/3 signal regulation. The second group of enriched 
upstream pathways include the vascular endothelial growth factor (VEGF) and VEGF 
receptor (VEGFR) signalling network and the tumour necrosis factor-related apoptosis 
inducing ligand (TRAIL) signalling pathway. Both share the downstream pathway of the 
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nuclear factor kappa light chain enhancer of activated B cells (NF-κB) signalling pathway, 
which was also enriched but not in the top 10 list. 
  
 
 
Figure 7-7 Relationship between top 10 enriched pathways  
 
Abbreviations: Akt: protein kinase B; AP: activator protein; NF-κ: nuclear factor kappa 
light chain enhancer of activated B cells TGF-β: transforming growth factor beta; PI3K: 
phosphoinositide 3-kinases; TRAIL: tumour necrosis factor-related apoptosis inducing 
ligand; VEGF(R): vascular endothelial growth factor (receptor). Note: *indicates pathways 
not included in the top 10 list. Arrows represent sub-pathway relationships. For example, 
the glypican 1 network is the sub-pathway of the glypican pathway.  
 
7.3.5 Interaction network of huang qi key compound–target–pathway 
To further elucidate the potential new drug candidates, an interaction network of the huang 
qi key bioactive compounds, related targets and corresponding pathways was constructed 
(Figure 7-9). Only chemicals directly interacting with at least 2 targets contained in the 
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enriched pathways were shown in the network. Therefore, quercetin, betulinic acid, 
calycosin, formononetin, kaempferol, isorhamnetin, bifendate, gamma-Sitosterol and 
(24S)-24-Propylcholesta-5-ene-3beta-ol were included in this compound–target–pathway 
network. Quercetin connected with the largest number of key targets (18), followed by 
kaempferol (8).  
 
 
Figure 7-8 Interaction network of huang qi key compounds, key targets and top ten 
pathways 
Note: Yellow node represent the herb huang qi; green nodes represent the bioactive 
compounds with multiple direct connections to key targets; pink nodes represent targets 
shared by huang qi compounds and top 10 enriched pathways. 
 
7.4 Discussion 
Huang qi is used in clinical practice to treat a range of conditions including DKD. In the 
field of nephrology, huang qi was reported to be effective in reducing proteinuria and 
improving renal function in patients with membranous nephropathy or chronic kidney 
disease [361, 362]. By systematically evaluating the evidence of both classical and 
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contemporary literature, it was revealed that huang qi was the most promising herb for the 
treatment of DKD. However, a lack of information regarding its action mechanism(s) raises 
safety concerns. especially in the renal-impaired population [2, 5, 248]. It is imperative to 
elucidate the molecular basis corresponding to the therapeutic effect of huang qi. In this 
network pharmacology study, 38 bioactive compounds of huang qi and a group of key 
targets are proposed. The treatment effect of huang qi appeared to be mainly mediated by 
the anti-oxidation, anti-inflammation and apoptosis related pathways according to the 
functional analysis results.  
 
7.4.1 Bioactive compounds of huang qi 
The chemical properties of bioactive compounds of huang qi identified in this study are 
slightly different from previous knowledge about drug chemistry profiles. Of the 38 
bioactive compounds, twelve of them (32%) are large molecules with a weight over 500 
g/mol, which does not fit Lipinski's rule of five indicating it has drug-likeness. But three 
of these large molecular compounds still satisfy OB and DL parameters, contributing 4 to 
13 targets to the herbal targets network. Likewise, each of the 8 compounds that failed to 
meet the OB or DL criteria are associated with at least 6 targets. Seven compounds with 
exceptional molecular weight, OB or DL parameters were found to be directly influential 
on some of the key targets. It should be noted that the value of conventional chemistry 
parameters is not compromised by the above exceptions, as the 9 bioactive compounds 
with direct connection to multiple key targets all fit in the criteria. 
 
7.4.1.1 Flavonoids 
Among the 38 herbal compounds, 9 have direct connection with two or more key targets 
in the top 10 enriched pathways, indicating their important roles in the huang qi–DKD 
interaction network. Of the 9 compounds, quercetin is associated with far more targets than 
other compounds, in addition to direct interaction with 18 key targets of predominant 
pathways. Quercetin is a plant-source flavonoid and is ubiquitous in food, with anti-
oxidative, anti-inflammatory and anti-proliferation properties [363]. In vivo studies 
reported that quercetin significantly reduced serum creatinine level and urinary protein 
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excretion in streptozotocin (STZ)-induced diabetic rats/mice [364-366]. But the effect of 
quercetin on controlling plasma glycaemic level was uncertain [365-367]. Renal 
pathological changes of glomerular swelling, glomerulosclerosis, tubulointerstitial fibrosis 
and renal cortex lymphocytes infiltration were attenuated after quercetin treatment [364, 
366]. Quercetin alleviated oxidative stress injury in kidney tissues, as the activity of 
superoxide dismutase (SOD) was increased and reactive oxygen species (ROS) production 
was reduced in these animal studies. Moreover, it suppressed the neutrophil adhesion and 
intercellular adhesion molecular-1 (ICAM-1) expression in endothelial cells to exert anti-
inflammation properties [364]. The renal fibrosis lesions in diabetic rats were also 
attenuated by administration of quercetin, mediated by inhibition of fibrogenic cytokine 
overexpression and epithelial–mesenchymal transition (EMT) in renal tubular proximal 
epithelial cells [367, 368].  
 
Although the above experimental studies suggested that quercetin possessed a variety of 
protective activities in different parts of the renal system, the safety data regarding long-
term use of quercetin in human subjects is limited. Quercetin has been tested in a small 
sample of healthy people and patients with obesity, chronic hepatitis C, chronic pelvic pain 
syndrome or prostatic disease [369]. In previous clinical studies, oral quercetin was used 
at up to 1000 mg/day with a treatment duration no longer than 12 weeks. In general, the 
adverse events attributed to administration of quercetin was mild and rare, and no 
significant change was observed in terms of kidney and liver function. It should be noted 
that the dose of quercetin used in these studies was low to moderate compared to daily diet 
intakes (about 25-250 mg/day). A chronic toxicity study reported that chronic nephropathy 
was developed in male F344/N rats after being fed with mild- and high- dose of quercetin 
for 2 years and the incidence of renal tubule adenoma or adenocarcinoma was higher in the 
high-dose male rats group (corresponding to 140 g/day intake of quercetin in a 70 kg 
individul)  [370]. Eventhough the renal tubule tumor development of the chronic toxicity 
study was considered no relevance for extrapolation to humans, more data is needed to 
confirm the safety of long-term and high-dose supplement of quercetin, especially in 
patients with exiting renal lesions [371]. 
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For other flavonoids which directly linked to the key DKD targets, experimental evidence 
related to anti-DKD bioactivities of kaempferol, isorhamnetin, calycosin and formononetin 
was also identified. Kaempferol, isorhamnetin and calycosin exhibited anti-inflammatory, 
anti-oxicant effects in high glucose-induced glomerular mesangial and/or endothelial cells, 
mediated by the NF-κB pathway [372-374]. In addition, calycosin decreased endothelial 
cell apoptosis and dysfunction induced by advanced glycation end products (AGE) [375].  
Calycosin and formononetin reduced nitric oxide production and promoted endothelial 
nitric oxide synthase expression, resulting in regulation of endothelium-dependent 
vasodilation [376]. Kaempferol reduced the expression of profibrotic factors and 
inflammatory cytokines by inhibiting RhoA/Rho-kinase in both rat and human renal 
tubular epithelial cells [377]. Anti-hyperglycaemic effects were observed in animal 
experiments of formononetin  [378, 379]. In a rat model of type 2 diabetes, lower serum 
creatinine level, improved creatinine clearance and decrease glycaemia was observed after 
16 weeks of formononetin treatments [380].  
 
However, smiliar to quercetin, toxicity information of flavonoids is insuffient to confirm 
their clinical safety. In vitro studies suggested that kaempferol may promote mixed lineage 
leukemia translocations in blood stem cells and increase risk of reproductive tract and 
estrogen-dependent tumors (such as breast cancer) due to its estrogenic activity [381]. But 
in animal studies,  genotoxic and carcinogenic effects of kaempferol was not observed, and 
meta-analysis of epidemiologic studies indicated that the risk of breast cancer was about 
20% lower in women with high intake of flavonols and flavones compared with women 
with low intake [382, 383]. More toxicology testing regarding the long-term use and 
supplementary dose of kaempferol, isorhamnetin, formononetin and calycosin are needed 
for rigorous safety evaluation.   
 
7.4.1.2 Triterpenoids 
Of the 9 candidate compounds, betulinic acid, gamma-sitosterol and (24S)-24-
propylcholesta-5-ene-3beta-ol are triterpenoids. Betulinic acid is a natural product isolated 
from the bark of birch trees and is known for its anti-HIV, antineoplastic and anti-
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inflammatory properties [384]. Lowering glycaemia and insulin effect of betulinic acid was 
reported in a STZ-induced diabetic rat model, along with amelioration of renal 
histopathological changes [385, 386]. Both studies indicated that betulinc acid exerted its 
renal protective effect via surpression of NF-κB pathway acticity in kidney tissues, which 
is consistent with the findings of network pharmacology. Experiments found that betulinic 
acid appeared to be safe at a dose of 100 mg/kg in rats, and a phase I/II clinical trial 
indicated that betulinic acid treatments for 20 days was well tolerated in HIV patients with 
a single oral dose of 250 mg/day [387, 388]. However, clinical data regarding the efficacy 
and safety of betulinic acid in renal impariment patients is not available and further research 
is needed. 
 
Gamma-sitosterol also showed anti-diabetic proterties in STZ-induced diabetic rats in 
addition to hyperlipidemia regulation effect, therefore it was considered to be a protential 
therapeuitic agent for diabetes [389]. A subsequent toxicity study revealed that gamma-
sitosterol induced DNA damage in human peripheral blood mononuclear cells so it is 
discourage to be consumped as a natural supplement [390]. 
 
7.4.1.3 Bifendate 
Bifendate was discovered as an intermediate during the synthetic process of Schisandrin C 
[391]. Because of its alanine aminotransferase (ALT) lowering effect, bifendate has been 
adjuvantly used for patients with chronic hepatitis or other liver injuries to reduce the serum 
level of ALT in China [392, 393]. But the anti-hepatitis B virus and anti-hepatic fibrosis 
effect of bifendate is still controversial, and it is unclear whether lowering ALT by 
bifendate leads to improvement of clinically relevant outcomes [394, 395]. In the field of 
nephology, bifendate has been studied in kidney transplant patients for decreasing the 
plasma concertration of immunosuppressants [396, 397]. Evidence of bifendate as a 
potential therapy for diabetes and its complications have not been identified. 
 
The evidence from network pharmacology results and existing publications suggests that 
some of the chemicals contained in huang qi, including quercetin, kaempferol, 
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isorhamnetin, formononetin, calycosin and betulinic acid could be the bioactive 
components corresponding to its therapeutic effect.  
 
7.4.2 Action mechanisms of huang qi 
Notably, there were two distinct action patterns of huang qi’s bioactive compounds. One 
is the direct regulation of targets involved in disease processes, as the putative action targets 
of huang qi shared 21 known DKD-related targets. In contrast, the alternative pattern is to 
modulate the molecular interaction network rather than a single target. By exploring the 
PPI relationship, a complex DKD network consisting of thousands of targets was identified. 
This could be the reason why current target-based agents are partially effective. Although 
only a quarter of DKD targets directly interacted with huang qi’s bioactive compounds (the 
first action pattern), over 80% of targets in the DKD–PPI network were covered by the 
huang qi–PPI network. The wide overlap area of PPI networks implied the network 
regulation function of huang qi. The second action pattern also confirmed the multi-
component, multi-target features of herbal products. 
  
Although the target number for huang qi is extensive, it seems that the key targets of the 
huang qi–DKD PPI network are markedly enriched in biological pathways related to signal 
transduction. Induced by the haemodynamic and metabolic changes, abnormal activation 
of diverse signal transduction pathways in renal cells has been observed and is closely 
related to the pathogenesis of DKD [398]. The TGF-β receptor signalling pathway is 
involved in angiogenesis, extracellular matrix production, immunosuppression and 
apoptosis induction, and it is a recognised pathogenic pathway of kidney diseases [399]. 
The TGF- β /Smad signalling pathway is highly activated in DKD, contributing to  
glomerular and tubulointerstitial cell fibrosis mediated mainly by Smad3 [400]. TGF-β 1 
and high ambient glucose also stimulate ILK expression in podocytes and the upregulation 
of ILK signalling promotes podocytes EMT, migration and ultimately protein leakage 
through podocytes [401]. In vivo studies showed that proteinuria can be attenuated by 
inhibitions of TGF-β 1/ILK signalling pathways [401, 402].  
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The NF-κB signalling pathway is another well-known element of DKD pathogenesis which 
can be activated by hyperglycaemia or haemodynamic stretch [403]. Increased activity of 
the NF-κB pathway is mainly observed in diabetic tubular epithelial cells and podocytes. 
The activated NF-κB pathway induces production of cytokines, chemokines, adhesion 
molecules and proliferative proteins, resulting in circulating inflammatory cells infiltrating 
into the kidneys and initiating intra-renal inflammatory injuries, leading to DKD [403, 404]. 
The role of these signal transduction pathways in the development of DKD is well 
established based on existing experimental evidence, and the treatment effect of huang qi 
may be mediated by these pathways synergistically based on the findings of the enrichment 
analysis. 
 
The roles of the VEGF-VEGFR signalling pathway and TRAIL signalling pathway in the 
pathogenesis of DKD have not been completely elucidated. The VEGF-VEGFR signalling 
pathway is known to be related to proliferation, migration and permeability of vascular 
endothelial cells [405]. It has been reported that VEGF signalling is abnormal, increased 
in early DKD and decreased in later stages. Elevated VEGF resulted in glomerulus 
endothelial cell proliferation and reduction led to cell apoptosis and glomerulosclerosis 
formation [398]. As for the TRAIL pathway, TRAIL was expressed most in tubular 
epithelial cells in DKD patients’ renal samples and the expression level was correlated to 
the severity of tubulointerstitial pathological changes. However, in a study using TRAIL 
gene knock-out mice model, deficiency of TRAIL exacerbated inflammation, renal damage 
and insulin resistance, indicating a protective role of TRAIL [406]. It is uncertain whether 
the interaction between huang qi’s compounds and these two pathways exerts protective 
or detrimental effects.  
 
7.4.3 Limitations 
The potential bioactive compounds and action mechanism of huang qi explored by this 
network pharmacology approach have several limitations. Firstly, some chemical 
compounds with actual bioactivity may be missing due to the absorption, distribution, 
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metabolism and excretion (ADME) screening criteria. As techniques develop, new 
bioactive compounds of huang qi may be identified based on other parameters. Secondly, 
considering the herbal putative targets were collected from experimental evidence and in 
silico prediction, it is possible that a different set of targets will be found by new 
experiments or other prediction methods [407]. Finally, only PPI was explored in this study, 
whereas other interactions including generic regulatory networks, RNA networks and 
metabolic networks were not studied [408]. Collectively, the key bioactive compounds and 
action mechanisms of huang qi have been systematically explored in this study. 
 
7.4.4 Implication for future studies 
The multi-compound, multi-target, multi-pathway characteristics of huang qi in the 
treatment of DKD are presented in this study. In addition to the larger target number for 
huang qi than for DKD (327 versus 103, respectively), the size of the herbal PPI network 
is much bigger than the DKD PPI network. The broad effects and complex action 
mechanisms of huang qi bring concerns about potential toxicity and adverse herb–drug 
interactions. To reduce the potential risk, herbal therapy should be refined based on 
network pharmacology findings, called “component-based Chinese medicine” [409]. In 
this study, 9 herbal compounds of huang qi have been identified having direct regulation 
potential for key DKD targets. Some of these herbal compounds have also shown promise 
in pre-clinical experiments. However, only one ongoing phase II clinical trial evaluating 
the effects of quercetin plus Dasatinib in advanced DKD patients has been found [410].  
Further research evaluating dosage, effect, safety and possible combinations of the 8 herbal 
compounds (excluding the gamma-sitosterol) may lead to novel poly-compound drugs for 
DKD. 
 
The finding about the glypican pathway involved in the action mechanism of huang qi 
provides new insight with regard to the pathogenesis of DKD. Glypicans are a family of 
heparin sulfate proteoglycans anchored in the outer surface of the cell membrane. In the 
kidneys, glomerular endothelial cells mainly express glypican-1 while the epithelial cells 
express the glypican-5. A knockdown model of zebrafish revealed that deficiency in 
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glypican-1 caused endothelial cell injuries and loss of glypican-5, resulting in focal 
podocyte effacement, eventually manifested as oedematous phenotypes [411]. In a separate 
in vivo study, increased expression of glypican-5 and enhanced signal activity were 
observed in diabetic mesangial regions [412]. The role of glypicans and their related 
pathways in DKD need to be further confirmed by human cohort data.  
  
7.5  Conclusion 
The network pharmacology approach identified 38 bioactive compounds of huang qi, with 
8 compounds promising for new drug development. The bioactive compounds of huang qi 
exert synergistic therapeutic effects by regulating the disturbed DKD molecular network, 
probably involving the TGF-β/Smad signalling pathway, ILK signalling pathway and NF-
κB pathway. Glypican pathways may contribute to the pathogenesis of DKD and are 
potentially regulated by huang qi. Further experiments are required to confirm the action 
hypothesis generated in this study.    
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8 General Discussion and Conclusions 
 
8.1 Summary of the research 
As one of the microvascular complications of diabetes, DKD is prevalent and particularly 
in the context of the global diabetes epidemic. DKD has been the leading cause of end stage 
kidney disease (ESKD) for decades and substantially increases the risk of cardiovascular 
events and mortality. Current pharmacotherapies for DKD such as glycaemia management, 
BP control and renin-angiotensin system (RAS) inhibitors are only partially effective. An 
unmet need exists for novel or improved treatments targeting diabetic kidney injury. 
Chinese herbal medicine (CHM) has been used for treating symsptoms related to kidney 
disorders for many centuries. Knowledge from traditional use of CHM for symptoms 
relevant to those identified in modern diagnosis of DKD may provide new leads and 
innovative therapies. In this research project, evidence of classical and modern literature 
with regards to the use of CHM for DKD has been rigorously gathered and evaluated. 
Promising herbal candidates identified from literature evidence were further studied using 
a network pharmacology approach to decipher the bioactive compounds and potential 
action mechanisms related to DKD. With this “whole evidence” framework, herbal 
compounds with new drug development potential are proposed for future studies. 
  
8.1.1 Classic Chinese medicine literature 
The assessment of ancient evidence was performed by text-mining classical CM books. In 
a collection of 1156 CM books, three ancient disease terms of DKD (Shen Xiao, Xia Xiao, 
and Xiao Shen) retrieved 278 classical citations with treatment information. As early as the 
Han Dynasty, descriptions highly consistent with DKD already existed in the book 
Variorum of Experiential Prescriptions集验方. Based on the historical text content and 
the contemporary DKD definition, the classical citations were divided into four groups to 
classify their similarity to DKD. Frequency analysis revealed that Ba wei wan, Liu wei di 
huang wan and Hui xiang san were the most commonly mentioned formulae for DKD 
among citations of different pools. The six herbal ingredients of Liu wei di huang wan were 
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frequently cited in all citation pools. Additionally, huang qi (Astragalus membranaceus 
(Fisch.) Bge. var. mongholicus (Bge.) Hsiao), ren shen (Panax ginseng C. A. Mey.), wu 
wei zi (Schisandra chinensis (Turcz.) Baill.), tian hua fen (Trichosanthes kirilowii Maxim.) 
and huang lian (Coptis chinensis Franch.) were high-frequency herbs repeatedly appearing 
in different citation pools. Notably, the herb huang qi was commonly used in citations with 
turbid urine descriptions, indicating a potential role of huang qi for proteinuria. 
   
8.1.2 Contemporary Chinese medicine literature 
To evaluate the contemporary evidence, a systematic review assessed the overall efficacy 
and safety of CHM as adjunctive therapy for DKD. Due to the large number of clinical 
trials in this field, this review only included RCT of oral CHM compared with matched 
placebo to reduce the potential risk of bias. A comprehensive search in both English and 
Chinese databases identified 20 eligible RCTs with 2719 adult DKD patients involved. 
Seventeen studies investigated herbal formulae with multiple ingredients and five showed 
highly similar compositions. Huang qi, di huang and da huang were the top three most 
commonly used herbs of included RCTs. Low to moderate quality of evidence suggests 
that CHM is favourable in decreasing albuminuria/proteinuria, irrespective of concurrent 
use of ACEi/ARB. When used in combination with ACEi/ARB, CHM preserved eGFR 
(moderate-quality evidence). All CHM used in included studies were aristolochic acid 
(AA)-free and safety concerns related to CHM were not identified. The findings of this 
systematic review provide preliminary modern evidence of renal protective potential of 
CHM in general.    
 
Comparing the common CHM in ancient literature and those in contemporary clinical trials, 
preservation of traditional use and innovative development are both observed. Huang qi as 
the herb specific for turbid urine in classical literature was applied in 15 out of 20 included 
RCTs. The second most common herb in clinical trials was di huang, which was the 
primary component of the classical formula Liu wei di huang wan. Although a substantial 
proportion of herbs used in included RCTs were commonly cited in classical literature, 
only one randomised, placebo-controlled trial of a traditional formulae was found in the 
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systematic review. The herbal composition of formulae in other collected RCTs were 
constructed and modified based on researchers’ preferences, rather than direct use of 
classical formulae. The herbs commonly cited in classical literature are highly consistent 
with the herbs most frequenly used in contemporaty RCTs. But the formulae identified in 
classical literature and modern RCTs are different. The consistency of herbs and variations 
in formulae between classical and modern evidence may imply a process of both 
inheritance and evolution of CHM knowledge for DKD. 
  
Since evidence of classical and contemporary literature both pointed out the frequent 
application of huang qi in the treatment for DKD and its typical symptoms, a systematic 
review focusing on huang qi preparations was performed to evaluate its efficacy and safety 
as adjunctive therapy. Consequently, 66 RCTs with 4785 DKD patients employing sole 
huang qi preparations without any concurrent use of herbal products was assessed. Adding 
huang qi preparations to current pharmacotherapies appeared to be beneficial and well-
tolerated in short-term reduction of albuminuria/proteinuria and serum creatinine (Scr) 
concentrations in adult DKD patients. Notably, positive results for huang qi were 
dominated by the 61 RCTs using injected preparations. Although a promising trend for 
huang qi was observed, confidence in this finding was compromised due to the overall low 
methodological quality of included RCTs, imprecision of estimated effect and potential 
publication bias.  
 
8.1.3 Network pharmacology 
A network pharmacology approach was used in order to better understand the molecular 
basis corresponding to the therapeutic effect of huang qi in the context of DKD. In total, 
38 potential bioactive compounds of huang qi were identified with 327 putative interactive 
targets. The network analysis of the huang qi–DKD PPI network revealed the 127 key 
targets involved in the mechanisms of action of huang qi, which are markedly enriched in 
signal transduction pathways including but not limited to TGF-β/Smad, ILK and NF-κB 
pathways. The complex interactions among the herbal bioactive compounds, multiple key 
targets and diverse related pathways underline the synergic effect of huang qi, clearly 
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demonstrated in the network approach. Moreover, quercetin, calycosin, formononetin, 
kaempferol, isorhamnetin and betulinic acid are proposed as chemical candidates for future 
anti-DKD new drug development.   
 
Based on the case of huang qi, the network pharmacology approach showed its unique 
advantages in studying herbal medicine and complex diseases. First and foremost, the 
network analysis technique facilitated the rapid identification of the key bioactive 
compounds from the raw herbs and the corresponding targets, narrowing down the 
subsequent experimental scope. In addition, the protein-protein interaction networks 
provided a comprehensive understanding of the spectrum of biological effects exerted by 
the herbal components. The overall action mechanisms and toxicity profile of specific 
herbs can therefore be predicted and explored. Potential detrimental herbal compounds can 
be excluded during the development stage to avoid unexpected adverse effects. [409]. With 
the advances of network pharmacology, raw herbs with diverse components can be further 
simplified and developed as a group of bioactive compounds with fixed proportion and 
clear active mechanisms, leading to better quality control, efficacy and safety of herbal 
therapy.  
 
8.2 Overall limitations of the research 
In this research, a “whole evidence” strategy was employed with the attempt to identify 
and provide potential CHM as new therapeutic candidates for DKD. Several limitations 
need to be considered when interpreting the results. Firstly, the subject of the network 
pharmacology study (huang qi) was selected based on the available classical CM and 
contemporary CM evidence. With regards to the evidence from the classical literature, 
some DKD-related records are likely to be missing in the current analysis since only 
ancient disease terms were used to retrieve citations. More citations may be yeiled if 
ancient terms of the symptoms for diabetes and kidney diseases can be searched in 
combination. The commonly known formulae and herbs in classical literature may increase 
if the citation pool is expanded. Additional herbal candidates may be identified from 
network pharmacology studies of other high-frequency formulae and herbs.  
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In addition, the quality of current clinical evidence of huang qi preparations is low and 
evidence regarding its long-term benefit and safety, especially on clinically relevant 
outcomes, is lacking. In toxicity studies based on animal models, acute and sub-chronic 
toxicity of huang qi was not observed [246]. In clinical practice, the most frequently 
reported adverse effect of huang qi is allergic reactions when it used in high doses [245]. 
The actual effect and safety of huang qi preparations for DKD is inconclusive. When it 
comes to huang qi injection, some herbal compounds may be detrimental when 
intravenously administrated [245, 413].  
 
Moreover, the included clinical trials did not provide information regarding the herbal 
chemical profile. The chemical constiuents of huang qi and the concentration of each 
compound employed in these clinical trials were unknown and could be different from the 
bioactive compounds used for network pharmacology study. Collectively, the bioactivity 
and pharmacological actions of the candidate compounds identified in huang qi need to be 
confirmed by further biological and pharmacological experiments.  
 
8.3  Directions for future research 
Currently, the formulae and their herbal ingredients identified in classical and 
contemporary CM research were only analysed for frequency. Advanced analysis methods 
such as cluster analysis may reveal the underlying relationships across ingredients (such as 
synergistic effect) within a formula and the prescription patterns between individual DKD 
symptoms and specific herbs [414, 415]. 
 
In current CM guidelines and textbooks, herbal therapies derived from the classical 
formulae Ba wei wan and Liu wei di huang wan have been recommended for DKD without 
support from clinical evidence [167-169]. As mentioned above, the number of high-quality 
RCTs evaluating the effect and safety of classical formulae is limited. The knowledge gap 
between traditional formulae and their actual clinical effects and safety for DKD needs to 
be established through adequately powered, well-conducted RCTs using validated primary 
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outcome measures. 
 
Eight chemicals contained in huang qi showed potential therapeutic relevance to DKD. 
Subsequent experiments to test their individual and combined effects in both in vivo and in 
vitro DKD models are necessary for novel therapeutic agent development. Experimental 
testing for safety and toxicity of the herbal compound candidates is also required, 
particularly examination of potential nephrotoxicity and hepatoxicity.  
 
According to the pathway analysis results, in addition to established pathways related to 
inflammation, oxidative stress and apoptosis, the renal protective properties of huang qi 
could be mediated via the glypican pathway. Decreased glypican-1 level in skin blood 
vessels is observed in diabetic patients, and exogenous supplements of glypican-1 
improved perfusion and vessel formation in ischaemic diabetic mice [416]. Glypican-4, 
which is known as an insulin sensitiser, increased in the impaired glucose tolerance stage 
and then decreased after progressed to established diabetes [417, 418]. It remains unclear 
whether regulation of the glypican pathway may impact on the onset and progression of 
DKD, thus further studies are needed. 
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Appendices 
Appendix 1 Herbs included in the thesis 
Pin yin name 
Simplified Chinese 
characters 
Scientific name Pharmaceutical name 
Ba ji tian 巴戟天 1. Morinda officinalis How                               Morindae Officinalis Radix 
Bai bian dou 白扁豆 1. Dolichos lablab L.                               Lablab Semen Album 
Bai zhu 白朮 1. Atractylodes macrocephala Koidz.                               Atractylodis Macrocephalae Rhizoma 
Bo he 薄荷 1. Mentha haplocalyx Briq.                               Menthae Haplocalycis Herba  
Bu gu zhi 补骨脂 1. Psoralea corylifolia L.                               Psoraleae Fructus 
Che qian zi 车前子 
1. Plantago asiatica L.                  
2. Plantago depressa Willd.                            
Plantaginis Semen 
Chi shao 赤芍 
1. Paeonia lactiflora Pall. 
2. Paeonia veitchii Lynch  
Paeoniae Radix Rubra  
Chi shi zhi 赤石脂 1. Hydrated aluminium silicate Halloysitum Rubrum 
Chong wei zi 茺蔚子 1. Leonurus japonicus Houtt.                               Leonuri Fructus 
Chuan lian zi 川楝子 1. Melia toosendan Sieb. et Zucc. Toosendan Fructus 
Chuan xiong 川芎 1. Ligusticum chuanxiong Hort.                               Chuanxiong Rhizoma 
Ci shi 磁石 1. Ferroferric oxide  Magnetitum 
Da huang 大黄 
1. Rheum palmatum L.                  
2. Rheum tanguticum Maxim. ex Balf. 
3. Rheum officinale Baill.                       
Rhei Radix et Rhizoma 
Dan shen 丹参 1. Salvia miltiorrhiza Bge.                               Salviae Miltiorrhizae Radix et Rhizoma 
Dang gui 当归 1. Angelica sinensis (Oliv.) Diels                              Angelicae Sinensis Radix 
Di gu pi 地骨皮 
1. Lycium chinense Mill.                
2. Lycium barbarum L.                            
Lycii Cortex 
Di huang 地黄 1. Rehmannia glutinosa Libosch.                               Rehmanniae Radix 
Du zhong 杜仲 1. Eucommia ulmoides Oliv.                               Eucommiae Cortex 
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Pin yin name 
Simplified Chinese 
characters 
Scientific name Pharmaceutical name 
E zhu 莪术 
1. Curcuma phaeocaulis Val.         
2. Curcuma kwangsiensis S. G. Lee et C. F. Liang                                
3. Curcuma wenyujin Y. H. Chen et C. Ling  
Curcumae Rhizoma 
Fu ling 茯苓 1. Poria cocos (Schw.) Wolf Poria 
Fu pen zi 覆盆子 1. Rubus chingii Hu                               Rubi Fructus 
Fu shen 茯神 1. Poria cocos (Schw.) Wolf Poriae Sclerotium Pararadicis 
Fu zi 附子 1. Aconitum carmichaelii Debx.   Aconiti Radix Lateralis Praeparata 
Gan cao 甘草 
1. Glycyrrhiza uralensis Fisch.       
2. Glycyrrhiza inflata Bat.                   
3. Glycyrrhiza glabra L.                         
Glycyrrhizae Radix et Rhizoma 
Gan jiang 干姜 1. Zingiber officinale Rosc.  Zingiberis Rhizoma 
Ge gen 葛根 1. Pueraria lobata (Willd.) Ohwi                              Puerariae Lobatae Radix 
Gou qi zi 枸杞子 1. Lycium barbarum L.                               Lycii Fructus 
Gua lou 瓜蒌 
1. Trichosanthes kirilowii Maxim.    
2. Trichosanthes rosthronii Harms                            
Trichosanthis Fructus 
Han shui shi a 寒水石 
1. Calcite 
2. Gypsum rubrum 
Glauberitum 
He shou wu 何首乌 1. Polygonum multiflorum Thunb.                               Polygoni Multiflori Radix 
Hong qu 红曲 1. Monascus purpureus Went. Fermentum Rubrum 
Hu lu ba 胡芦巴 1. Trigonella foenum-graecum L.                               Trigonellae Semen 
Hua shi 滑石 1. Hydrated magnesium silicate  Talcum 
Huai mi tan 槐米炭 1. Styphnolobium japonicum (L.) Schott. Flos Sophorae Immaturus 
Huang bo (Huang 
bai) 
黄柏 1. Phellodendron chinense Schneid.                               Phellodendri Chinensis Cortex 
Huang lian 黄连 
1. Coptis chinensis Franch.              
2. Coptis deltoidea C. Y. Cheng et Hsiao                                                   
3. Coptis teeta Wall.                     
Coptidis Rhizoma 
Huang qi 黄芪 
1. Astragalus membranaceus (Fisch.) Bge. var. mongholicus 
(Bge.) Hsiao                                        
2. Astragalus membranaceus (Fisch.) Bge.                      
Astragali Radix 
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Pin yin name 
Simplified Chinese 
characters 
Scientific name Pharmaceutical name 
Huang qin 黄芩 1. Scutellaria baicalensis Georgi                               Scutellariae Radix 
Huang shu kui hua 黄蜀葵花 1. Abelmoschus manihot (L.) Medic.                              Abelmoschi Corolla 
Huo xiang 藿香 
1. Pogostemon cablin (Blanco) Benth.                                                    
2. Agastache rugosa (Fisch. & Mey.) O. Ktze.                           
Pogostemonis/Agastaches Herba 
Ji nei jing 鸡内金 1. Gallus gallus domesticus Brisson Galli Gigerii Endothelium Corneum 
Jiang can 僵蚕 
1. Bombyx mori Linnaeus.           
2. Beauveria bassiana (Bals.) Vuillant 
Bombyx Batryticatus 
Jiang huang 姜黄 1. Curcuma longa L.                               Curcumae Longae Rhizoma 
Jie geng 桔梗 1. Platycodon grandiflorum (Jacq.) A. DC.                             Platycodonis Radix 
Jin ying zi 金樱子 1. Rosa laevigata Michx.                               Rosae Laevigatae Fructus 
Jue ming zi 决明子 
1. Cassia obtusifolia L.                     
2. Cassia tora L.                            
Cassiae Semen 
Ku shen 苦参 1. Sophora flavescens Ait.                               Sophorae Flavescentis Radix 
Lian qiao 连翘 1. Forsythia suspensa (Thunb.) Vahl                              Forsythiae Fructus 
Lian zi 莲子 1. Nelumbo nucifera Gaertn.                               Nelumbinis Semen 
Long gu 龙骨 1. Fossilised bone - various species Fossilia Ossis Mastodi (Draconis Os) 
Lu hui 芦荟 
1. Aloe barbadensis Miller (syn. Aloe vera)          
2. Aloe ferox miller                                  
Aloe 
Lu jiao 鹿角 
1. Cervus elaphus Linnaeus            
2. Cervus nipponTemminck  
Cervi Cornu 
Lu rong 鹿茸 
1. Cervus nippon Temminck            
2. Cervus elaphus Linnaeus 
Cervi cornus pantotrichum 
Mai dong (Mai 
meng dong) 
麦冬 (麦门冬) 1. Ophiopogon japonicus (L.f) Ker-Gawl.                              Ophiopogonis Radix 
Mang xiao 芒硝 1. Hydrated sodium sulfate Natrii Sulfas 
Mian bi xie 绵萆薢 
1. Dioscorea spongiosa J. Q. Xi, M. Mizuno et W. L. Zhao                    
2. Dioscorea futschauensis Uline ex R. Kunth                  
Dioscoreae Spongiosae Rhizoma 
Mu dan pi 牡丹皮 1. Paeonia suffruticosa Andr.                               Moutan Cortex 
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Pin yin name 
Simplified Chinese 
characters 
Scientific name Pharmaceutical name 
Mu li 牡蛎 
1. Ostrea gigas Thunberg               
2. Ostrea talienwhanensis Crosse  
3. Ostrea rivularis Gould 
Ostreae Concha 
Mu xiang 木香 1. Aucklandia lappa Decne.                               Aucklandiae Radix 
Niu bang zi 牛蒡子 1. Arctium lappa L.                               Arctii Fructus 
Niu xi 牛膝 1. Achyranthes bidentata Bl.                               Achyranthis Bidentatae Radix 
Nü zhen zi 女贞子 1. Ligustrum lucidum Ait.                               Ligustri Lucidi Fructus 
Pu huang 蒲黄 
1. Typha angustifolia L.                  
2. Typha orientalis Presl                            
Typhae Pollen 
Qian shi 芡实 1. Euryale ferox Salisb.                               Euryales Semen 
Qing dai 青黛 
1. Baphicacanthus cusia (Nees) Bremek.  
2. Polygonum tinctorium Ait.          
3. Isatis indigotica Fort.                        
Indigo Naturalis 
Qing feng teng 青风藤 
1. Sinomenium acutum (Thunb.) Rehd. et Wils. 
2. Sinomenium acutum (Thunb.) Rehd. et Wils. var. 
cinereum Rehd. et Wils 
Sinomenii Caulis 
Ren shen 人参 1. Panax ginseng C. A. Mey.                             Ginseng Radix et Rhizoma  
Rou cong rong 肉苁蓉 
1. Cistanche deserticola Y. C. Ma   
2. Cistanche tubulosa (Schrenk) Wight 
Cistanches Herba 
Rou gui 肉桂 1. Cinnamomum cassia Presl  Cinnamomi Cortex 
Ru xiang 乳香 
1. Boswellia carterii Birdw.              
2. Boswellia bhaw-dajiana Birdw.                            
Olibanum 
San qi (Tian qi) 三七 (田七) 1. Panax notoginseng (Burk.) F.H.Chen                              Notoginseng Radix et Rhizoma 
Sang piao xiao 桑螵蛸 
1. Tenodera sinensis Saussure       
2. Statilia maculata (Thunberg)  
3. Hierodula patellifera (Serville) 
Mantidis Oötheca 
Sha ren 砂仁 
1. Amomum villosum Lour.             
2. Amomum villosum Lour. var. xanthioides T. L. Wu et 
Senjen       
3. Amomum longiligulare T. L. Wu                
Amomi Fructus 
Shan yao 山药 1. Dioscorea opposita Thunb.                               Dioscoreae Rhizoma 
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Pin yin name 
Simplified Chinese 
characters 
Scientific name Pharmaceutical name 
Shan zhu yu 山茱萸 1. Cornus officinalis Sieb. et Zucc.                             Corni Fructus 
She chuang zi 蛇床子 1. Cnidium monnieri (L.) Cuss.                              Cnidii Fructus 
Sheng di  生地 1. Rehmannia glutinosa Libosch. Rehmanniae Radix 
Shi gao 石膏 1. Hydrated calcium sulfate  Gypsum Fibrosum 
Shi geng teng ye 匙羹藤叶 1. Gymnema sylvestre (Retz.) R.Br. ex Sm. Gymnema latifolium 
Shi hu 石斛 
1. Dendrobium nobile Lindl.            
2. Dendrobium chysotoxum Lindl.    
3. Dendrobium fimbriatum Hook. 
Dendrobii Caulis 
Shu di huang 熟地黄 1. Rehmannia glutinosa Libosch.                               Rehmanniae Radix Praeparata 
Shui zhi 水蛭 
1. Whitmania pigra Whitman           
2. Hirudo nipponica Whitman          
3. Whitmania acranulata Whitman 
Hirudo 
Tian dong 天冬 1. Asparagus cochinchinensis (Lour.) Merr.  Asparagi Radix 
Tian hua fen (Gua 
lou gen) 
天花粉 (栝蒌根) 
1. Trichosanthes kirilowii Maxim.    
2. Trichosanthes rosthornii Harms                            
Trichosanthis Radix 
Tu bie chong (Zhe 
chong) 
土鳖虫 (䗪虫) 
1. Eupolyphaga sinensis Walker       
2. Steleophaga plancyi (Boleny) 
Eupolyphaga/ Steleophaga 
Tu si zi 菟丝子 
1. Cuscuta australis R. Br.              
2. Cuscuta chinensis Lam. 
Cuscutae Semen 
Wei mao 卫矛 1. Euonymus alatus (Thunb.) Sieb Euonymus alatus 
Wu bei Zi 五倍子 
1. Rhus chinensis Mill. 
2. Rhus potaninii Maxim.  
3. Rhus punjabensis Stew. var. sinica (Diels) Rehd. et Wils.  
4. Melaphis chinensis (Bell) Baker 
Galla Chinensis 
Wu wei zi 五味子 1. Schisandra chinensis (Turcz.) Baill.                              Schisandrae Chinensis Fructus 
Xi yang shen 西洋参 1. Panax quinquefolium L.                               Panacis Quinquefolii Radix 
Xia ku cao 夏枯草 1. Prunella vulgaris L.                               Prunellae Spica 
Xiao hui xiang 小茴香 1. Foeniculum vulgare Mill.                               Foeniculi Fructus 
Xuan shen 玄参 1. Scrophularia ningpoensis Hemsl.                               Scrophulariae Radix 
Yi mu cao 益母草 1. Leonurus japonicus Houtt.                               Leonuri herba 
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Pin yin name 
Simplified Chinese 
characters 
Scientific name Pharmaceutical name 
Yi zhi 益智 1. Alpinia oxyphylla Miq.                               Alpiniae Oxyphyllae Fructus 
Yin xing ye 银杏叶 1. Ginkgo biloba L.                               Ginkgo Folium 
Yin yang huo (Xian 
ling pi) 
淫羊藿 (仙灵脾） 
1. Epimedium brevicornum Maxim. 
2. Epimedium sagittatum (Sieb. et Zucc.) Maxim.  
3. Epimedium pubescens Maxim.  
4. Epimedium koreanum Nakai  
Epimedii Folium 
Yu gan zi 余甘子 1. Phyllanthus emblica L.                               Phyllanthi Fructus 
Yu yu liang 禹余粮 1. Basic ferric oxide Limonitum 
Yuan zhi 远志 
1. Polygala tenuifolia Willd. 
2. Polygala sibirica L.  
Polygalae Radix 
Ze xie 泽泻 1. Alisma orientalis (Sam.) Juzep.                              Alismatis Rhizoma 
Zhi mu 知母 1. Anemarrhena asphodeloides Bge.                               Anemarrhenae Rhizoma 
Zhi qiao (Zhi ke) 枳壳 1. Citrus aurantium L.    Aurantii Fructus 
Zhi zi 栀子 1. Gardenia jasminoides Ellis                               Gardeniae Fructus 
Zhu sha 朱砂 1. Mercuric sulfide  Cinnabaris 
Note: The use of some herbs may be restricted in some countries; readers are advised to comply with relevant regulations. Qian dan 铅
丹, jin bo 金箔, yin bo 银箔, tie fen 铁粉, bai shi zhi 白石脂, jian si 茧丝, hua cong rong 花苁蓉 and tu gua gen 土瓜根 were cited in 
classical literature but are not indexed in contemporary pharmacopoeia, thus scrientific and pharmatheutical names can not be provided.  
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Appendix 2 Example search strategy of systematic review of CHM for DKD  
Search block Search terms 
Intervention Traditional Chinese Medicine OR Chinese Traditional Medicine OR Chinese 
Herbal Drugs OR Chinese Drugs, Plant OR Medicine, Traditional OR 
Ethnopharmacology OR Ethnomedicine OR Ethnobotany OR Medicine, Kampo 
OR Kanpo OR TCM OR Medicine, Ayurvedic OR Phytotherapy OR Herbology 
OR Plants, Medicinal OR Plant Preparation OR Plant Extract OR Plants, Medicine 
OR Materia Medica OR Single Prescription OR Chinese Medicine Herb OR 
Herbal Medicine OR Herbs 
Condition Diabetic Nephropathies OR Diabetic Nephropathy OR Diabetic Kidney Disease 
OR Diabetic Kidney Diseases OR Kimmelstiel Wilson Syndrome OR Kimmelstiel 
Wilson Disease OR Diabetic Glomerulosclerosis OR Nodular Glomerulosclerosis 
OR Intracapillary Glomerulosclerosis OR albuminuria OR Microalbuminuria OR 
proteinuria OR Glomerulosclerosis OR Glomerulonephritis OR Kimmelstiel 
wilson nephropathy OR diabetic nephrosclerosis 
Study design Systematic[sb] OR "randomized controlled trial"[pt] OR "controlled clinical 
trial"[pt] OR "randomized"[tiab] OR "placebo"[tiab] OR "drug therapy"[sh] OR 
"randomly"[tiab] OR "trial"[tiab] OR "groups"[tiab] OR "cohort studies"[mesh] 
OR "case-control studies"[mesh] OR "comparative study"[pt] OR "risk 
factors"[mesh] OR "cohort"[tw] OR "compared"[tw] OR "groups"[tw] OR "case 
control"[tw] OR "multivariate"[tw] OR "case series"[tw] 
Note: The above search strategy was designed for MEDLINE. The three search blocks 
were connected with the Boolean operators “AND” to build the overall search terms.  
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Appendix 3 Subgroup analysis of primary outcomes in systematic review of CHM for DKD 
 
Outcome or subgroup No. of 
trials 
Pts Statistical 
method 
Effect estimate 
(95%CI) 
I2 p value 
Urinary albumin excretion 
Subgroup-CHM formulae 
      
  Qiwei Granules 2 104 MD -70.06 [-88.84, -51.28] 0% p <0.0001 
  Arctiin Granules 2 595 Std. MD -0.38 [-0.56, -0.20] 0%  p <0.0001 
  Tang shen ning Formulae group 2 330 MD -48.16 [-55.12, -41.20] 95% p <0.0001 
Subgroup-Measurement Units 
      
  CHM vs placebo-AER  1 186 MD -149.48 [-362.79, 63.83] NA  p =0.17 
  CHM vs placebo-ACR  2 124 MD -30.53 [-76.59, 15.53] 66% p =0.19 
  CHM vs placebo-UAE 5 711 MD -60.91 [-76.82, -45.01] 53% p <0.0001 
  CHM vs placebo + ACEi/ARB-AER 1 119 MD -48.85 [-53.30, -44.40] NA p <0.0001 
  CHM vs placebo + ACEi/ARB-UAE 2 330 MD -48.16 [-55.12, -41.20] 95% p <0.0001 
24-hour proteinuria 
Subgroup-baseline UP 
      
  CHM vs placebo-baseline UP < 0.5g/d 2 453 MD -378.34 [-649.90, -106.77] 63%  p =0.006 
  CHM vs placebo-baseline UP > 0.5g/d 2 246 Std. MD -1.49 [-3.97, 0.99] 97% p =0.24 
  CHM + ACEi/ARB vs placebo + ACEi/ARB 
     -baseline UP < 0.5g/d 
2 284 MD -31.30 [-68.61, 6.02] 61% p =0.10 
  CHM + ACEi/ARB vs placebo + ACEi/ARB 
     -baseline UP > 0.5g/d 
2 205 MD 0.11 [-0.67, 0.88] 74% p =0.79 
Subgroup-CHM formulae 
      
  Qiwei Granules 2 104 Std. MD -2.47 [-3.11, -1.83] 21% p <0.0001 
  Arctiin Granules 2 595 MD -407.65 [-732.24, -83.05] 45%  p =0.01 
  Tang shen fang group 2 205 MD 0.11 [-0.67, 0.88] 74% p =0.79 
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Outcome or subgroup No. of 
trials 
Pts Statistical 
method 
Effect estimate 
(95%CI) 
I2 p value 
Subgroup-Measurement Units 8 
     
  CHM vs placebo-g/24h 1 60 MD -0.93 [-1.13, -0.73] NA p <0.0001 
  CHM vs placebo-mg/24h 3 639 MD -324.42 [-485.15, -163.69] 30%  p <0.0001 
  CHM + ACEi/ARB vs placebo + ACEi/ARB-g/24h 2 205 MD 0.11 [-0.67, 0.88] 74%  p =0.79 
  CHM + ACEi/ARB vs placebo + ACEi/ARB-mg/24h 2 284 MD -31.30 [-68.61, 6.02] 61% p =0.10 
Serum creatinine level 
Subgroup-baseline Scr 
      
  CHM + ACEi/ARB vs placebo + ACEi/ARB 
     -baseline Scr normal 
3 227 MD -2.12 [-6.48, 2.23] 0% p =0.34 
   CHM + ACEi/ARB vs placebo + ACEi/ARB 
     -baseline Scr abnormal 
2 368 MD -9.99 [-17.71, -2.26] 0% p =0.01 
  CHM vs placebo + ACEi/ARB-baseline Scr normal 3 434 MD -4.07 [-6.13, -2.01] 0% p =0.0001 
  CHM vs placebo + ACEi/ARB-baseline Scr abnormal 1 156 MD -2.84 [-18.18, 12.50] NA p =0.72 
Subgroup-CHM formulae 
      
  Tang shen fang group 2 286 MD -6.06 [-14.60, 2.47] 0%  p =0.16 
  Tang shen ning Formulae group 2 330 MD -3.96 [-6.13, -1.78] 6% p =0.0004 
Glomerular filtration rate 
Subgroup-baseline GFR 
      
  CHM + ACEi/ARB vs placebo + ACEi/ARB 
     -baseline GFR>90 
2 249 MD 9.38 [1.07, 17.70] 4%  p =0.03 
  CHM + ACEi/ARB vs placebo + ACEi/ARB 
     -baseline GFR<90 
2 286 MD 5.22 [0.69, 9.74] 0% p =0.02 
  CHM vs placebo + ACEi/ARB-baseline GFR>90 1 90 MD -9.99 [-13.62, -6.36] NA p <0.0001 
  CHM vs placebo + ACEi/ARB-baseline GFR<90 3 452 MD 4.48 [-1.32, 10.28] 70%  p =0.13 
Subgroup-CHM formulae 
      
  Tang shen fang group 2 286 MD 5.22 [0.69, 9.74] 0% p =0.02 
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Outcome or subgroup No. of 
trials 
Pts Statistical 
method 
Effect estimate 
(95%CI) 
I2 p value 
  Tang shen ning Formulae group 2 330 MD -0.89 [-18.62, 16.85] 99% p =0.92 
Subgroup-Measurements 
      
  CHM + ACEi/ARB vs placebo + ACEi/ARB-Ccr 1 144 MD 5.80 [1.01, 10.59] NA p =0.02 
  CHM + ACEi/ARB vs placebo + ACEi/ARB-eGFR 3 391 MD 7.13 [-0.29, 14.56] 11% p =0.06 
  CHM vs placebo + ACEi/ARB-Ccr 2 246 MD -4.14 [-15.81, 7.53] 93% p =0.49 
  CHM vs placebo + ACEi/ARB-eGFR 2 296 MD 5.25 [-4.65, 15.15] 46% p =0.30 
Abbreviations: ACEi: angiotensin-converting enzyme inhibitors; ACR: albuminuria-to-creatinine ratio; AER: albuminuria excretion 
rate; ARB: angiotensin receptor blockers; Ccr: creatinine clearance; CHM: Chinese herbal medicine; CI: confidence interval; GFR: 
glomerular filtration rate; MD: mean difference; NA: not applicable; Pts: patients; Std: standard.; Scr: serum creatinine concentration; 
UAE: urinary albuminuria excretion; UP: urinary proteinuria. 
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Appendix 4 Sensitivity analysis of primary outcomes in systematic review of CHM for DKD 
 
Outcome Studies Participants Statistical method Effect estimate 
(95% CI) 
I2 p value 
Urinary albumin excretion 
    
 CHM vs placebo 4 798 Std. Mean Difference -0.54 [-0.85, -0.22] 73% p =0.0009 
  CHM+ACEi/ARB vs 
placebo+ACEi/ARB 
3 330 Std. Mean Difference -0.56 [-1.04, -0.08] 64%  p =0.02 
24-hour proteinuria 
     
  CHM vs placebo 2 595 Mean Difference -407.65 [-732.24, -83.05] 45% p =0.01 
  CHM+ACEi/ARB vs 
placebo+ACEi/ARB 
3 429 Std. Mean Difference -0.12 [-0.60, 0.37] 81%  p =0.63 
  CHM vs placebo+ACEi/ARB 2 260 Std. Mean Difference 0.00 [-0.32, 0.32] 26% p =1.00 
Serum creatinine level 
    
  CHM vs placebo 1 41 Mean Difference 10.31 [-2.26, 22.88] NA p =0.11 
  CHM+ACEi/ARB vs 
placebo+ACEi/ARB 
4 535 Mean Difference -5.59 [-10.61, -0.58] 0% p =0.03 
  CHM vs placebo+ACEi/ARB 2 260 Mean Difference -6.23 [-19.51, 7.05] 0% p =0.36 
Glomerular filtration rate 
    
  CHM+ACEi/ARB vs 
placebo+ACEi/ARB 
4 535 Mean Difference 6.28 [2.42, 10.14] 0% p =0.001 
  CHM vs placebo+ACEi/ARB 2 212 Mean Difference 1.50 [-3.08, 6.09] 0% p =0.52 
Abbreviations: ACEi: angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CHM: Chinese herbal medicine; 
CI: confidence interval; NA: not applicable; Std: standard. 
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Appendix 5: Example search strategy in systematic review of huang qi for DKD 
 
Step Search block Search terms  
#1 Condition Diabetic Nephropathies OR Diabetic Nephropathy OR Diabetic 
Kidney Disease OR Diabetic Kidney Diseases OR Kimmelstiel Wilson 
Syndrome OR Kimmelstiel Wilson Disease OR Diabetic 
Glomerulosclerosis OR Nodular Glomerulosclerosis OR Intracapillary 
Glomerulosclerosis OR albuminuria OR Microalbuminuria OR 
proteinuria OR Glomerulosclerosis OR Glomerulonephritis OR 
kimmelstiel wilson nephropathy OR diabetic nephrosclerosis 
#2 Intervention Astragal*[Title/Abstract] OR "A. membranaceus"[Title/Abstract] OR 
vetch [Title/Abstract] OR "Astragalus Plant"[Mesh:NoExp] OR "radix 
astragali"[Text Word] OR Milkvetch OR Astragalus OR Huangqi OR 
"huang qi" OR "Astragalus membranaceus" 
#3 Condition 
combined with 
Intervention 
#1 AND #2 
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Appendix 6: Subgroup analysis and of primary outcomes of syetematic review of huang qi for DKD 
 
Outcome Subgroups Studies Participants Statistical method Effect estimate 
[95% CI] 
I2 p value 
Albuminuria 
Duration < 1 month 22 1551 Std. Mean Difference -2.43 [-3.05, -1.82] 95% p <0.0001 
1-3 months 13 877 Std. Mean Difference -1.25 [-1.61, -0.89] 83% p <0.0001 
Baseline kidney 
function 
Normal 8 511 Std. Mean Difference -1.50 [-2.28, -0.71] 93% p =0.0002 
Mild-moderate imparied 1 56 Std. Mean Difference -1.22 [-1.79, -0.64] NA p <0.0001 
Measurement Albuminuria excretion rate (µg/min) 12 814 Mean Difference -30.86 [-41.54, -20.17] 89% p <0.0001 
24-hour albuminuria excretion (mg/24h) 17 1211 Mean Difference -50.21 [-61.54, -38.87] 98% p <0.0001 
Albuminuria-concentration (mg/L) 7 464 Mean Difference -14.63 [-19.42, -9.85] 95% p <0.0001 
Astragalus 
Injection dosage 
20 mL 5 312 Std. Mean Difference -2.18 [-3.10, -1.27] 90% p <0.0001 
30 mL 4 270 Std. Mean Difference -1.18 [-1.80, -0.55] 82% p =0.0002 
40 mL 13 950 Std. Mean Difference -1.62 [-2.30, -0.94] 95% p <0.0001 
50 mL 5 414 Std. Mean Difference -2.80 [-4.36, -1.24] 97% p =0.0004 
60 mL 5 307 Std. Mean Difference -3.23 [-4.79, -1.67] 94% p <0.0001 
Proteinuria 
Duration < 1 month 19 1312 Std. Mean Difference  -2.00 [-2.64, -1.35] 95% p <0.0001 
1 - 3 months 8 526 Std. Mean Difference  -1.34 [-1.89, -0.79] 87% p <0.0001 
Baseline kidney 
function 
Normal 1 43 Std. Mean Difference  -0.36 [-0.96, 0.24] NA p =0.24 
Mild-moderate impaired 4 263 Std. Mean Difference  -1.73 [-2.77, -0.68] 92% p =0.001 
Measurement 24-hour proteinuria excretion (g/24h) 20 1239 Mean Difference  -0.43 [-0.52, -0.34] 90% p <0.0001 
24-hour proteinuria excretion (mg/24h) 7 599 Mean Difference  -59.64 [-74.32, -44.97] 96% p <0.0001 
20 mL 13 866 Std. Mean Difference  -1.94 [-2.67, -1.21] 95% p <0.0001 
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Outcome Subgroups Studies Participants Statistical method Effect estimate 
[95% CI] 
I2 p value 
Astragalus 
Injection dosage 
30 mL 4 290 Std. Mean Difference  -1.02 [-1.80, -0.25] 89% p =0.009 
40 mL 8 512 Std. Mean Difference  -1.50 [-2.23, -0.78] 92% p <0.0001 
50 mL 1 110 Std. Mean Difference  -4.97 [-5.74, -4.20] NA p <0.0001 
60 mL 1 60 Std. Mean Difference  -2.72 [-3.43, -2.00] NA p <0.0001 
Serum Creatinine Concentration 
Duration < 1 month 28 2284 Mean Difference  -14.50 [-19.02, -9.99] 97% p <0.0001 
1 - 3 months 9 656 Mean Difference  -13.78 [-26.74, -0.83] 98% p =0.04 
Baseline kidney 
function 
Normal 5 314 Mean Difference  -5.27 [-8.93, -1.61] 74% p =0.005 
Mild-moderate impaired 3 213 Mean Difference  -53.98 [-105.61, -2.35] 99% p =0.04 
Astragalus 
dosage 
20 mL 8 756 Mean Difference  -14.17 [-21.11, -7.23] 93% p <0.0001 
30 mL 8 559 Mean Difference  -18.95 [-27.80, -10.10] 97% p <0.0001 
40 mL 12 934 Mean Difference  -15.21 [-25.46, -4.96] 98% p =0.004 
50 mL 5 444 Mean Difference  -7.65 [-17.05, 1.75] 95% p =0.11 
60 mL 4 247 Mean Difference  -6.11 [-11.68, -0.55] 77% p =0.03 
Glomerulus Filtration Rate 
Duration < 1 month 1 43 Mean Difference  -1.10 [-11.44, 9.24] NA p =0.83 
1 - 3 months 3 180 Mean Difference  -3.83 [-10.93, 3.28] 60% p =0.29 
Measurement Cockcroft-Gault equation  3 171 Mean Difference  -0.22 [-5.02, 4.58] 0% p =0.93 
Serum creatinine based estimation 1 52 Mean Difference  1.46 [-6.29, 9.21] NA p =0.71 
Abbreviations: CI: confidence interval; g: gram; L: litre; mg: milligram; mL: milliliter; min: minutes; NA: not applicable; Std: standard.
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Appendix 7 Central indices of key targets of huang qi–DKD network 
 
Entry Gene symbol Key target name Degree 
centrality 
Betweenness 
centrality 
Closeness 
centrality 
Eigenvector 
centrality 
P00519 ABL1 Tyrosine-protein kinase ABL1  159 0.0046215 0.4910154 0.0426866 
P60709 ACTB Actin, cytoplasmic 1  147 0.0035973 0.4822454 0.0463436 
P07550 ADRB2 Beta-2 adrenergic receptor  234 0.0160922 0.4789863 0.0409904 
P31749 AKT1 RAC-alpha serine/threonine-protein kinase  209 0.0080394 0.4992296 0.0498464 
P05067 APP Amyloid-beta A4 protein  505 0.0815621 0.5506191 0.0749063 
P10275 AR Androgen receptor  207 0.005169 0.4887931 0.0501535 
P49407 ARRB1 Beta-arrestin-1  151 0.0039702 0.4813243 0.045303 
P32121 ARRB2 Beta-arrestin-2  185 0.0038177 0.4830671 0.0621951 
O14965 AURKA Aurora kinase A  146 0.0031807 0.4804067 0.0466104 
P38398 BRCA1 Breast cancer type 1 susceptibility protein  234 0.0083851 0.4920807 0.0571401 
Q9Y297 BTRC F-box/WD repeat-containing protein 1A  144 0.004185 0.4721066 0.0344338 
P0DP23 CALM1 Calmodulin-1 155 0.0028264 0.4824505 0.0429281 
P0DP24 CALM2 Calmodulin-2 155 0.0028264 0.4824505 0.0429281 
P0DP25 CALM3 Calmodulin-3 155 0.0028264 0.4824505 0.0429281 
Q86VP6 CAND1 Cullin-associated NEDD8-dissociated protein 1  251 0.0044444 0.4817332 0.0847493 
P22681 CBL E3 ubiquitin-protein ligase CBL  145 0.0027306 0.4720083 0.0348361 
Q9H0W5 CCDC8 Coiled-coil domain-containing protein 8 241 0.0060203 0.4967149 0.0709077 
Q16543 CDC37 Hsp90 co-chaperone Cdc37  132 0.0031839 0.4770719 0.0338707 
P06493 CDK1 Cyclin-dependent kinase 1  132 0.0026883 0.4749738 0.0369049 
P38936 CDKN1A Cyclin-dependent kinase inhibitor 1  129 0.001941 0.4758708 0.0391395 
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Entry Gene symbol Key target name Degree 
centrality 
Betweenness 
centrality 
Closeness 
centrality 
Eigenvector 
centrality 
Q00610 CLTC Clathrin heavy chain 1  144 0.0027881 0.479594 0.0468696 
Q92905 COPS5 COP9 signalosome complex subunit 5  299 0.0082385 0.5072691 0.0957184 
Q92793 CREBBP CREB-binding protein  191 0.004252 0.4733876 0.0441258 
P68400 CSNK2A1 Casein kinase II subunit alpha  165 0.0032998 0.4917606 0.0541033 
Q8NEV1 CSNK2A3 Casein kinase II subunit alpha 3  165 0.0032998 0.4917606 0.0541033 
P35222 CTNNB1 Catenin beta-1  204 0.0067945 0.5028825 0.052706 
Q13617 CUL2 Cullin-2  198 0.0028157 0.474775 0.0701126 
Q93034 CUL5 Cullin-5  182 0.0027184 0.4714197 0.065828 
Q14999 CUL7 Cullin-7  303 0.0064753 0.5013263 0.0914254 
O75530 EED Polycomb protein EED  201 0.0030079 0.4672435 0.065134 
P68104 EEF1A1 Elongation factor 1-alpha 1  206 0.0047365 0.491974 0.0752915 
P00533 EGFR Epidermal growth factor receptor  428 0.0339661 0.5346535 0.0871741 
Q09472 EP300 Histone acetyltransferase p300  253 0.0079286 0.4981331 0.0642302 
P03372 ESR1 Estrogen receptor  392 0.0183197 0.52102 0.1067129 
Q01844 EWSR1 RNA-binding protein EWS  222 0.0072926 0.494333 0.0608807 
Q9NRD1 FBXO6 F-box only protein 6  248 0.0081874 0.4846154 0.065012 
P21333 FLNA Filamin-A  150 0.0036073 0.4857571 0.0473432 
P02751 FN1 Fibronectin  392 0.0255727 0.5246357 0.1081054 
P35637 FUS RNA-binding protein FUS  166 0.0025004 0.4855491 0.0610937 
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase  132 0.0020629 0.4891093 0.0473812 
P62993 GRB2 Growth factor receptor-bound protein 2  284 0.0149739 0.511502 0.066884 
P16104 H2AFX Histone H2AX  142 0.0014854 0.4692737 0.0495455 
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Entry Gene symbol Key target name Degree 
centrality 
Betweenness 
centrality 
Closeness 
centrality 
Eigenvector 
centrality 
Q13547 HDAC1 Histone deacetylase 1  231 0.0058815 0.483479 0.0557269 
Q92769 HDAC2 Histone deacetylase 2  142 0.0017343 0.4606947 0.042542 
Q9UQL6 HDAC5 Histone deacetylase 5  233 0.0036348 0.4820404 0.0751394 
Q9UBN7 HDAC6 Histone deacetylase 6  130 0.0021674 0.4756711 0.0406083 
P68431 
  
  
  
  
  
  
  
  
HIST1H3B 
HIST1H3G 
HIST1H3I 
HIST1H3H 
HIST1H3J 
HIST1H3D 
HIST1H3A 
HIST1H3E 
HIST1H3C 
Histone H3.1  
  
  
  
  
  
  
  
  
194 0.001495 0.470539 0.059863653 
P09651 HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1  217 0.0054863 0.5023256 0.0759059 
P61978 HNRNPK Heterogeneous nuclear ribonucleoprotein K  142 0.0019441 0.4817332 0.0562167 
Q00839 HNRNPU Heterogeneous nuclear ribonucleoprotein U  214 0.0035583 0.4884773 0.0814565 
P07900 HSP90AA1 Heat shock protein HSP 90-alpha  348 0.0203087 0.5271967 0.0899352 
P08238 HSP90AB1 Heat shock protein HSP 90-beta  299 0.0135303 0.5120795 0.0807293 
P34932 HSPA4 Heat shock 70 kDa protein 4  175 0.0036682 0.4957377 0.0577682 
P11021 HSPA5 Endoplasmic reticulum chaperone BiP  229 0.0061049 0.5024369 0.0801503 
P11142 HSPA8 Heat shock cognate 71 kDa protein  214 0.0054351 0.5034406 0.0703956 
P38646 HSPA9 Stress-70 protein, mitochondrial  129 0.0014099 0.4870088 0.0494896 
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P04792 HSPB1 Heat shock protein beta-1  152 0.0046431 0.4802033 0.0453476 
P10809 HSPD1 60 kDa heat shock protein, mitochondrial  119 0.002378 0.4849262 0.0477492 
Q7Z6Z7 HUWE1 E3 ubiquitin-protein ligase HUWE1  253 0.0051529 0.4936874 0.0797692 
Q14164 IKBKE Inhibitor of nuclear factor kappa-B kinase subunit epsilon  179 0.0031282 0.4702467 0.0462451 
Q9Y6K9 IKBKG NF-kappa-B essential modulator  185 0.0048081 0.481938 0.048876 
Q12906 ILF3 Interleukin enhancer-binding factor 3  152 0.0018507 0.4652308 0.0620917 
P46940 IQGAP1 Ras GTPase-activating-like protein IQGAP1  122 0.0016852 0.474477 0.036837 
P05412 JUN Transcription factor AP-1  248 0.0116773 0.4936874 0.0467012 
Q92993 KAT5 Histone acetyltransferase KAT5  117 0.0023257 0.4703443 0.0349824 
Q13233 MAP3K1 Mitogen-activated protein kinase kinase kinase 1  135 0.0014275 0.4704418 0.0448479 
P28482 MAPK1 Mitogen-activated protein kinase 1  155 0.0043458 0.4859653 0.0367602 
P49736 MCM2 DNA replication licensing factor MCM2  392 0.0151963 0.5195876 0.1168254 
Q00987 MDM2 E3 ubiquitin-protein ligase Mdm2  219 0.0064859 0.5002206 0.0614188 
P01106 MYC Myc proto-oncogene protein  245 0.007601 0.5001103 0.0626991 
P35579 MYH9 Myosin-9  141 0.0028013 0.478481 0.042804 
P19338 NCL Nucleolin  151 0.0017594 0.4779768 0.0617038 
P19838 NFKB1 Nuclear factor NF-kappa-B p105 subunit  132 0.0022238 0.4681115 0.0388613 
P06748 NPM1 Nucleophosmin  285 0.0068373 0.5101215 0.1054719 
P04150 NR3C1 Glucocorticoid receptor  145 0.0040541 0.4740803 0.0340242 
P04629 NTRK1 High affinity nerve growth factor receptor  602 0.0479781 0.5546588 0.1348422 
O75147 OBSL1 Obscurin-like protein 1 243 0.0045966 0.4873227 0.0759854 
Q504Q3 PAN2 PAN2-PAN3 deadenylation complex catalytic subunit 
PAN2  
192 0.0035701 0.4686919 0.0647358 
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O60260 PARK2 E3 ubiquitin-protein ligase parkin  219 0.0050026 0.4944408 0.0626109 
P09874 PARP1 Poly [ADP-ribose] polymerase 1  139 0.0022108 0.4691767 0.0484355 
P12004 PCNA Proliferating cell nuclear antigen  123 0.001906 0.4655172 0.0407847 
P30153 PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A alpha isoform  
107 0.0016333 0.4684015 0.0373462 
P78527 PRKDC DNA-dependent protein kinase catalytic subunit  139 0.0018396 0.4842015 0.0526348 
P25788 PSMA3 Proteasome subunit alpha type-3  128 0.0029856 0.4692737 0.0367463 
P63244 RACK1 Receptor of activated protein C kinase 1  147 0.0029851 0.4823479 0.0542875 
Q04206 RELA Transcription factor p65  182 0.0049022 0.4829642 0.0483719 
Q99496 RNF2 E3 ubiquitin-protein ligase RING2  271 0.0072138 0.4920807 0.0735229 
P62979 RPS27A Ubiquitin-40S ribosomal protein S27a  183 0.0038531 0.4911217 0.0627856 
Q9UBS0 RPS6KB2 Ribosomal protein S6 kinase beta-2  141 0.0013986 0.46504 0.0473431 
P29353 SHC1 SHC-transforming protein 1  163 0.0032561 0.4854452 0.0395685 
Q96EB6 SIRT1 NAD-dependent protein deacetylase sirtuin-1  117 0.0020885 0.4628571 0.035949 
Q9NRC8 SIRT7 NAD-dependent protein deacetylase sirtuin-7  226 0.0041181 0.4814265 0.0670389 
Q15796 SMAD2 Mothers against decapentaplegic homolog 2  170 0.0044045 0.4791887 0.0389447 
P84022 SMAD3 Mothers against decapentaplegic homolog 3  176 0.0064495 0.4898488 0.039211 
P51532 SMARCA4 Transcription activator BRG1  129 0.0017867 0.4609756 0.0385377 
Q9HCE7 SMURF1 E3 ubiquitin-protein ligase SMURF1  211 0.0052269 0.4881619 0.0595604 
P08047 SP1 Transcription factor Sp1 124 0.0016153 0.4671473 0.0353158 
Q13501 SQSTM1 Sequestosome-1  120 0.0016697 0.4729927 0.0338386 
P12931 SRC Proto-oncogene tyrosine-protein kinase Src  208 0.0099392 0.5003309 0.0435959 
Q9UNE7 STUB1 E3 ubiquitin-protein ligase CHIP  129 0.0024094 0.4828614 0.0367776 
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Q13148 TARDBP TAR DNA-binding protein 43  160 0.0015336 0.4740803 0.0626446 
P04637 TP53 Cellular tumor antigen p53  428 0.0206154 0.5265846 0.1212566 
Q9Y4K3 TRAF6 TNF receptor-associated factor 6  246 0.0075369 0.501992 0.0580968 
Q71U36 TUBA1A Tubulin alpha-1A chain  107 0.0015459 0.4708325 0.0357413 
P07437 TUBB Tubulin beta chain  142 0.0018779 0.4918673 0.0545581 
P0CG48 UBC Polyubiquitin-C [Cleaved into: Ubiquitin] 351 0.0164442 0.5227011 0.0918362 
P63279 UBE2I SUMO-conjugating enzyme UBC9  195 0.0061405 0.4878469 0.045404 
P11441 UBL4A Ubiquitin-like protein 4A  168 0.0022958 0.4700518 0.0609625 
P55072 VCP Transitional endoplasmic reticulum ATPase  264 0.0086621 0.507837 0.0786998 
P40337 VHL von Hippel-Lindau disease tumor suppressor  220 0.0069128 0.4941177 0.0633963 
P08670 VIM Vimentin 118 0.0021536 0.4793913 0.0342221 
O14980 XPO1 Exportin-1  330 0.0174564 0.5137033 0.0807309 
P12956 XRCC6 X-ray repair cross-complementing protein 6  143 0.002279 0.4772727 0.0523876 
P31946 YWHAB 14-3-3 protein beta/alpha  145 0.0033159 0.4877419 0.0419516 
P62258 YWHAE 14-3-3 protein epsilon  174 0.0035815 0.4859653 0.0565228 
P61981 YWHAG 14-3-3 protein gamma  169 0.0040403 0.4974775 0.0542314 
P27348 YWHAQ 14-3-3 protein theta  205 0.0043804 0.4893204 0.0606994 
P63104 YWHAZ 14-3-3 protein zeta/delta  285 0.0094144 0.5131222 0.0887801 
 
